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Abstract 
 
The protein tau has gained notoriety due its role in many neurodegenerative disorders 
including the most prevalent form of dementia, Alzheimer’s disease, as well as the 
hereditary frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-
17). The development of novel systems for investigating tau-mediated dysfunction and 
possible ways in which this may be reversed or even prevented are therefore essential.  
 
The present study provides primary characterisation of a novel transgenic mouse model 
of tauopathy, known as TauD35. This model harbours transgenic human tau containing 
the FTDP-17 mutation, P301L, under the control of the CaMKII! promoter. As 
demonstrated in Alzheimer’s disease, hippocampal neurones are particularly vulnerable 
to tau dysfunction, fuelling the decision to choose the hippocampus as the site of this 
initial characterisation. Molecular biology, immunohistochemistry, behavioural and 
electrophysiological techniques were employed at 4, 13 and 24 months of age in order to 
investigate pathology development over time. 
 
Investigations revealed two sublines within the TauD35 model, with one line harbouring 
approximately double the number of transgene copies (HIGHTAU) compared to the other 
(LOWTAU). Both transgenic lines developed intraneuronal inclusions formed from 
pathological tau species relevant to human tauopathies in an age- and dose-dependent 
manner, as tested with specific antibodies. At 4-months, prior to tau aggregation, an 
increase in paired-pulse ratio was detected at entorhinal cortex to dentate gyrus synapses. 
At 13-months, the two lines exhibited large disparity in NFT load, with HIGHTAU 
animals displaying behavioural changes consistent with the symptoms of FTDP-17 
patients. Neuronal loss was evident in the CA1 region of HIGHTAU mice by 17.5 months 
of age, coinciding with the development of a pathological phenotype. These data show 
that both TauD35 models mimic cardinal features of human tauopathies, and thus 
provide valuable tools in which to study tau dysfunction as well as assess possible 
therapeutics. 
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IMPORTANT PREFACE 
 
 
Data presented herein describes the initial hippocampal characterisation of a novel 
mouse model of tauopathy, TauD35, which overexpresses human tau containing the 
P301L mutation under the CaMKII! promoter. The mouse model was developed at 
GlaxoSmithKline (GSK) in order to study the effects of tau dysfunction and the 
development of tau pathology within the mouse brain, as a model of frontotemporal 
dementia with parkinsonism linked to chromosome-17 (FTDP-17) and other 
neurodegenerative tauopathies. 
 
Primary investigations concentrated on analysis of synaptic transmission within the 
TauD35 line, at a comparable age (4-months) to other transgenic mouse models (in 
particular the APPSWE x PS1M146V model of rising amyloid-") used within the lab. This 
would allow for the identification of the earliest possible common alterations in synaptic 
transmission resulting from changes in either tau or amyloid-".  
 
Over the following year and half, mice were aged at UCL for behavioural and further 
electrophysiological testing. During this time, it became apparent that a proportion of the 
TauD35 transgenic mice within the colony developed a moribund phenotype at 
approximately 17-20 months of age. Of the 28 transgenic mice maintained until this age, 
only 8 were seen to develop this pathological phenotype. This observation initiated 
questions as to why this phenotype was seen only in a small proportion of transgenic 
animals. Later communication with GSK Neurosciences Therapeutic Area (Shanghai, 
China) highlighted additional inconsistences within the TauD35 line that they had 
observed during histological experimentations.  
 I was therefore prompted to further examine the transgene properties of this 
novel mouse line. I sought advice and technical assistance from Stuart Martin (Head of 
the Molecular Biology Unit at UCL), and together we were able to design a qPCR 
experiment using uniquely designed TaqMan® primers/probe for the CaMKII! promoter 
sequence in order to investigate the transgene copy number.  
 
With only one year of my PhD remaining, I discovered that indeed two transgenic lines 
existed within the TauD35 mouse line, with one line harbouring approximately double 
the number of transgene copies as the other. The two transgenic models were appointed 
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HIGHTAU and LOWTAU respectively. These differences in transgene copy number, as 
determined using qPCR (see below), may be the result of genetic recombination or two 
independent integration events. Following this important discovery, I confirmed these 
findings using Western blot and histological techniques.  
 
Separating electrophysiological and behavioural data collected previously from 
transgenic mice has resulted in low/inconsistent sample numbers for some experiments. 
Without prior knowledge of differences in transgene copy number, and thus measures to 
selectively breed both lines, the HIGHTAU line has been seen to decline in numbers. This 
has unfortunately resulted in difficulty in attempts to increase sample numbers, in 
particular for aged animals.  
 
Separate breeding colonies have now been established within the lab, however, 
additional experiments cannot now be completed within the time frame of my PhD, as 
these mice will not have reached a sufficient age.  
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CHAPTER 1 
 
An introduction to the present study 
 
The present study concentrates on tau, a protein that has gained notoriety due its role in 
many neurodegenerative disorders known collectively as tauopathies. This heterogenous 
group of diseases includes the most prevalent form of dementia, Alzheimer’s disease 
(AD), making the development of novel systems in which to investigate tau dysfunction, 
and possible ways in which this may be reversed or even prevented, essential. 
 
The novel mouse model presented harbours human cDNA containing the frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17) missense mutation, 
P301L, and is known as TauD35. The transgene lies under the control of the 
Ca2+/calmodulin-dependent protein kinase (CaMKII!) promoter, and is thus strongly 
expressed within the hippocampus (www.mouse.brain-map.org (Lein et al., 2007)). With 
the obvious vulnerability of the hippocampus to tau pathology development and neurone 
loss (discussed below), one may expect early, substantial changes within the 
hippocampus in such a model. Therefore initial work concentrates within this brain 
structure. A description of hippocampal neuroanatomy is thus provided, with literature 
linking tau dysfunction and the hippocampus discussed. 
 
As a new transgenic line, with no current publications detailing its characterisation, my 
PhD project aims to employ current techniques to provide an initial description of this 
mouse model, so that this may provide a reference source for future work. The present 
study confirms functionality of the line through the use of molecular biology and 
histological techniques, as well as providing initial insight into the functional 
consequences of tau dysfunction, using behavioural and electrophysiological testing. A 
short introduction into the use of these functional experiments within the hippocampus is 
given at the end of this chapter. 
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An introduction to tau 
 
As the average life expectancy of man continues to increase, it leads us towards a 
dramatic increase in the incidence of dementia. The term ‘dementia’ does not describe a 
single disease, but rather a set of symptoms often described under a blanket term as 
cognitive decline; that principally include memory loss, personality and behavioural 
changes, as well as problems with language, attention and problem solving. The most 
prevalent form of dementia is by far Alzheimer’s disease (AD), which accounts for 
approximately 50-60% of all dementia cases (Blennow et al., 2006). Apart from the huge 
economic burden caused by the ever-increasing cases of dementia, the enormous 
emotional distress caused by this set of diseases means we must intensify our search for 
a preventative therapy. 
 
In 1986 it was identified that the neurofibrillary tangles (NFTs) first described by Alois 
Alzheimer 80 years prior, were in fact aggregates of abnormally hyperphosphorylated 
protein tau (Grundke-Iqbal et al., 1986a, Grundke-Iqbal et al., 1986b, Ihara et al., 1986, 
Kosik et al., 1986). From this discovery sprung much interest in this protein tau, with 
large amounts of work over the next few years concentrating on its isolation and 
characterisation.  
 
The physiological role of tau 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 1.1. The 6 isoforms of tau present within the human central nervous system. Alternative 
splicing of the MAPT gene produces 6 isoforms of tau in the human central nervous system. Isoforms 
are split into 2 groups containing either three or four microtubule binding repeats (3R or 4R) in the 
carboxyl terminal of the protein (shown in orange). The isoforms also differ in the presence of either: 
zero, one or two inserts (0N, 1N or 2N) in the amino terminal of the protein (shown in green).  
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The principle function of tau protein is to promote the assembly of microtubules (MTs) 
(Weingarten et al., 1975). MTs play a crucial role in many cellular functions, including: 
maintaining the structure of cells as part of the cytoskeleton, allowing the transport of 
intracellular cargoes, and in spindle formation during mitosis. Physiologically, the 
majority of tau is primarily located in the axons of mature neurones (Binder et al., 1985, 
Li et al., 2011) and (in different isoforms (Avila et al., 2004)) is found in both the central 
(CNS) and peripheral nervous systems. There are six known isoforms of tau in the 
human CNS, resulting from the alternative splicing of exons 2, 3 and 10 of the 
microtubule associated protein tau (MAPT) gene (Ballatore et al., 2007) (Figure 1.1). 
The isoforms differ from each other in the number of MT binding repeats (MTBRs) they 
contain (either 3 (3R) or 4 (4R)) (Goedert et al., 1989b), as well as the presence of either 
zero (0N), one (1N) or two (2N) 29-amino acid long inserts in the amino (projection) 
terminal of the protein (Goedert et al., 1989a). In contrast to human tau, murine tau only 
ever exists in four isoforms, with only three isoforms (0N4R, 1N4R and 2N4R) present 
in adult mice (Liu and Gotz, 2013). The precise physiological roles of these different 
isoforms remain unknown. While they are likely to be broadly functionally similar, it has 
been shown that 4R tau isoforms display a greater potency in promoting tubulin 
assembly than do 3R isoforms (Goedert and Jakes, 1990), whereas 3R isoforms bind 
with a far greater affinity to the Src family tyrosine kinase, Fyn (Bhaskar et al., 2005). In 
the human adult brain 3R and 4R tau are expressed in a 1 to 1 ratio, with changes to this 
ratio towards an increase 4R tau indicative of neurodegenerative tauopathies (Goedert 
and Jakes, 2005). Recent work has also uncovered the differential cellular location of 
murine tau isoforms containing different numbers of amino terminal inserts, indicating 
functional differences exist between these different isoforms (Liu and Gotz, 2013).  
 
Through its close association with MTs, it is probable tau takes on a key role in 
regulating axonal transport. Physiologically, tau is in an equilibrium, bound to, and 
detached from MTs (Ballatore et al., 2007), and it is likely this plays some function in 
transport along MTs. Studies by Dixit et al., (2008) showed that tau may regulate the 
motor proteins dynein and kinesin differently, implying the critical role of its spatial 
location on cellular transport.  
 
In 1977 it was determined that tau is a phosphoprotein (Cleveland et al., 1977). Tau 
contains approximately 85 phosphorylation sites, of which only a handful are 
phosphorylated under physiological conditions 
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[http://cnr.iop.kcl.ac.uk/hangerlab/tautable (Hanger et al., 2009)]. This relatively 
dephosphorylated state is believed to increase the ability of tau to promote MT formation 
(Lindwall and Cole, 1984), thus implying that the phosphorylation status of tau plays a 
regulatory role in its function, including axonal transport (Ballatore et al., 2007). More 
recently it has become clear that under pathological circumstances, including various 
dementias, an atypical phosphorylation of tau occurs leading tau to become 
‘hyperphosphorylated’. Some evidence indicated that this pathological addition of 
phosphate groups may occur in a temporal cascade (Kimura et al., 1996, Bertrand et al., 
2010a), performed by proline-directed kinases, such as glycogen synthase kinase-3 
(GSK-3), cyclin-dependent kinase 5 (cdk5), mitogen-activated protein kinase (MAPK) 
and c-Jun N-terminal kinases (JNKs) (Mandelkow and Mandelkow, 2012).  
Hyperphosphorylation is not, however, an absolute indicator of disease, with higher 
levels of phosphorylation also present in the foetal brain (Brion et al., 1993) and in 
hibernating animals (Arendt et al., 2003, Arendt and Bullmann, 2013). Other conditions 
resulting in a reduction in body temperature and stress on the body, have also been 
shown to cause the hyperphosphorylation of tau, such as starvation, cold water stress and 
anaesthesia (Yanagisawa et al., 1999, Okawa et al., 2003, Planel et al., 2007, Petry et al., 
2014), possibly due to effects on the balance of kinase/phosphatase activity (Planel et al., 
2007). 
 
Along with stabilizing and promoting MT assembly, tau also engages with a whole host 
of other proteins and structures, including: presenilin-1 (part of the catalytic core of the 
!-secretase enzyme, one of the enzymes responsible for the cleavage of the amyloid 
precursor protein) (Takashima et al., 1998), the protein actin (which forms 
microfilaments, one of the major components of the cytoskeleton), the plasma membrane 
(Brandt et al., 1995), adenosine triphosphate (ATP) (Farid et al., 2013) and SH3 domains 
of the Src family of tyrosine kinases (Src, Lck and Fyn) (Lee et al., 1998), to name just a 
few (a full table of the binding partners of tau is given in Mandelkow and Mandelkow 
2012), with these interactions also likely influenced by the phosphorylation state of tau. 
While research over the last decade or so has focused on tau’s relationship with MTs, it 
is likely that these various other interactions may indeed be important in the function of 
tau and its role in disease, with the relationship between tau and Fyn (along with 
additional, related interactions) presently the topic of intense research (Ittner et al., 2010, 
Mondragon-Rodriguez et al., 2012, Boehm, 2013).  
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While the accumulation of hyperphosphorylated tau in the pathological state is the most 
prominent modification, it is noteworthy that tau has also been found to undergo various 
additional post-translational modifications in the brains of patients affected by various 
dementias. These include: nitration, ubiquitination, glycation, glycosylation and 
truncation (Pevalova et al., 2006).  
 
The role of tau in dementia 
 
In the years following the discovery that tau protein was the major constituent of NFTs, 
it was learnt that familial forms of AD (fAD) were caused by mutations in the genes that 
play a role in the production of amyloid-" (Goate et al., 1991). This work, coupled with 
earlier observations linking Down’s syndrome with AD (Glenner and Wong, 1984), soon 
prompted the complete Amyloid Hypothesis of AD (Hardy and Higgins, 1992), and 
studies into the role of tau in neurodegeneration began to decline. However, it seemed 
that, although the evidence was pointing towards amyloid-" being the main causative 
factor of AD, the characteristic amyloid-" plaques did not correlate to the severity of 
disease. Instead, NFTs composed of tau protein, along with neuronal and synaptic loss, 
correlated far better with the degree of cognitive decline and memory impairment in AD 
(Terry et al., 1991, Arriagada et al., 1992, Gomez-Isla et al., 1996, Gomez-Isla et al., 
1997, Giannakopoulos et al., 2003).  
 
In 1994, an autosomal dominant inherited form of frontotemporal dementia with 
parkinsonism (FTDP) was linked to chromosome 17 (FTDP-17) (Wilhelmsen et al., 
1994), in particular the specific region within chromosome 17 in which the tau gene lies 
(17q21.31). By 1998, it had been shown that genetic mutations within the tau gene 
resulted in FTDP-17 (Hutton et al., 1998).  
FTDP-17 is a rare form of dementia, which displays a highly heterogeneous 
phenotype even between members of the same family. However, there are three 
fundamental features including behavioural changes, cognitive decline and 
parkinsonism, of which patients usually display at least two once the disease is fully 
developed (Wszolek et al., 2006).  Currently, approximately 100 families harbouring 38 
different mutations in the MAPT gene have been identified (ibid). These mutations can 
be split broadly into 2 groups: 1) those that affect the alternative splicing of the MAPT 
gene, with the majority increasing levels of 4R tau and 2) those that have their effect at 
the protein level, by disrupting MT binding (although several mutations do effect both) 
(ibid). It has been shown that 4 of the most studied missense mutations (G272V, 
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V337M, R406W and P301L) make tau a more susceptible substrate for 
hyperphosphorylation (Alonso Adel et al., 2004) and it is therefore possibly via this 
modification that these mutations disrupt MT binding. The majority of FTDP-17 cases 
present an early onset, typically around 40-60 years of age, an age similar to cases of 
fAD (Selkoe and Podlisny, 2002). While mutations in the MAPT gene account for the 
vast majority of cases of FTDP-17, it is of note that the remaining instances that are not 
found to result from MAPT mutations directly, still see a genetic link to the same region 
of chromosome 17q21 (Wszolek et al., 2006).   
 
FTDP-17 is not, however, the only disease to exhibit tau pathology exclusively. Instead, 
it is just one of a heterogeneous group of diseases all displaying abundant tau deposition 
and neuronal degeneration, including: progressive supranuclear palsy, Pick’s disease, 
argyrophilic grain disease and corticobasal degeneration (Cairns et al., 2007). 
Collectively, these disorders (as well as AD) are known as tauopathies. 
 Along with Pick’s disease, FTDP-17 also falls under the umbrella term of 
frontotemporal lobar degeneration (FTLD), due to the predominant loss of the frontal 
and temporal lobes in this group of diseases (ibid).  In addition to these tauopathy 
disorders, other forms of FTLD exist, in which tau pathology is not noted. These forms 
of FTLD present different pathological inclusions, such as those positive for ubiquitin, 
possibly comprised of TAR DNA-binding protein 43 (TDP-43) (ibid). It is typical for 
FTLD patients to present with the clinical syndrome of frontotemporal dementia (FTD), 
which presents as a change in behaviour, such as increased disinhibition or impulsivity. 
Others regularly exhibit the syndromes of semantic dementia or primary progressive 
non-fluent aphasia, observed as dysfunctions in language. Parkinsonism also manifests 
in a proportion of FTLD patients, as well as a clinical diagnosis of amyotrophic lateral 
sclerosis in certain individuals (ibid).  
 
Interestingly tau has also been shown to have links to Parkinson’s disease (PD) 
(reviewed in (Wray and Lewis, 2010). PD is primarily thought of as a movement 
disorder caused by neuronal loss in the substantia nigra and is associated with protein 
aggregates of !-synuclein, known as Lewy bodies. However, the research field now 
recognises PD as a more complex entity. Most patients display some level of cognitive 
decline, with a proportion developing clinically diagnosed dementia. Of these patients, 
50% see the occurrence of senile plaques and NFTs, resulting in a secondary diagnosis 
of AD (Irwin et al., 2013). As well as these human cases, it has been observed that a 
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mouse model of PD harbouring the E46K !-synuclein mutation develops abundant 
neuronal tau inclusions, with the origin of these tau aggregates attributed to both a direct 
and indirect action of the mutated !-synuclein protein (Emmer et al., 2011). Genome-
wide association studies have also revealed that mutations in MAPT provide a genetic 
risk factor for the development of PD (Simon-Sanchez et al., 2009). Together, these 
distinct studies reveal an important relationship between tau and PD. Presently the most 
active area of research into links between PD and tau concentrate on the interesting 
possibilities of synergistic effects between !-synuclein and tau in causing fibrillisation 
of each other (Giasson et al., 2003, Guo et al., 2013a), as is discussed below. 
 
Tau risk factors for dementia 
 
Despite the discovery that specific mutations in the MAPT gene can directly result in 
familial tauopathy disorders, the causes of sporadic nonhereditary tauopathies, including 
the vast majority of AD cases, remain unidentified. For patients presenting with a 
sporadic form of a disease, it may be that while they are not harbouring a direct genetic 
cause, they may possess certain genetic risk factors that contribute to disease 
development. With regards to the development of tauopathy disorders, an enhanced risk 
has been associated with the inheritance of a particular haplotype from chromosome 17.   
The MAPT gene lies within a ~900kb region of DNA on chromosome 17 that 
can be inherited in 2 forms, created as a consequence of an ancient inversion of this 
section of DNA, known as haplotype 1 and 2 (H1 and H2) (Stefansson et al., 2005). 
Inheritance of H1 (or particular subtypes of H1 such as H1c) has been shown to increase 
the risk of developing certain neurodegenerative tauopathies, including progressive 
supranuclear palsy, corticobasal degeneration and AD, as well as possibly PD (reviewed 
by Pittman et al., (2006)). The consequences of this inversion are unknown, but it likely 
gives rise to changes in MAPT transcription levels or splicing through haplotype specific 
single-nucleotide or insertion-deletion polymorphisms (Myers et al., 2007).  
 
It is clear that changes in tau protein can play an important part in the development of 
various neurodegenerative disorders, as is evidenced by its role in a variety of different 
neurodegenerative tauopathy disorders. Moreover, tau dysfunction alone is proved to be 
sufficient to cause such disorders, as is seen with the observation that mutations in 
MAPT result in FTDP-17. With a large social and economic burden being presented by 
such diseases, it is critical to determine the exact effects of such dysfunction, their time 
course and if and where intervention would be most effective.   
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What makes tau ‘toxic’? 
 
The defining feature of all tauopathies is the presence of NFTs. For many years it was 
assumed that since NFTs were detectable, they must mediate the observed toxicity 
culminating as neurodegeneration. However, within the last decade or so, both for tau 
and other amyloidogenic proteins, such as amyloid-", it has been suggested that this is 
not the case (review for tau: Spires-Jones et al., 2011, Kopeikina et al., 2012; for 
amyloid-": Klein et al., 2001, Haass and Selkoe, 2007, Klein, 2013), possibly with the 
formation of such insoluble aggregates even acting as a protective mechanism (Alonso 
Adel et al., 2006, Gotz et al., 2008, Treusch et al., 2009) as has been described for 
huntingtin (Arrasate et al., 2004). 
 
It is now widely agreed that the major (or at least initial) harmful species of amyloid-" 
comes in the form of diffusible, soluble amyloid-" oligomers (Walsh and Selkoe, 2007) 
(although elucidating the exact toxic species of amyloid-" has not been easy (Lesne, 
2013)). The idea that tau toxicity is induced in a similar way, by undefined soluble 
species, began based on the observation that some patients with FTDP-17 display high 
tau phosphorylation, along with a large amount of neurodegeneration, while only 
showing mild NFT formation (Bird et al., 1999); conversely young cognitively healthy 
individuals had been found to display interneuronal tau lesions while appearing 
cognitively normal (Braak and Braak, 1997). More recently, SantaCruz et al., (2005) 
used a regulatable transgenic mouse model carrying a FTDP-17 related mutation 
(P301L) under the CaMKII promoter, to show that suppression of the transgene even for 
a brief period of 6-8 weeks, resulted in the recovery of memory deficits and the cessation 
of neuronal death; with longer suppression (4-4.5 months) even resulting in an increased 
brain weight. However, the most striking result was that despite this reversal of 
transgene effects, and independently of transgene expression, NFTs continued to 
accumulate, arguing that NFTs cannot be the toxic species of tau. In 2011, Fox et al., 
showed that NFT-bearing neurones are just as likely as non-NFT-bearing neurones to 
express the intermediate-early gene, Arc, following exposure to an enriched 
environment. This result implies that the presence of a pathological tau aggregate does 
not impair the ability of individual hippocampal neurones to respond to physiologically 
relevant stimuli. Reinforcing the results of SantaCruz et al., (2005), they then showed 
that following suppression of the transgene for 6 weeks, Arc expression in transgenic 
brains equalled that of control brains despite the continuous presence of NFTs. Further 
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work on this mouse model has also identified early multimeric tau species, which were 
found to correlate far better with memory loss than NFTs (Berger et al., 2007). In line 
with this work, Rocher et al., (2010) showed through electrophysiological techniques 
that, while the expression of mutated tau caused significant structural and functional 
changes in cortical neurones, this was independent of whether or not the neurones 
contained NFTs.  
 Along with the research discussed above, many more studies have linked 
soluble, rather than fibrillar forms of tau to toxic effects (Jaworski et al., 2009, Lasagna-
Reeves et al., 2011, Patterson et al., 2011); an idea also supported by work in a 
drosophila model of human tauopathy (Feuillette et al., 2010). Taken all together, it is 
highly likely that the toxic species of tau is an unspecified intermediate of single tau 
monomers and large aggregated fibrils.   
 
As well as being small low-order aggregates, the toxic species of tau is also likely to be 
hyperphosphorylated (Feuillette et al., 2010, Hoover et al., 2010, Zempel et al., 2010; 
discussed by Iqbal et al., 2009). As mentioned, hyperphosphorylation is not an indicator 
of a disease state per se, but rather hyperphosphorylation may contribute to tau toxicity 
through either: 1) initiating the missorting of tau from its physiological axonal location 
through reducing MT binding (Zempel et al., 2010), or allowing tau to by-pass a 
diffusion barrier (Li et al., 2011). This would disrupt the physiological functions of tau 
within the axon, as well result in further possibly deleterious effects, such as increasing 
the targeting of Fyn to the postsynaptic site, which may contribute to raising neuronal 
excitotoxicity (discussed below). 2) Facilitating tau misfolding (Jeganathan et al., 2008), 
perhaps enabling the formation of an aggregation nucleus, which may work to form 
soluble oligomeric species, disrupting naïve tau in addition to facilitating pathology 
propagation (also discussed below). 
Indeed, therapeutics in which tau toxicity is targeted through the development of 
kinase inhibitors or restoration of phosphatase activity are in development, and present 
potentially viable treatment options for the future (Iqbal et al., 2014).  
 
There may also be a role for truncated forms of tau in neurodegenerative disease. Tau 
contains many cleavage sites available to a host of proteases, including, calpain, 
puromycin-sensitive aminopeptidase and caspases (Mandelkow and Mandelkow, 2012). 
Of these many possible cleavage sites, one of the most studied is the caspase-mediated 
cleavage of tau at aspartic acid 421 (D421) (Gamblin et al., 2003). While it has been 
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shown that this truncated form of tau does not generally increase cell death (as was once 
thought) (de Calignon et al., 2010), it may play a role in increased cell death when cells 
are subjected to stressors (Matthews-Roberson et al., 2008), as well as promoting 
aggregation through the prevention of tau adopting its preferred ‘paperclip’ formation 
(Jeganathan et al., 2006). Other tau fragments have also been reported to have pro-
aggregation properties (Frost et al., 2009a, McMillan et al., 2011), with an apparent 
importance placed on the MTBRs in fibril formation, a property likely due to the "-
structure of the second and third MTBRs (Mandelkow and Mandelkow, 2012).  
 
The findings outlined above support the view that ‘toxic tau’ is not yet in the form of 
large aggregated NFTs, but instead exists in a yet unspecified, soluble state. They also, 
however, highlight the unknown with regards to this soluble toxic tau, be it 
hyperphosphorylated, truncated, conformationally changed, oligomeric or all of the 
above. Amplifying these uncertainties is the large variety of tauopathy disorders. How 
does one explain the heterogeneity of these disorders if a single toxic entity of tau is the 
same for all? Interestingly, recent investigations have worked to answer this question. 
These data suggest, that specific oligomeric conformations may exist that produce 
distinctive toxicity in different tauopathy disorders (Sanders et al., 2014), perhaps 
targeting specific brain areas or neuronal types. This idea of ‘strains’ of toxic tau may go 
some way to explaining the variability of this group of diseases.  
 
Assuming the toxicity of small soluble oligomers of amyloid-" or diffusible 
hyperphosphorylated tau, rather than large insoluble aggregates, allows one to imagine 
how early ‘undetectable’ toxicity might occur, and also how this toxicity may even be 
able to propagate, allowing for the progression of the disease (discussed below).  It is, 
however, conceivable that the long-term presence of NFTs within neurones will result in 
deleterious effects, even if just by presenting a physical obstruction within the neurone 
and thus contributing to dysfunction later in the disease.  
 
Alzheimer’s disease: The most prevalent tauopathy  
 
Due to the prevalence and long history of investigation, a significant amount of research 
into the role of tau dysfunction in disease has concentrated on its role in AD. In 
understanding the part that tau plays in the development of this widespread dementia, 
clues may be provided that are found to be applicable to other tauopathies.  
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While for years theories on the aetiology of AD had omitted tau, the importance of tau in 
AD now seems to be well established. This was highlighted by several studies that 
indicated tau is a vital component on the pathway to amyloid-" toxicity. An early report 
by Rapoport et al., (2002) demonstrated that neurones cultured from tau knockout (tau-/-) 
mice were resistant to amyloid-" induced degeneration. Despite the use of a high 
concentration of amyloid-" in this experiment (20#M), this led to further work on the 
role of tau in facilitating amyloid-" toxicity. Roberson and colleagues (2007) blocked 
amyloid-" induced neuronal dysfunction via a reduction in tau expression, through the 
use of transgenic mouse models. Importantly, these results were later supported by 
similar experiments (Ittner et al., 2010, Jin et al., 2011). It has even been shown that the 
robust result of amyloid-"-induced impairment of long-term potentiation (LTP) in the 
hippocampus is dependent on the presence of tau (Shipton et al., 2011). Along with 
preventing dendritic toxicity induced by amyloid-", a reduction in tau has also been 
shown to prevent amyloid-" defects in axonal transport in cultured neurones (Vossel et 
al., 2010).  
 
While it has been shown that tau is essential in mediating the effects amyloid-", several 
lines of evidence support the notion that the primary dysfunction occurring in AD 
involves amyloid-". The first piece of evidence for this is the fact that familial forms of 
AD (fAD) are the result of genetic mutations in either amyloid precursor protein (APP) 
(Goate et al., 1991) or the presenilins (1 or 2) (Schellenberg et al., 1992, Levy-Lahad et 
al., 1995). Each of these mutations results in increased levels of extracellular amyloid-"1-
42 (Scheuner et al., 1996), therefore leading to the hypothesis that mutations causing fAD 
may initiate development of the disease through increases in amyloid-" levels. 
Mutations in MAPT can cause FTDP-17, a tauopathy that does not display amyloid-" 
pathology; however, these mutations do not result in the development of AD. Similarly, 
mice expressing a tau transgene do not develop any amyloid-" pathology, whereas 
amyloid transgenic mice can display hyperphosphorylated tau, although full NFTs are 
not observed (Duyckaerts et al., 2008). More recently however, Umeda et al., (2014) 
have worked with the hypothesis that the lack of full NFT formation in amyloid-" 
transgenic models is due to the low propensity of murine tau to aggregate in vivo. They 
therefore introduced a low level (10% of endogenous) of WT human tau into a model 
expressing mutant amyloid precursor protein (APP) at near endogenous levels and saw 
an acceleration of pathology, with NFT development by 18 months of age.  
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Further work has also shown that tau pathology is aggravated by intracranial 
injection of synthetic amyloid-" (Gotz et al., 2001b), as well as amyloid-" containing 
brain extract (Bolmont et al., 2007). This is also the case in APP and tau double 
transgenic mice, where tau pathology is exacerbated but there is no effect on amyloid-" 
pathology compared to single transgenic counterparts (Lewis et al., 2001, Bolmont et al., 
2007, Terwel et al., 2008, Hurtado et al., 2010). In addition, it has been shown that in a 
triple transgenic mouse model (APPxPS1xTau), intraneuronal amyloid-" 
immunoreactivity is one of the first detectable pathological signs (Oddo et al., 2003b). 
One must be careful, however, of claims that, because amyloid-" deposition precedes tau 
deposition, this is evidence that amyloid-" acts upstream of tau (Oddo et al., 2003a). 
Indeed we see that there is certainly some controversy over which protein first appears as 
insoluble deposits (Schonheit et al., 2004, Braak and Del Tredici, 2011b, Braak et al., 
2011).  
 
The nature of the fundamental interaction between amyloid-" and tau has yet to be 
elucidated. If the cascade of events in AD begins with amyloid-", what occurs 
downstream of this, involving a crucial role for tau, and ending in widespread aggregate 
deposition and neuronal loss?  
 
Dysfunction at the synapse 
 
As mentioned, it has long been known that physiologically, tau is enriched within axons 
(Binder et al., 1985) where it plays a role in the stabilization of MTs, possibly through 
providing protection from severing proteins (Jean and Baas, 2013). Considering this 
location and function, it is reasonable that pathological tau, which has become 
hyperphosphorylated and detached from MTs, may contribute to presynaptic dysfunction 
through disrupting axonal transport (reviewed by Millecamps and Julien, 2013). More 
recent data has, however, placed tau more specifically at the synapse, with evidence 
from humans suggesting that low levels of unphosphorylated monomeric tau are present 
in both pre- and postsynaptic terminals under physiological conditions (Tai et al., 2012). 
This presynaptic localisation may be further enhanced under pathological circumstances, 
with data collected using a mouse model in which human tau carrying the P301L 
mutation was overexpressed within the entorhinal cortex (EC), indicating that 
pathologically phosphorylated tau accumulates within presynaptic boutons of the 
perforant path (PP). This accumulation was associated with enlarged presynaptic 
terminals and ultrastructural abnormalities including, enlarged synaptic vesicles, fewer 
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small synaptic vesicles, as well as the presence of vesicular-tubular structures (Harris et 
al., 2012).  
 
In addition to potentially deleterious presynaptic functions, intriguing data has also 
placed tau at the postsynaptic site. Despite the long held recognition of an association 
between tau and the Src family tyrosine kinase, Fyn (Lee et al., 1998), it wasn’t until 
2010, that work by Ittner et al., uncovered that the nature of this interaction was the tau-
dependent targeting of Fyn to the postsynaptic site, revealing a novel dendritic function 
for tau, as well as exposing an association of tau with the postsynaptic density protein 95 
(PSD-95). This finding was later corroborated by Mondragon-Rodriguez et al., (2012), 
who placed tau at the postsynaptic site under physiological conditions in rat 
hippocampal cultures, where it was found to interact with a complex containing PSD-95, 
Fyn and the N-methyl-D-aspartate glutamate receptor (NMDA-R). These studies led to 
the suggestion that tau is present in dendrites under normal conditions at very low levels, 
with its presence becoming particularly significant in disease.  The discovery of even 
low levels of tau in the dendrites of neurones under physiological conditions provided an 
interesting link in solving the puzzle of the cellular mechanisms involved in AD, 
spurring a considerable amount of research into tau and its interactions at the 
postsynaptic site.  
 Even without a physiological role for postsynaptic tau, it is possible that 
pathologically, tau may be present postsynaptically. It is well established that a rather 
early occurrence in tau pathology is its mislocalisation from the axon to the 
somatodendritic compartment, with this thought to largely result from 
hyperphosphorylation (Avila et al., 2004). One established function of tau 
phosphorylation (at least the phosphorylation of the KXGS motifs in the MTBR domains 
(Zempel et al., 2010)) is to negatively regulate its binding to MTs (Lindwall and Cole, 
1984). It is therefore possible that detachment from tubulin caused by 
hyperphosphorylation may simply lead to unbound tau diffusing down its concentration 
gradient into the somatodendritic compartment, and possibly into dendritic spines 
(Hoover et al., 2010). It is also possible that the phosphorylation of particular sites, but 
not others, promotes missorting of tau into dendritic compartments (Zempel et al., 2010). 
Indeed, pathologically phosphorylated tau has been associated with the postsynaptic 
terminal using a variety of techniques in a variety of models, including: array 
tomography in a transgenic mouse model (Kopeikina et al., 2013), green fluorescent 
protein-tagged tau transfection in dissociated rat hippocampal primary neurone cultures 
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(Hoover et al., 2010) and immunostaining of synaptic terminals from human AD patients 
(Tai et al., 2012).  
 
Unlike tau, the endogenous function of amyloid-" remained controversial for many 
years despite great interest in the protein with regards to its role in disease. Relatively 
recent research, however, has suggested that physiologically amyloid-" is involved in 
synaptic transmission, a finding that holds particular interest when looking at the 
pathological involvement of amyloid-" in AD. Abramov et al., (2009) showed, through 
use of a competitive inhibitor to the amyloid-" degrading enzyme neprilysin, that 
endogenous amyloid-" peptides positively regulate the release probability (Pr) of 
neurotransmitter, reporting no observed effect on postsynaptic function. Consistent with 
the idea that amyloid-" plays a role in regulating Pr, Cummings et al., (2015) 
demonstrated that an increase in Pr is one of the earliest changes detected in transgenic 
mice with raised amyloid-". Puzzo et al., (2011) also found that depleting endogenous 
amyloid-" prevented the induction of LTP, possibly via reducing post-tetanic 
potentiation (PTP). Amyloid-" reduction also impaired learning and memory in 
behavioural tasks. Taken together, these results suggest a presynaptic role for 
endogenous amyloid-" in regulating transmitter release, a crucial function for both basal 
synaptic operation and learning and memory. 
 
A synaptic function for both amyloid-" and tau is fitting, considering that the synapse 
provides the site for some of the earliest changes in AD (Oddo et al., 2003b, Scheff et 
al., 2006), and that it is well established that synaptic loss provides one of the best 
correlates of cognitive decline in AD (DeKosky and Scheff, 1990, Terry et al., 1991). In 
keeping with this, current opinion has gone on to suggest that the toxic interaction 
between amyloid-" and tau may occur at the synapse, as will be discussed below 
(reviewed by Ittner and Gotz, 2011 and Spires-Jones and Hyman, 2014). 
 
Toxic effects of tau at the synapse with links to amyloid-! 
 
For the synaptic localisation of tau and amyloid-" to be relevant to the field of AD, more 
than just their presence is required. They must also be shown to exert toxicity, resulting 
in either synaptic dysfunction, or the synapse loss that correlates so well with 
characteristic cognitive decline of patients (DeKosky and Scheff, 1990, Terry et al., 
1991). In the case of tau, such effects have been demonstrated by multiple studies over 
recent years through the use of transgenic mouse models of tauopathy, including spine 
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loss (Rocher et al., 2010, Crimins et al., 2012, Xu et al., 2014), or more subtle (often 
earlier) changes in synaptic function (Yoshiyama et al., 2007, Hoover et al., 2010, Dalby 
et al., 2014). The specific mechanisms by which such alterations occur, however, remain 
controversial.  
 
One of the primary synaptotoxic actions of pathological tau is thought to centre on its 
role in disruptions to MT-dependent axonal transport. In particular, disruption of 
anterograde transport via interactions with kinesin (Dubey et al., 2008, Ittner et al., 2009, 
Kanaan et al., 2011), with one of the most important cargoes in terms of toxicity thought 
to be mitochondria (discussed by Eckert et al., 2014). Due to their large elongated shape 
and high-energy demands, neurones are particularly dependent on the efficient transport 
of mitochondria throughout the cell. As well as providing vital ATP, synaptic 
mitochondria are involved in the regulation of intracellular Ca2+ concentration; functions 
essential for synaptic vesicle release and thus effective synaptic transmission (Vos et al., 
2010).  
In addition to being implicated in disruptions to mitochondrial transport, tau has 
also been associated with impairing mitochondrial function directly. Expression of 
P301L mutated tau in both neuroblastoma cell cultures (Schulz et al., 2012) and 
transgenic mice (David et al., 2005, Rhein et al., 2009) has been shown to specifically 
inhibit the activity of complex I of the electron transfer chain, with increasing age and 
pathology development in mice resulting in a significant reduction in ATP production. A 
large reduction in ATP production was also noted in the neuroblastoma cells, along with 
a reduction of mitochondrial membrane potential and increased susceptibility to 
oxidative stress. The mechanism by which this occurs, however, is still not understood 
and may indeed represent an indirect effect of tau dysfunction (Eckert et al., 2014). 
Amyloid-" oligomers have also been found to cause a range of alterations in the function 
of synaptic mitochondria (as is discussed by Pagani and Eckert, 2011). One of the most 
highlighted effects is the reduction in complex IV activity induced by amyloid-", 
observed in both isolated mitochondria from cultured neuroblastoma cells and in 
transgenic animal models of amyloid-" dysfunction (Rhein et al., 2009, Lim et al., 
2010). Interestingly, the distinct actions of tau and amyloid-" on mitochondrial function 
were shown to have synergistic effects in a triple transgenic mouse model, resulting in 
an accelerated reduction in mitochondrial membrane potential and increased reactive 
oxygen species production with age (Rhein et al., 2009).  
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Mitochondria are dynamic organelles, undergoing continual fragmentation and 
elongation through processes known as fission and fusion, respectively. This flexibility 
allows for renewal and redistribution, and is key for healthy mitochondria and thus cell 
survival (Chan, 2006). Both tau and amyloid-" have been reported to have affects on 
mitochondrial dynamics, however, possibly resulting in opposing results. It seems that 
overall, amyloid-" induces mitochondrial fragmentation possibly through reducing 
levels of the mitochondrial fusion protein, OPA1 (Wang et al., 2009). Results for tau are 
somewhat less clear, yet recent evidence suggests that tau causes mitochondrial 
elongation (DuBoff et al., 2012), resulting in possible consequences on the elimination 
of damaged mitochondria.   
 
In addition to the combined effects on mitochondrial transport and function, pathological 
tau and amyloid-" have also been linked to synaptotoxicity through interactions with 
synaptic receptors. In terms of amyloid-", numerous binding partners have been 
identified at the synapse, with the issue of which may be functionally important in AD 
still the matter of hot debate. Central, however, appears to be the direct and indirect 
actions of amyloid-" on postsynaptic glutamate receptors, with both the activation of 
processes involved in excitotoxicity and neuronal death, and the initiation of 
mechanisms involved in long-term depression (LTD) and synapse loss, being reported 
(Spires-Jones and Hyman, 2014).  A simplified overview of some of the significant and 
most highlighted interactions of amyloid-" at the synapse is given in Figure 1.2. 
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Figure 1.2. Simplified schematic of some of the cooperative actions of amyloid-! and tau at 
the synapse. Hyperphosphorylation and mislocation of tau to the somatodendritic compartment 
may affect axonal transport of essential cargoes, including mitochondria, to the presynaptic 
terminal (Dubey et al., 2008, Ittner et al., 2009, Kanaan et al., 2011). Both amyloid-" and tau 
have been shown to inflict deleterious effects on mitochondrial function (depicted here in the 
presynaptic terminal), including a role for tau in reducing activity of complex I (Rhein et al., 
2009, Schulz et al., 2012), and amyloid-" in reducing complex IV activity (Rhein et al., 2009, 
Lim et al., 2010).  
 
The actions of tau in targeting Fyn to the postsynaptic site are depicted (Ittner et al., 2010). Here 
Fyn works to phosphorylate NMDA-Rs, thus facilitating their interaction with PSD-95, 
stabilizing them within the synapse and thus increasing Ca2+ influx (Ittner et al., 2010). Tau has 
also been proposed to disrupt NMDA-R and AMPA-R trafficking and anchoring (Hoover et al., 
2010).  
Key amyloid-"-binding partners relating to glutamate receptor alterations are shown. 
While there is no evidence for the direct binding of amyloid-" to NMDA-Rs, many studies have 
demonstrated binding in close proximity, with the suggestion that the effects of amyloid-" are 
NMDA-R-dependent (De Felice et al., 2007, Decker et al., 2010). Amyloid-" has also been 
shown to alter synaptic NMDA-R expression via an interaction with !7-nicotinic acetylcholine 
receptors (!7aCh-Rs) (Snyder et al., 2005) and the NMDA-R regulatory receptor, Eph2B (Cisse 
et al., 2011). PrPc has been shown interact directly with amyloid-" (Lauren et al., 2009), 
activating Fyn via an as yet unknown intermediary (Um and Strittmatter, 2013), which in turn 
phosphorylates tau, as well as NMDA-Rs (Larson et al., 2012, Um et al., 2012). In addition to 
interactions with ionotropic glutamate receptors, the metabotropic glutamate receptor 5 
(mGluR5-R) has also been implicated in facilitating amyloid-" synaptotoxicity. Renner et al. 
(2010) showed that amyloid-" caused clustering of mGluR5-Rs by inhibiting lateral diffusion, 
increasing Ca2+ influx and neurotoxicity.  
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One interesting suggestion as to how tau brings about changes in synaptic functioning 
was alluded to above, revolving around the role of tau in mediating the targeting of Fyn 
to the postsynaptic compartment (Ittner et al., 2010). This interaction provides another 
viable route to link tau dysfunction with amyloid-", making theories regarding this 
relationship appealing. Within the postsynaptic terminal, Fyn works to phosphorylate the 
GluN2B subunit of the NMDA-R, stabilizing it through facilitating the interaction of the 
receptor with PSD-95. As disruption of this interaction prevents excitotoxic damage, it 
seems that it is via its interaction with PSD-95, that these NMDA-Rs are linked to 
excitotoxic signalling. Ittner et al., (2010) showed that in tau knock-out (tau-/-) mice, as 
well as in mice harbouring a truncated form of tau ($tau), there was reduced 
postsynaptic Fyn localization, resulting in lower NMDA-R phosphorylation, destabilized 
NMDA-R/PSD-95 interaction and therefore protection from amyloid-"-induced 
excitotoxicity. Intriguingly, in 2012, it was demonstrated that cellular prion protein 
(PrPc), which was already known to bind amyloid-" (Lauren et al., 2009), formed a 
complex with amyloid-" and Fyn (Larson et al., 2012, Um et al., 2012). This resulted in 
Fyn activation and thus the phosphorylation and stabilization of the NMDA-R at the 
postsynaptic site.  This work provided a mechanism by which amyloid-" oligomers 
could result in increased NMDA-R mediated excitotoxicity. Roberson and co-workers 
(2011) supported these findings by showing that a reduction in tau was protective against 
the detrimental synergistic actions of amyloid-" and Fyn on synaptic transmission and 
network activity. These data strengthen the idea of cooperation between amyloid-", Fyn 
and tau, possibly through tau-dependent targeting of Fyn to the postsynaptic site (Ittner 
et al., 2010). Interestingly, it has been reported that mutations in MAPT, as well as the 
phosphorylation of tau, increase its interaction with Fyn (Bhaskar et al., 2005). This 
increased association could in theory increase dendritic targeting of Fyn by tau, further 
perpetuating amyloid-" toxicity. 
 Of note, it has been demonstrated that the NMDA-R open channel blocker, 3,5-
dimethyladamantan-1-amine (memantine), preferentially blocks activation of GluN2B 
containing NMDA-Rs (Grimwood et al., 1996), and thus it is perhaps through inhibiting 
toxicity created via Fyn activation, that the drug provides beneficial effects both 
experimentally (De Felice et al., 2007) and as a symptomatic treatment for AD patients 
(Zadori et al., 2014).  
 
As depicted in Figure 1.2., the process of amyloid-" toxicity at the synapse is 
complicated, with many interrelated and seemingly conflicting mechanisms of action 
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reported. Through tau-dependent interactions with Fyn, amyloid-" is linked to increased 
excitatory activity and neuronal excitotoxicity (Roberson et al., 2011, Boehm, 2013). 
This mechanism of toxicity appears distinct from the synaptic depression and spine loss 
so often reported as a consequence of amyloid-" (as discussed by Koffie et al., 2011). In 
this vein, amyloid-" has even been linked to the activation of the striatal-enriched 
phosphatase (STEP) (Snyder et al., 2005), which actually works to inactivate Fyn. It is, 
however, feasible that these conflicting actions operate in a temporal manner, with Fyn 
activation occurring rapidly and STEP working with a delay of a few minutes (Boehm, 
2013).  
Pathological species of tau have also been linked to changes in glutamate 
receptor densities and functioning through the work of Hoover et al., (2010). This study 
suggested that one of the earliest consequences of tau hyperphosphorylation and 
mislocation from the axonal compartment is its entry into dendritic spines. They 
demonstrated that this pathological tau was able to disrupt glutamatergic synaptic 
transmission through reducing synaptic expression of NMDA and AMPA receptors, 
likely via the impairment of receptor trafficking or anchoring to the PSD.  
 
Overall, the picture of toxicity at the synapse is extremely complicated. Current evidence 
for the role of pathological tau in synaptotoxicity has focused on disruption to axonal 
transport, as well as deleterious effects on mitochondrial and glutamate receptor 
functioning; however, with the physiological role of tau at the postsynapse now exposed, 
understanding of the part played by tau in synapse dysfunction and loss is set to increase.  
 
Tau staging in AD 
 
The initial observations by Braak & Braak (1991) that tau pathology in AD patients 
follows a defined course of progression set the groundwork for some very interesting 
work investigating tau propagation in AD. They set out six ‘Braak stages’ of tau 
pathology progression, which are still widely used today. Each stage sees involvement of 
a new brain region, along with a worsening of pathology in areas already affected. Stage 
1 sees involvement of the transentorhinal cortex, particularly the Pre-! projection 
neurones; in stage 2, pathology is evident in the hippocampus, in particular the Cornu 
Ammonis area 1 (CA1) and subiculum; stage 3 sees involvement from the entorhinal 
region proper. In most cases at this point there are also some mild changes in parts of the 
limbic system. Stage 4 features a far stronger involvement of the limbic regions with 
mild involvement of the isocortex. The main feature of stage 5 is that the isocortex is 
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severely affected, with a more pronounced alteration of the subcortical nuclei. Lastly, in 
stage 6, all prior areas mentioned now display severe alterations, including considerable 
cell loss and ghost tangles. All isocortical and subcortical nuclei are now severely 
affected.  
Since this original staging, Heiko Braak has revised these ideas to possibly 
include an earlier ‘stage 0’, in which intraneuronal pretangle material can be seen in the 
lower brainstem, namely the noradrenergic neurones of the locus coeruleus, even before 
the age of 30 and with no involvement of the cerebral cortex (Braak and Del Tredici, 
2011b, a). It is, however, of note here, that in order draw the conclusion that the locus 
coeruleus presents the initial site of tau dysfunction based on data collected from pre-
symptomatic individuals, one must assume that pathologically related alterations in tau 
(such as the phosphorylation of S202 and T205, as recognised by the AT8 antibody used 
by Braak and Del Tredici) do not regress. One may argue, however, that examples of 
transient tau phosphorylation (at sites including the AT8 epitope) during hibernation 
(Arendt et al., 2003), or even anaesthesia (Planel et al., 2007), provide us with a basis to 
challenge this assumption. Also noteworthy, is that a proportion of the 38 cases 
displaying tau positive neurites and cell bodies within the locus coeruleus had suffered 
acute head trauma or viral infections prior to death. As is the case of head trauma in 
chronic traumatic encephalopathy (Ling et al., 2015), it is not impossible that these 
insults have driven the tau pathology noted, rather than the pathology representing the 
first stage of AD development.  
 
A staging scheme for the development of NFTs has also been created in a transgenic 
mouse model of tau and amyloid-" pathology. Within this model, the spatiotemporal 
pattern of NFT development appeared relatively similar to that seen in sporadic AD 
patients despite the obvious differences in the form of tau expressed, levels of expression 
and use of a non-physiological promoter. This highlights the vulnerability of specific cell 
groups, in particular the authors emphasise parallels in EC and hippocampal pathology 
(Hurtado et al., 2010).  
 
Specific vulnerability 
 
It is from this work by Braak and Braak (1991) that the pattern of tau pathology 
development through synaptically connected areas in AD was made obvious. This 
observation initiated the idea that tau pathology might spread through anatomically 
connected areas by transferring its pathological structure, in a way not dissimilar to prion 
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proteins (discussed further below). However, despite the apparent synaptic spread, the 
question of what instigates pathology/neurodegeneration in the primary cells, and why 
some neurones along the synaptic path appear more susceptible, remained. In answer to 
these questions, the differential vulnerability of neurones is often offered as an 
explanation. However, what it is that makes certain neurone types more vulnerable is 
still an area of debate.  
 
As we have seen, pretangle material has been detected in subcortical nuclei of very 
young (<30 year-old) individuals (Braak and Del Tredici, 2011b). The authors propose 
that neurones of the locus coeruleus may more easily revert to an undifferentiated state 
due to their extremely long, unmyelinated axons. They suggest this may be facilitated by 
the relative instability of unmyelinated axons compared to those displaying a high degree 
of myelination, with axonal sprouting possibly acting as a trigger for tau 
phosphorylation.  
This theory is in keeping with the more general view on what causes neuronal 
vulnerability in a variety of neurodegenerative disorders. Commonly, it is the size of 
neurones, along with the myelination and length of axons that is assumed to be 
responsible for their susceptibility (reviewed in Morrison et al., 1998 and Mattson and 
Magnus, 2006), a reasonable hypothesis due to the high-energy demands and critical 
dependence on axonal transport of these large neurones. Myelination is also known to 
reduce the amount of energy used by the neurone, as well as possibly providing trophic 
support (Nave, 2010). A lack of myelin may therefore result in a higher energy turnover 
and possible increased risk of oxidative stress, thus causing these neurones to be more 
susceptible to dysfunction and death. However, size and myelination does not account 
for all neuronal vulnerability, and thus additional factors must contribute. These may 
include: increased risk of excitotoxicity due to high numbers of AMPA and NMDA 
glutamate receptors, or low levels of calcium-binding proteins such as calbindin; 
compromised neurotrophic factor signalling; high concentrations of somatodendritic 
neurofilament; or lowered ability to deal with misfolded proteins based on proteasomal 
degradation ability (Morrison et al., 1998, Mattson and Magnus, 2006).  
In fact, the true reason for such specialised susceptibility in all 
neurodegenerative disorders remains only speculative, and likely relies on a combination 
of factors including: morphology, neurochemical and functional characteristics and 
location within neuronal networks, including the properties of surrounding cells such as 
glia.  
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Propagating tau 
 
The highly conserved pattern of NFT formation in AD led to the theory that tau may in 
some way be able propagate through the brain in a similar way to prion proteins. Ideas 
about the prion-like properties of tau have flourished within the last 5 years, and it is 
currently one of the most ‘fashionable’ ideas within the world of AD and tauopathy 
research. What is possibly most exciting is that these ideas are not solely applicable to 
tau, but reach into other neurodegenerative disorders, including !-synuclein in PD, 
which also displays a stereotypical pattern of propagation in the brain (Goedert et al., 
2010).   
 
One very interesting case report published in 1997 provides some strong and invaluable 
evidence that tau pathology is capable of spreading through the brain via anatomically 
connected areas. Duyckaerts et al., describe the unusual case of a woman with AD, who 
27 years prior had suffered the disconnection of a region of cortex from adjoining 
cortical areas and basocortical afferents following surgery to remove a tumour.  Upon 
post-mortem examination this disconnected area showed almost no tau pathology, 
despite adjacent cortical areas, as well as the contralateral cortex, displaying many 
NFTs. The disconnected area, however, did exhibit amyloid-" pathology.  
 
For tau to be able to propagate in a way similar to prion proteins, it must be able to 
confer a pathological state. Some of the first evidence for this was provided by 
Clavaguera et al., (2009), when they showed that injection of brain extract from 
transgenic mice harbouring the P301S mutation into the brains of mice transgenic for 
wild-type human tau, induced the assembly of the wild-type human tau, not only at the 
site of injection, but also at distant anatomically connected areas. In an almost 
simultaneous publication, Frost et al., (2009a) demonstrated that extracellular tau 
aggregates, made up of truncated tau (containing only MTBRs), but not monomers, were 
taken up into C17.2 cultured cells where they induced the fibrillisation of intracellular 
full-length tau. These intracellular tau fibrils were found to be capable of promoting 
further aggregation. This work has since been supported by many studies, using both 
exogenous application of tau fibrils to cultured cells (Guo and Lee, 2011, Sanders et al., 
2014), as well as intracerebral injection of synthetic tau fibrils into transgenic tau mice 
(Iba et al., 2013, Peeraer et al., 2015) to demonstrate the ability of tau fibrils to seed 
further tau aggregation. Further to this, exogenous tau has been found to prompt the co-
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aggregation of endogenous tau, showing that its pathological properties are capable of 
being transmitted to the host protein (Mocanu et al., 2008, de Calignon et al., 2010). 
 
Getting from cell to cell 
 
It is possible that the process of how a pathological form of a protein propagates through 
the cellular network is different for the various amyloidogenic proteins involved in 
different diseases, giving rise to diverse patterns of distribution. In the case of tau, it 
seems that spread occurs synaptically to anatomically connected areas. A recent 
publication by de Calignon et al., (2012) used a novel mouse model, expressing mutated 
(P301L) human tau selectively in layer II of the entorhinal cortex (ECII), to examine the 
progression of tau pathology up to 24 months. Tau misfolding was detected in the axons 
of entorhinal cortical neurones at 3 months of age; and by 6-months, misfolded tau was 
present in the soma of these neurones. From here, these neurones displayed a 
progression towards the later stages of tau pathology with the development of aggregates 
by 12-months. As predicted, tau pathology was next identified in the dentate gyrus (DG) 
of the hippocampus (the terminus of the PP, the main output of the ECII/III to the 
hippocampus), with tau aggregates present in granule cell soma by 18 months of age. 
CA1 and CA3 also showed aggregation of tau in the soma of cells by 21-months. This 
sequential development of pathology in areas that (largely) do not express the transgene, 
does indeed suggest that tau pathology spreads to downstream neurones. These data 
were corroborated by a similar study in which Lui et al., (2012) generated a comparable 
mouse model, expressing P301L mutated tau confined to the EC. Again, tau pathology 
was seen to spread from the EC to anatomically connected neurones over the lifetime of 
the mouse.  
 
It is perhaps conceivable that as tau is physiologically an axonal protein, and is linked to 
axonal transport, that it might use these systems to spread through the brain. However, 
the mechanisms underlying how this may be achieved remain unknown. Aguzzi & 
Rajendran (2009) provide an interesting review on the subject of transcellular spread, in 
which they examine how aggregates may be released from cells and then taken up into 
others. Among the most commonly suggested mechanisms for protein aggregate release 
are: that it could be part of the normal synaptic physiology; it may occur during 
degradation of the neurone, axon or synapse, or perhaps it is part of an exocytotic 
process as a means of clearance, in an attempt to avoid toxicity (Simon et al., 2012). 
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 The picture is similarly speculative with regards to the uptake of tau following its 
release (discussed in detail by Gerson and Kayed, 2013). Currently, the strongest 
evidence indicates that tau oligomers/small aggregates gain entry to neurones through an 
endocytotic process, evidenced by the observed co-localisation of internalised tau with 
the glycan, dextran (Frost et al., 2009a, Wu et al., 2013). Wu et al., extended this through 
the observations that tau internalisation was inhibited by the dynamyin inhibitor, 
Dynasore, and that tau was then observed to co-localise with the early endosomal and 
lysosomal markers, Rab5 and Lamp1, respectively. This suggests that tau is transported 
through the endosomal pathway to lysosomes where it is destined to be degraded; 
however, only a small amount would need to escape this degradation and gain access to 
the cytosol in order to work as a seeding nucleus for naïve tau aggregation.  
 
Based on existing literature, it seems feasible that small intracellular tau aggregates are 
released by cells (in exosomes) as a means of eliminating excess protein, or indeed upon 
the degradation of the neurone or axon. These low weight aggregates could then be taken 
up via pinocytosis by synaptically connected cells (as the synapse is where the cells are 
in closest contact) and transported either anterogradely or retrogradely within the cell 
(Wu et al., 2013), where they could cause naïve tau misfolding, as is discussed below.  
 
What makes tau likely to misfold and aggregate? 
 
Tau is a naturally disordered and unfolded protein, containing only a low amount of 
secondary structures throughout its length (Mandelkow and Mandelkow, 2012). It is also 
highly soluble and heat stable due to its hydrophilic nature (ibid), causing its aggregation 
to perhaps seem unlikely. However, as is evidenced from the multiple tauopathies 
discussed above, tau certainly holds the ability to aggregate, creating the NFTs 
characteristic of many neurodegenerative disorders.  
 
The key factor that may lie at the heart of tau’s tendency for aggregation, is the 
occurrence of 2 groups of 6 specific amino acids, present at the beginning of the second 
and third MTBRs (R2 and R3) (Mandelkow and Mandelkow, 2012). These domains 
exhibit a high propensity to form "-structures and therefore provide tau with the ability 
to form highly ordered cross "-sheets (Berriman et al., 2003), a property shared by many 
other amyloidogenic proteins (reviewed by Soto, 2003).  
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With the amino- and carboxy-domains of tau cleaved, the MTBR region aggregates 
readily in vitro to form filaments comparable to those observed in AD (Wille et al., 
1992, Frost et al., 2009a). In fact it has since been shown, that the truncation of tau at 
only D421 is sufficient to allow the initiation of aggregation in vivo (de Calignon et al., 
2010), suggesting that even alterations (without full removal) of the possibly ‘protective’ 
terminal domains can be enough to permit fibril formation. This spontaneous 
aggregation, however, cannot be achieved with full-length tau without the addition of 
further reagents or modifications of the protein (Frost et al., 2009a).  
Aggregate inducing reagents commonly used in vitro include polyanions, such as 
heparin, as well as free fatty acids, such as arachidonic acid. Although the exact 
mechanism by which such reagents work is incompletely understood, their action is 
believed to be based in their ability to compensate the positive charge in the middle 
section of the tau protein, thus reducing the repulsion between tau molecules, and 
facilitating aggregation (Chirita et al., 2003, Mukrasch et al., 2007).  Due to their low 
concentration within the brain, it is unlikely these reagents work in vivo, although similar 
acidic co-factors within neurones are possible.  
 Even though tau is a disordered protein, recombinant tau has been shown to 
have an affinity for an overall suprastructure when in solution, in which the ends of the 
tau protein fold inwards towards the centre, creating a paperclip-like structure 
(Jeganathan et al., 2006). A hypothesis proposed by Iqbal et al., (2009), suggests that the 
amino- and carboxy-domains act to protect tau from self-aggregating. When they 
become phosphorylated however, they unfold, exposing the "-structures of R2 and R3, 
allowing aggregation. There is, however, evidence to contradict this mechanism. 
Jeganathan et al., (2008) demonstrated that rather than opening the ‘paperclip’ structure, 
in vitro pseudo-phosphorylation (specifically of the AD-associated AT8, AT100 and 
PHF-1 epitopes) worked to further compact this configuration. The contraction was 
associated with an increase in MC1 reactivity, an antibody recognising a ‘pathological 
conformation’ of tau occurring early on in disease development (Weaver et al., 2000). 
Consequently, it may be through the compaction and stabilization of tau’s folded global 
structure that hyperphosphorylation promotes aggregation, possibly through exposing 
the "-structure motifs, although exactly how this may occur is unknown.  
The inclusion of FTDP-17 mutations increases the susceptibility of tau to 
become hyperphosphorylated (Alonso Adel et al., 2004), and this may in turn be the path 
by which mutations such as P301L increase the tendency of tau to form "-sheets and 
consequently aggregate. Certain FTDP-17 mutations also act to increase the ratio of 
 44 
4R:3R tau (Goedert and Jakes, 2005), thus possibly increasing the propensity to 
aggregate by simply increasing the amount of susceptible "-structure regions present in 
the tau molecule. It is also possible, that the physical effect of a mutation such as P301L 
directly facilitates the ability of tau to form a "-sheet structure (von Bergen et al., 2001).  
 
Despite aggregation-enabling modifications of tau, nucleation still requires a high 
enough local concentration of the exposed R2 and R3 domains to overcome the entropy 
opposing the formation of ordered fibres (Eisenberg and Jucker, 2012).  A large increase 
in tau concentration has been noted in AD brains previously (Khatoon et al., 1992), as 
well as possibly providing a major contributing factor in many animal models of 
tauopathy, where exogenous tau is highly overexpressed (Lewis et al., 2000, SantaCruz 
et al., 2005).  
 
Misfolded tau can ‘seed’ the misfolding of naïve tau 
 
All of these elements help tau to overcome the nucleation barrier and form an 
aggregation nucleus. This may then be used to ‘seed’ further aggregation of naïve 
intracellular soluble tau, and as described above, propagate this from cell to cell.  
  
The ability of tau to seed further tau aggregation is certainly well established, 
demonstrated through a variety of experiments using both cell systems (Frost et al., 
2009a, Guo and Lee, 2011, Kfoury et al., 2012, Sanders et al., 2014) and animal models 
(Clavaguera et al., 2009, de Calignon et al., 2012, Liu et al., 2012, Iba et al., 2013, 
Peeraer et al., 2015). How exactly this seeding is achieved is another question, which has 
begun to be addressed by the Diamond laboratory through a series of key experiments.                                                                                        
 Initially, the group demonstrated that a distinct fibril conformation formed using 
recombinant tau protein harbouring FTDP-17 related mutations, was able to be 
transmitted to WT tau protein. This conformation was different to that adopted by WT 
protein when induced to aggregate through incubation with arachidonic acid alone (Frost 
et al., 2009b). This study suggested that the conformational change in the protein that 
leads to aggregation is transmitted via templating. In order to confirm a direct protein-
protein interaction between the aggregate seed and unfolded protein, Kfoury et al., 
(2012) then used Fluorescence Resonance Energy Transfer (FRET) to reveal that the tau 
protein of the donor cells and corresponding tau of recipient cells were indeed in direct 
contact. More recently, Sanders et al., (2014) have extended the idea of tau aggregates 
existing and propagating as distinct strains. They established 2 individual tau aggregate 
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species based on multiple tests including morphological, biochemical and toxicity 
analysis. These strains were also found to harbour different seeding efficiencies, and 
using both non-neuronal cell and in vivo models the group were able to demonstrate 
robust inheritance of each species. This study corroborated the earlier work presented, 
providing further evidence that tau aggregates work to seed fibrillisation via a template 
induction mechanism which works through direct protein-protein interaction.   
 
With regards to seeding, however, is it only tau that is able to induce tau aggregation 
(homotypic seeding), or are other amyloidogenic proteins containing similar amyloid-
forming segments also able to promote the aggregation of tau (heterotypic seeding)? 
 
Seeding by other amyloidogenic proteins 
 
The seeding of tau pathology by other amyloidogenic proteins is a very interesting 
concept. While some studies suggest that heterotypic seeding does not occur (Frost et al., 
2009a, Sanders et al., 2014), others have provided evidence that under certain 
circumstances, other proteins are indeed able to instigate the aggregation of tau. 
 
The most compelling evidence has been demonstrated using !-synuclein to seed tau 
aggregation. In 2013, Guo et al., showed that a particular !-synuclein fibril strain was 
able to promote tau aggregation both in vitro and in vivo. The fibrillar aggregates of !-
synuclein and tau were found to be closely associated with one another intracellularly, 
supportive of the mechanism of physical templating described above. In vivo, the 
injection of these !-synuclein preformed fibrils resulted not only in tau pathology at the 
site of injection, but also in distant, anatomically connected areas, indicating that these 
heterotypic seeded tau aggregates were able to propagate.  
 This study provided conformation of earlier work performed in vitro, in which !-
synuclein preformed fibrils were seen to promote the aggregation of tau in non-neuronal 
cells (Waxman and Giasson, 2011), as well as a study that demonstrated synergistic 
fibril promotion between !-synuclein and tau (Giasson et al., 2003).  
 
While !-synuclein aggregates do occur alongside tau and amyloid-" pathology in a 
proportion of AD cases, as well as NFTs and plaques commonly existing in PD 
(reviewed in Galpern and Lang, 2006), the co-occurrence of these pathologies is not 
assured.  Of course, in AD however, plaques and tangles always occur in parallel. 
Following the ‘amyloid hypothesis’ as well as evidence presented above, it does indeed 
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seem that in AD amyloid-" initiates disease progression. One may therefore consider the 
tempting theory that small amyloid-" aggregates may seed the fibrillisation of tau.  
 
Amyloid-" has been shown to exacerbate tau pathology using a variety of protocols, 
from intracranial injection of amyloid-" (Gotz et al., 2001b, Bolmont et al., 2007), to 
cross breeding of amyloid-" and tau transgenic mice (Lewis et al., 2001, Bolmont et al., 
2007, Terwel et al., 2008, Hurtado et al., 2010). While these studies confirm a role for 
amyloid-" in intensifying or even initiating tau pathology, they do not establish amyloid-
" as capable of seeding tau fibrillisation. In fact, on the contrary, evidence has suggested 
that amyloid-" is not capable of directly seeding tau aggregation (Giasson et al., 2003, 
Sanders et al., 2014). The reason why some proteins such as !-synuclein appear to be 
capable of seeding tau, while others such as amyloid-" are not, however, remains 
unclear.  
 
Existing mouse models of tauopathy 
 
Much of the research discussed within this introduction was dependent on the 
development and use of transgenic animal models. In particular transgenic mice, which 
since their development during the early 1980s, have provided an invaluable tool for 
research into the aetiology, mechanisms and possible therapy of countless human 
diseases. The success of mice as disease models is a result of the relative ease with 
which they can be genetically modified, their sufficient genetic and neuroanatomical 
similarity to humans, as well as their size and short life-span, which makes them 
relatively inexpensive and time efficient with regards to pathology development and 
breeding.  
 
The development of tauopathy mouse models began in 1995, with a transgenic model 
expressing the longest isoform of human tau protein, under the human Thy-1 promoter 
(Gotz et al., 1995). This transgenic tau was seen to mislocate to the somatodendritic 
compartment of neurones, as well as show phosphorylation at AD relevant sites, 
although it did not form NFTs. Following this study, further mouse models were 
developed, each overexpressing different WT isoforms of tau under a variety of 
promoters, with differing pathological results (a table of transgenic tau strains is given in 
Gotz and Ittner, 2008).  
 It was only after the identification of the first FTDP-17 genetic mutations 
(Hutton et al., 1998), however, that transgenic models of tauopathy surged. In 2000, 
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Lewis et al., published the first transgenic mouse model presenting prompt NFT 
formation, using a tau transgene harbouring the P301L mutation. Subsequently many 
more lines have been established, carrying different FTDP-17 mutations under several 
promoters (Gotz and Ittner, 2008). Of particular interest is the more recent development 
of a line expressing human tau carrying the P301L mutation, which can be supressed 
following doxycycline administration due to the inclusion of a Tet-Off system within the 
transgene (rTg4510) (SantaCruz et al., 2005). This model has enabled many key findings 
since its creation, including the observation reported within the original description: that 
following transgene suppression and the reversal of memory deficits and cell loss 
cessation, NFTs continued to accumulate. This finding provided one of the first 
indications that NFTs are not sufficient to cause cognitive decline or neuronal 
degeneration.  
 
 
In 2012, the progressive nature of research using transgenic animals was demonstrated 
when two groups simultaneously developed mouse lines expressing transgenic P301L 
tau confined within the EC (primarily layer II of the medial EC). This was achieved 
through crossbreeding rTg4510 mice with a line expressing a tetracycline transactivator 
under the control of the neuropsin promoter (de Calignon et al., 2012, Liu et al., 2012). 
Advanced transgenic models such as these provide a novel way in which to answer more 
specific questions related to the mechanism of a disease; in this case, resolving questions 
on the propagation of tau.  
 
In contrast to animals engineered to overexpress particular tau constructs, tau-/- models 
have also provided insight into the role of tau in disease. The first tau-/- mouse was 
created by Harada et al., (1994) by inserting a neomycin resistance cassette into exon 1 
of the tau gene. Surprisingly, these mice displayed a relatively mild phenotype, with the 
role of tau seemingly compensated by another MT-associated protein within large 
calibre axons. Some smaller calibre axons however, did show disruption to MT 
organisation and stability, with a later study revealing some muscle weakness and 
behavioural changes (Ikegami et al., 2000). This seeming lack of overt pathology argued 
that tau was not in fact essential to axon development nor did it seem to critically effect 
normal neuronal functioning. Subsequent to this, two further tau-/- models were 
developed using similar methods (Dawson et al., 2001, Tucker et al., 2001), which have 
been utilised in critical experiments for AD, exposing the dependence of amyloid-" 
effects on tau (Rapoport et al., 2002, Roberson et al., 2007, Shipton et al., 2011).  
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Another significant line of experiments arising from the creation of tau-/- models, was the 
role that endogenous murine tau plays in the development of pathology resulting from 
the insertion of human tau transgenes. This line of study was initiated by the work of 
Andorfer et al., (2003), who discovered that the removal of endogenous tau facilitated 
the development of pathology produced by the overexpression of WT human tau. The 
pathology development in the absence of murine tau appeared to be the consequence of 
an altered tau isoform ratio, with 3R tau expressed at a higher-level then 4R tau in these 
animals. This situation is abnormal in mice, which physiologically express only 4R 
isoforms during adulthood (Liu and Gotz, 2013), and thus it seemed that altering the 
isoform ratio in mice was sufficient to result in pathology, as is the case in certain 
tauopathies (Goedert and Jakes, 2005). A lack of isoform ratio alteration may then be 
used to explain the absence of pathology in a model expressing only the longest 4R2N 
human tau isoform on a murine tau null background (Terwel et al., 2005). In contrast, 
this reasoning does not clarify the apparent exacerbating effect of endogenous tau 
removal in mice overexpressing the 4R1N human isoform carrying the G272V and 
P301S mutations (Ando et al., 2011). It is hypothesised by Ando et al., that the 
aggravated pathology in this line may be due to a lack of interference from WT murine 
tau. Human and murine tau are heterogeneous at their amino-terminals, possibly causing 
murine tau to harbour a lower tendency to aggregate due to it being less prone to 
phosphorylation, less negatively charged or less likely to adopt a pathological 
conformation. This finding is an important consideration for the study of tau pathology 
initiation in models still expressing endogenous murine tau.  
 
The disadvantages of mouse models of tauopathy 
 
As we have seen, the variety of mouse models available for tauopathy research is already 
sizable, and has given us the ability to make great advances in understanding of the role 
of tau in disease. The potential for more sophisticated models is even greater, providing 
the opportunity to answer specific questions, such as the mechanisms of tau propagation, 
in a way previously impossible. However, critical to our progression, is a better 
understanding of exactly what questions can be asked of a mouse model, a point which 
will be discussed further following consideration of the drawbacks of mouse models of 
tauopathy. 
 
The first criticism often offered revolves around the fact that the majority of tau models 
are based on genetic mutations that cause the relatively rare familial FTDP-17, when 
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many tauopathies (including all AD cases) are not the result of mutations in the MAPT 
gene. Of course, disease development requires an initiating factor and as has been 
touched upon, certain mouse models have indeed attempted to instigate the disease 
process simply through the overexpression of a single human WT 4R isoform (Gotz and 
Ittner, 2008) in the hope of modelling certain tauopathies that see a shift towards 4R tau 
(Goedert and Jakes, 2005). More recently an interesting mouse model has been 
established, which carries AD-related genetic mutations at endogenous levels, in the 
presence of all human tau isoforms on a murine tau null background (Guo et al., 2013b). 
This model provides a more physiologically relevant line for the study of AD, where 
amyloid-" can provide the initiating element for tau dysfunction. Disappointingly, 
however, such models show a relative lack of tau pathology, with no NFTs observed, 
likely due either to the amount of time needed to develop pathology, or to inherent 
differences between mice and humans. 
 Neurodegenerative diseases develop over decades in humans, while mice 
provide only a 2-2.5 year window in which to replicate the full disease. We know that 
NFTs can form extremely quickly within mice (<24 hours) (de Calignon et al., 2010), 
and thus rather than the actual formation of aggregates, it is the slow initiation of this 
process which may take time beyond the bounds of the life span of a mouse. This 
unavoidable issue may provide one explanation as to why tau pathology is difficult to 
obtain without the high overexpression of mutated human tau accelerating the process. 
The other possibility is that factors critical to pathology development are different in 
mice, such as differences in misfolded protein degradation or even variations in the 
immune response. These aspects may modify the processes leading to disease, in effect 
making mice more resistant to disease development through the more common, 
‘physiologically-relevant’ routes. 
 
Inherent differences between mice and humans may be further exaggerated by the 
frequent use of inbred background strains, such as the C57Bl/6 line. While these 
genetically uniform strains do provide significant benefits in facilitating reproducibility, 
use of such inbred lines does mean that we are looking for pathological changes in a 
homogeneous population that aim to be relevant in the highly heterogeneous group of 
human patients. To overcome this problem, robust pathological changes should be 
identified in multiple animal models in order to increase reliability. For this we need a 
variety of models, which is why the development of different animal models is still 
important. In the tauopathy field, the rTg4510 mouse line has dominated research since 
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its development. The mouse I present in this thesis provides a complementary model to 
accompany the rTg4510. It harbours the same mutation under the same promoter, but is 
on a different background line, expressing a different level of tau compared to 
endogenous protein. To test a therapeutic treatment (such as tau immunotherapy) in both 
of these models would provide a better grounding for further clinical work than the use 
of only one of these models.   
 
What should we aim to gain from mouse models? 
 
Transgenic mouse models have been undeniably useful thus far in furthering our 
understanding of many diseases, however, it is also important to recognise their 
drawbacks and design experiments moulded to their benefits. In terms of tau, two main 
questions must be answered: 1) what is the defining moment of pathological tau 
generation? Here, models in which pathology develops slowly (such as that created by 
Andorfer et al., (2003), which expresses WT human tau on a murine tau null 
background) provide a larger window, and possibly more physiological relevance for 
functional studies into the consequences of tau phosphorylation, mislocation and 
oligomer formation; 2) how does pathological tau cause neurodegeneration? For this 
question, a later stage model is required, and thus overexpressing models that show 
significant neurodegeneration are suitable. Also important for AD is dissection of the 
interaction between amyloid-" and tau. While the model created by Guo et al., (2013b) 
did not show NFT pathology or neurodegeneration, it still provides a useful model for 
early interactions between the 2 proteins. Electrophysiological experiments may be 
suited here, in an attempt to uncover subtle changes in synaptic transmission, with 
comparisons drawn between the tau expressing and tau-/- models.  
 
The hippocampus  
 
The hippocampal formation (or hippocampus) describes a unique neuronal network 
consisting of various subregions, found relatively conserved within mammals. It 
includes the EC, DG, hippocampus proper (CA1, CA2 and CA3), subiculum, 
presubiculum and parasubiculum, and is found in humans sitting deep within the medial 
temporal lobe of the brain. From here it forms widespread connections to other brain 
regions via outputs through the EC and fimbria. Within the hippocampus lies the famous 
excitatory trisynaptic loop, a relatively simple, largely unidirectional circuitry that 
connects the subregions of the formation.  This, along with the organised distribution of 
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many of its inputs has made the hippocampus the most common site for studies into 
synaptic plasticity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A schematic of the intrinsic hippocampal connections is seen in Figure 1.3. This 
somewhat simplified view serves to show the unique organisation of the hippocampus, 
as well as providing some basis for later reference.  The circuit begins in the EC, where, 
from cortical layer II, the medial (mPP) and lateral (lPP) perforant paths project to the 
DG and CA3 regions (van Groen et al., 2003). A direct connection is also made between 
layer III of the EC and the CA1 and CA3 regions (ibid). The principle cells of the DG, 
known as granule cells, project to the large pyramidal cells of CA3 through what are 
termed mossy fibres (MF). Two branches of axons then extend from the CA3 region; 
one leaves the hippocampus via the fimbria, while the other is sent through CA2 to the 
pyramidal cells of CA1, as the Schaffer collateral (SC) pathway. These fibres are 
correctly termed the Schaffer commissural-collateral pathway as they include 
commissural projections from the contralateral CA3 region, however, for the purpose of 
Figure 1.3. Simplified schematic of the hippocampal network. The network is principally 
unidirectional. Input from the entorhinal cortex connects to the dentate gyrus and CA3 regions via the 
medial and lateral perforant paths (mPP and lPP, respectively). CA3 cells receive input from the 
dentate gyrus via mossy fibres (MF). CA3 then connects to CA1 via the Schaffer collateral-
commisural (SC) pathway, as well as forming collateral connections with other CA3 neurones. CA1 
also receives direct input via the perforant path from layer III of the entorhinal cortex. CA1 neurones 
provide input to the subiculum, which in turn forms the main output of the hippocampus to the deep 
layers of the entorhinal cortex.  
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the present study we shall simply refer to the SC pathway. CA3 neurones are also highly 
connected to each other, by way of CA3-CA3 collateral connections. Finally, the CA1 
region projects to an area known as the subiculum, with both the CA1 and subiculum 
projecting back to the EC (deep layers) forming the main output of the hippocampus. 
 
The hippocampus and neurodegenerative tauopathies 
 
As we have seen, NFT pathology follows a highly conserved topographical and 
hierarchical pattern of development in AD, with the hippocampus providing one of 
earliest brain regions to be affected (Braak and Braak, 1991). This characteristic pattern 
of tau pathology advancement is paralleled by (and often exceeded by (Gomez-Isla et al., 
1996, Gomez-Isla et al., 1997)) neuronal loss. Not only does the hippocampus suffer a 
considerable loss of neurones (particularly the CA1 region (West et al., 1994)), but it is 
also one of first and most quickly progressing areas of degeneration early in the disease 
(Scahill et al., 2002), with reductions in volume likely reflecting not only the loss of 
neurones, but also neuropil, including synapses. The selective distribution of NFT 
pathology and neuronal loss is compatible with the temporal development of cognitive 
symptoms in AD.  The hippocampus is believed to play a major role in the consolidation 
and retrieval of new declarative memories, in particular episodic memories (that is 
memories of experienced events), an idea first prompted by the discovery that lesions to 
the hippocampus in human patients severely impaired memories formed following the 
lesion (Scoville and Milner, 1957). It is defects in this type of memory that is so 
characteristic of the initial symptoms of AD, and it is likely due to isolation and 
degeneration of medial temporal lobe structures including the hippocampus. 
 
For FTDP-17, the pattern of NFT development and neurone loss is less well defined due 
to the rarity of cases and large heterogeneity of clinical and neuropathological features. 
Typical to the disease is substantial atrophy of the frontal and temporal lobes; however, 
tau pathology within the hippocampus has been described, including from cases 
possessing the P301L mutation (Spillantini et al., 1998, Mirra et al., 1999).  
In addition to human tauopathies, the rTg4510 murine model harbouring human 
tau carrying the P301L mutation under the CaMKII promoter displays particular 
vulnerability of hippocampal neurones (Spires et al., 2006). Combined, these 
demonstrations of vulnerability led us to select hippocampus as the site of the initial 
characterisation presented within this thesis. 
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Studying the function of the hippocampus 
 
The hippocampus and behaviour 
 
The role of the hippocampus in learning and memory was largely determined through 
observing behavioural deficits caused by selective lesions to this brain region. Through 
the use of this technique, numerous studies in various species have confirmed the 
importance of the hippocampus, and adjacent EC, in the memory and processing of 
spatial information (for example, a review of these data in rats is given by Jarrard, 1993). 
This function relies on the work of specialised neurones residing in the hippocampus and 
surrounding regions, which have been identified over the years using 
electrophysiological techniques. These cell types include: the place cells of the 
hippocampus and medial EC (O'Keefe and Dostrovsky, 1971, O'Keefe, 1979); head 
direction cells of the dorsal presubiculum (and other brain regions) (Taube et al., 1990, 
Taube, 2007); grid cells of the medial EC, pre- and parasubiculum (Hafting et al., 2005, 
Boccara et al., 2010); as well as the boarder cells of the medial EC (Solstad et al., 2008).  
Together, these neurones work to encode a representation of external space and the 
animals’ position within it.  
 In addition to the processing of spatial information, damage to the hippocampus 
and surrounding regions has also been observed to cause deficits in declarative memory, 
as was demonstrated by the well-known case of patient H.M. following surgery to 
correct for severe epilepsy (Scoville and Milner, 1957). Recently, Buzsaki and Moser 
(2013) have put forward an interesting theory linking the hippocampal/EC-dependent 
coding of spatial information, with both semantic and episodic memory in humans. They 
suggest that the more sophisticated mechanisms of memory in humans have evolved 
from navigations systems, with both based on the same fundamental network. The 
authors propose that the roots of semantic memory (memory of general facts 
independent of temporal context) lie in allocentric navigation (navigation of space using 
distal cues), while the origins of episodic memory (memory of autobiographical events 
that occurred at a particular time and place) lie in egocentric navigation (navigation 
using internally-generated cues).  
 
In order to test hippocampal function in rodents, various different tests incorporating 
spatial memory assessment have been developed. These include a variety of different 
mazes in which the animal must remember a particular location (such as the location of 
the platform in the Morris water maze (Morris, 1981)), as well as mazes in which the 
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animal must remember which location it has previously visited and alter its response 
accordingly (such as the T-maze or Y-maze).  
Due to the sensitivity of the T-maze forced alternation task to hippocampal 
dysfunction (Dudchenko, 2001), this test was chosen to examine the function of the 
hippocampus within the present study. This ‘working memory’ version of the T-maze 
has also been reported to show high sensitivity to the phenotype of a mouse model of 
amyloid-" dysfunction (Tg2576) (Stewart et al., 2011) despite its relative simplicity, 
further fuelling our decision to use this protocol to assess the effects of tau transgene 
expression within the hippocampus  
 
The hippocampus and electrophysiology 
 
The unique structure of the hippocampus lends itself particularly to electrophysiological 
study, due to its largely unidirectional circuitry and densely packed cell layers. As is 
described in Appendix 1, the tight lamina structure of the cell layers facilitates 
extracellular field recording due to the simultaneous synaptic stimulation of the 
postsynaptic neurones creating a current ‘sink’ large enough to be recorded. This current 
sink is recorded as the postsynaptic response, and can be stably recorded for long periods 
of time in various different tissue preparations. This ability to record for a long time 
from a population of cells led to the discovery of LTP (Bliss and Gardner-Medwin, 
1973, Bliss and Lømo, 1973), a phenomenon currently considered the best cellular 
model of learning and memory.  
 LTP recordings within the hippocampus are now commonly used to assess the 
capacity for learning and memory in models of dementia, performed both in vivo and in 
vitro.  From these studies using a variety of different preparations it has often been 
reported that amyloid-" oligomers inhibit LTP (Haass and Selkoe, 2007). In terms of 
LTP and tau dysfunction, the majority of studies have focused on the SC-CA1 synapse, 
where a reduction in LTP has been reported in ‘pro-aggregant’ tau transgenic mice 
(Sydow et al., 2011), in P301S transgenic mice recorded in vivo (Yoshiyama et al., 
2007), in rTg4510 transgenic mice harbouring the P301L mutation (Hoover et al., 2010), 
as well as under certain induction conditions in aged mice expressing human WT tau 
(Polydoro et al., 2009).  
In addition to extracellular field recordings, electrophysiology allows the 
identification of more subtle changes in synaptic transmission through the use of patch 
clamp experiments of single neurones within a network. Overall, few studies have 
employed patch clamp techniques to examine the effect of tau dysfunction on single 
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neuronal properties, basal synaptic transmission and evoked activity, however, those 
studies performed have concentrated within the hippocampus and cortex (Hoover et al., 
2010, Crimins et al., 2012).  
 
Conclusion 
 
The role of tau in neurodegenerative disease is well established, with it seeing 
involvement in rare forms of dementia including, FTDP-17, progressive supranuclear 
palsy, Pick’s disease, and corticobasal degeneration; as well as the most prevalent 
dementia, AD. Dissection of the aetiology of these diseases continues to rely heavily on 
the use of mouse models, which provide a way to model aspects of these disorders in a 
mammalian system. However, in order to further our understanding and test novel 
treatments for tauopathy disorders, additional complementary models are required to 
provide the variation necessary to establish effective therapies for the heterogeneous 
human population. 
  
Herein I describe the first characterisation of a novel mouse model of tauopathy. Using 
molecular biology techniques, I provide characterisation at the genetic and protein level 
in TauD35 mice, providing confirmation of the functionality of the transgene. This work 
is complemented by histological techniques, which allow investigation of age-dependent 
development of tau pathology and neuronal loss within these mice.  
Considerable evidence has so far pointed towards the synapse being the site of 
the initial dysfunction occurring in AD (Oddo et al., 2003b; Scheff et al., 2006). It 
therefore follows that I undertake electrophysiological characterisation of synaptic 
transmission in these mice at ages corresponding to histological data. Behavioural tests 
were also used to provide some insight into hippocampal-dependent memory as well as 
locomotor activity and anxiety.  
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CHAPTER 2 
 
 
Materials and Methods 
 
All experiments were conducted according to UK Home office regulations under the 
Animals (Scientific Procedures) Act 1986 and in agreement with the GlaxoSmithKline 
statement on the use of animals, as well as UCL local ethical guidelines.  
 
Mouse Model 
 
Transgenic TauD35 mice were generated by GlaxoSmithKline (Harlow, UK) on the 
background mouse line C57Bl/6J (Charles River, UK) via pronuclear injection. The 
mice harbour human tau cDNA for the 0N4R isoform carrying the P301L mutation 
under the alpha isoform of the Ca2+/ calmodulin dependent protein kinase II (CaMKII!) 
promoter. The present study represents the first characterisation of this novel mouse 
model. Non-transgenic littermates were used as wild-type (WT) controls. All mice used 
in the present study were male. Following weaning at 21 days of age, environmental 
enrichment of the mice began. Mice were group-housed at GSK in cages (20x35x45cm) 
with a maximum of 8 mice, with 12h light /12h dark cycle and ad libitum access to food 
and water. Environmental enrichment consisted of the placement of novel objects within 
the cage, including running wheels and plastic tubes, along with different forms of 
housing and bedding, which were changed once a week. Food location was also 
regularly changed. At approximately 3 months of age the mice were transported to 
University College London Biological Services Unit, where their enrichment was 
continued. Tails samples from all mice were collected post-mortem for re-genotyping 
using standard PCR protocols, as well as transgene copy number determination using 
TaqMan® qPCR.  
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Molecular Biology 
 
Conventional PCR 
 
Genotype confirmation was performed at UCL by Rivka Steinberg, using conventional 
PCR methods 
 
Briefly, genomic DNA was extracted using the ‘HotSHOT’ lysis method. Alkaline lysis 
reagent (25 mM NaOH, 0.2 mM EDTA, pH 12) was added to tissue samples prior to 
heating to 95°C for 30 minutes. The sample was then cooled to 4°C before the addition 
of neutralisation buffer (40 mM Tris-HCl, pH 5). The PCR reaction was performed 
through addition of MyTaq™ DNA Polymerase (Bioline) reaction buffer and primer 
pair: 5’-AAGACCAAGAGGGTGACACGG-3’, 5’-CCCGTCTTTGCTTTTACTGACC-
3’, using the cycling parameters: 94°C (2 mins), 58°C (30 secs), 72°C (4 mins) and 30 
second extension time, for 30 cycles. 
 
TaqMan® qPCR 
 
Copy number confirmation was performed by Stuart Martin, Head of Molecular Biology 
Unit, UCL  
 
Genomic DNA was extracted using the ‘HotSHOT’ lysis method described above. 
Unique TaqMan® primer and probe sequences were generated using Applied Biosystems 
custom design sequence using the published sequence for the CaMKII! promoter 
sequence (Accession# AJ222796). The qPCR assay was run with 4#l of genomic DNA 
per well, with each sample run in triplicate to reduce error, using the published protocol: 
Applied Biosystems TaqMan® copy number assays protocol, p21-25. 
 
Brain tissue extraction 
 
Brains were collected from WT, LOWTAU and HIGHTAU (where available) mice, at 4, 13 
and 24 months old. Brains were extracted on ice, hemisected, and dissected into 
cerebellum, cortex and hippocampus (<5 minutes) before being snap frozen on dry ice 
and stored at -80°C.  
 58 
Protein extraction 
 
Mouse hippocampal samples were sonicated (Branson Sonifier, 450) for 30 seconds at 9-
12W in RIPA buffer (1% [v/v] Triton X-100, 1% [w/v] sodium deoxycholate, 0.1% 
[w/v] SDS, 0.15M NaCl, 20mM Tris-HCl (pH 7.4), 2mM EDTA (pH 8.0), 50mM NaF, 
40mM "-glycerophosphate, 1mM EGTA (pH 8.0), 2mM sodium orthovanadate, protease 
inhibitor tablet (Roche), aprotinin and phosphatase inhibitor cocktail 1 and 2 (1:100; 
Sigma), 1mM PMSF: approximately 1ml for 100mg tissue).  
 
For total extract protein, homogenates were spun at 17,950g for 10 minutes at 4°C and 
the supernatant collected. Sample buffer (312.5mM Tris (pH 6.8), 10% [w/v] SDS, 
250mM DTT, 50% [v/v] glycerol, 0.025% [w/v] bromophenol blue) was added prior to 
boiling the samples at 95°C for 10 minutes and storing at -20°C. 
 
Sarkosyl-insoluble tau extracts were obtained as described previously (SantaCruz et al., 
2005) (Figure 2.1.) 90#l of homogenate was ultracentrifuged at 150,000g for 15 minutes 
at 4°C. The supernatant (S1) was removed for storage and the pellet re-homogenised in 4 
volumes of 10mM Tris (pH 7.4), 0.8M NaCl, 1mM EGTA, 10% sucrose, 1mM PMSF 
and ultracentrifuged as above. The resulting pellet was discarded and the supernatant 
incubated with 1% sarkosyl (30% sarkosyl NL30, BDH) for 1hr at 37°C, prior to 
ultracentrifugation at 150,000g for 30 minutes at 4°C. The supernatant was again 
collected for storage (S2) and the pellet re-suspended in 20#l 10mM Tris (pH 8) and 
1mM EDTA and labelled P3: sarkosyl insoluble tau. Sample buffer (312.5mM Tris (pH 
6.8), 10% [w/v] SDS, 250mM DTT, 50% [v/v] glycerol, 0.025% [w/v] bromophenol 
blue) was added to all fractions prior to boiling the samples at 95°C for 10 minutes and 
storing at -20°C. 
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Western blot analysis 
 
Protein corrected (Bradford assay) samples were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using 8-10% polyacrylamide gels. 
Molecular weights were verified using a molecular weight standard (BioRad, #161-
0374). Proteins were transferred to a nitrocellulose membrane (0.45#m, BioRad) using 
electroblotting (30V, overnight). Following transfer, membranes were washed in Tris-
buffered saline (TBS), prior to blocking against non-specific antibody binding in 5% 
milk/TSB for 1 hour at room temperature. Membranes were incubated in primary 
antibody (at the appropriate concentration, see below) in 5% milk/TBS overnight at 4°C. 
Following overnight incubation, membranes were washed in 0.05% Tween-20/TBS for 
five changes of 7 minutes each at room temperature, and then for 10 minutes in 5% 
milk/TSB. Horseradish peroxidase-conjugated goat anti-mouse (1:10,000; Jackson 
ImmunoResearch, #115-035-146) incubation was performed in 5% milk/TSB for 1 hour 
at room temperature. Membranes were washed again for five changes of 7 minutes in 
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Figure 2.1.  Schematic 
representation of procedures 
employed to gain total extract 
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tau fractions. P3 extraction 
procedure is as previously 
described (SantaCruz et al., 
2005). 
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0.05% Tween-20/TBS at room temperature, before a final wash of 5 minutes in TBS. 
Peroxidase activity was revealed using an enhanced chemiluminescence detection kit 
(ECL, Amersham). Image acquisition and densitometric analysis was performed using 
ImageLab (v4.1, BioRad) as described (Taylor et al., 2013).  
 
Density values for bands of interest were normalized against heat shock protein 9 
(HspA9, GRP75 (N52A/42) Cambridge Biosciences, #MMS-5164-100), or for sarkosyl-
insoluble extract, total protein per lane was detected using Amido Black (Sigma 
Aldrich).  
 
Antibodies 
 
 
Table 2.1. Primary tau antibodies used for Western blot analysis: 
Antibody (mouse monoclonal) Dilution Supplier (Catalogue #) 
HT7 Tau 159-163, human tau 1:5000 Pierce Antibodies (MN1000) 
DA9 Tau 102-140, total tau 1:5000 Gift from Peter Davies 
CP13 pS202 1:1000 Gift from Peter Davies 
PHF1 pS396/pS404 1:1000 Gift from Peter Davies 
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Histology 
 
Mice  
 
Three primary ages of mice were used for histological study (age in months (average age 
in months±SEM, sample number)): 4 (4.2±0.1, n=8), 13 (13.0±0, n=7) and 24 (23.9±0.3, 
n=7). For cell counts an additional time point was included at 17.5-months-old (17.7 ± 
0.37, n=4).  
 
Transcardial Perfusion  
 
All mice used for histological study were transcardially perfused unless otherwise stated.  
 
Animals were deeply anaesthetised via intraperitoneal injection of pentobarbital with 
local anaesthetic (1:10 Euthatal:Intra-Epicaine, National Veterinary Supplies). Once a 
surgical plane of anaesthesia was reached (established via toe pinch) the mice were 
transcardially perfused with Phosphate Buffer Saline (PBS) (0.1M, pH 7.2-7.4) followed 
by 10% Buffered Formal Saline (Pioneer Research Chemicals Ltd). The brains were 
removed and post-fixed in 10% buffered formal saline for ~24hrs, before being 
transferred to PBS/sodium azide (0.03%) for storage at 4°C.  
 
Slicing 
 
Prior to sectioning, brains were cryoprotected in sucrose solution (30% sucrose, 0.03% 
sodium azide, PBS 0.1M, pH 7.2-7.4) for ~24hrs.  Transverse hippocampal sections 
were cut at 30#m from the left hemisphere using a frozen sledge microtome (SM 2000 
R, Leica). In order to study NFT formation throughout the whole hippocampus, each 
hemisphere was sliced entirely and collected into a 24-well plate containing PBS/sodium 
azide (0.03%) for storage at 4°C. Of a total of ~6 transverse sections per well, 3-4 were 
found to contain complete and usable hippocampal sections. This provided sufficient 
separation of each hippocampal section (740#m), removing the risk of double counts.  
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Antibodies 
 
Table 2.2 Primary antibodies used for immunohistochemistry: 
Antibody (mouse monoclonal).  
Colour indicates the emission wavelength of the 
fluorophore-conjugated secondary antibody used to 
visualise each primary antibody listed. 
Dilution Supplier (Catalogue #) 
HT7 Tau 159-163, human tau 1:500 Pierce Antibodies (MN1000) 
AT8 
pS202/pT205 
1:300 Pierce Antibodies (MN1020) 
Early indicator of pathological tau 
(Su et al., 1994)  
CP13 
pS202 
1:200 Gift from Peter Davies 
Early indicator of pathological tau 
(Su et al., 1994) 
MC1 
Tau 7-9 and 326-330, 
conformational change.  1:200 Gift from Peter Davies 
Early indicator of pathological tau 
(Weaver et al., 2000) 
PHF1 
pS396/pS404 
1:200 Gift from Peter Davies 
Late indicator of pathological tau 
(Su et al., 1994) 
Iba1 
C-terminus of Iba1 
1:500 Wako (019-19741) Iba1 is a calcium-binding protein 
specific to microglia (Imai et al., 
1996) 
 
Immunohistochemistry (IHC) 
 
Standard IHC techniques were employed: sections were washed in PBS followed by 
PBS-Triton (0.3% Triton X-100 in PBS) before application of blocking solution (8% 
horse serum, PBS-Triton) for 1h. Incubation with primary antibody in blocking solution 
was performed overnight at 4°C. Sections were again washed with PBS-Triton. The 
appropriate secondary antibody (1:500 streptividin-AlexaFlour488 (Molecular Probes) 
or 1:500 goat anti-mouse-AlexaFlour594 (Invitrogen)) was added to blocking solution 
for 2h incubation at room temperature in the dark. Following PBS wash, DAPI 
(1:10,000) was applied to all sections for 5 minutes. Sections were washed for a final 
time in PBS before mounting. Age-matched sections from WT controls were stained in 
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parallel for all ages. Sections were mounted in anatomical order onto SuperFrost® Plus 
glass slides (VWR International) by floating on PBS/water. Fluoromount G 
(SouthernBiotech) mounting medium was added before applying the coverslip.  
 
Nissl Stain  
 
Sections were mounted as above and left to dry overnight prior to staining. For staining, 
sections were dipped in dH20 before being submerged in 1% w/v cresyl violet (Alfa 
Aesar, Massachusetts) for ~ 2 minutes and blotted to remove excess. Sections were de-
stained in 70% ethanol containing 1% glacial acetic acid for <1 minute. Sections were 
dried by submersion in 100% ethanol for ~ 2 minutes, prior to submersion in xylene (~3 
minutes) to remove H20 completely. DPX mounting medium (Sigma) was added before 
applying the coverslip.  
 
Imaging and data analysis 
 
Sections were imaged for quantification using an EVOS® FL Auto Cell Imaging System 
(Life technologies). For immunohistochemistry and Nissl staining, tile images were 
taken of the whole (transverse) hippocampus using a 20X objective. For 
immunohistochemistry and cell counts an area of 400#m x 240#m was defined in the 
CA1, CA3 and the inner blade of the DG. Due to high density Nissl staining in the DG, 
cell counts could not be reliably obtained for this area. Cell counts were preformed using 
Adobe Photoshop CS6. For NFT counts within the DG, only cells within the DG granule 
cell layer were included. NFT counts for double labelled sections (AT8/HT7) included 
only cells positive for both antibodies. Cell counts using Nissl staining included all 
principle cells within the defined area, with cells identified by their morphology. Where 
NFTs/cells could not be individually distinguished, but stain was present, a count of 1 
was awarded. NFT and cell counts are therefore an underestimate of true number. 
Sample sizes (n) given for immunohistochemistry and cell counts indicate the number of 
animals used to calculate means. A minimum of 3 sections were used to create a mean 
for each animal. All statistical analyses were performed using Microsoft Excel and 
PRISM v6 (Graphpad Software, Inc). Representative confocal images were taken using a 
laser scanning confocal microscope (Zeiss LSM 510) with a 60X Plan-Apochromat oil 
immersion objective (1.4 numerical aperture).  
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Behaviour 
 
Housing 
 
Prior to beginning behavioural testing, mice were single housed (in cages 30 x 19 x 
17cm) to allow for food consumption to be monitored during diet restriction. Mice were 
kept on a 12h light /12h dark cycle, with ad libitum access to water. A level of 
environmental enrichment was maintained, with the placement of one form of housing 
and a toy (for example, a plastic tube or wooden block) in each cage. Housing, bedding 
and toys were changed weekly. Free feeding weight was recorded for each mouse for 5 
days. The target weight for each mouse was set as 90% of the average of their free 
feeding weight. During this free feeding time mice were introduced to the food reward 
(Nestlé Carnation condensed milk) and handled each day to reduce anxiety during 
testing. Mice on a restricted diet were weighed, monitored and fed daily.  
 
For all behavioural tests, mice were transferred to the test room within their home cage. 
Transfer between the home cage and test apparatus was achieved using a single 
cardboard tube to which the mice were accustomed.  
 
T-Maze forced alternation task 
 
The protocol used for testing within the T-maze was adapted from that previously 
reported for use on mice (Cacucci et al., 2008). The maze was constructed from 3 clear 
Perspex arms (50 x 8 x 10cm), with the 2 goal arms positioned at 90° angles from the 
start arm, with a black floor. Black wooden blocks were used to block start and goal 
arms. A food reward (Nestlé Carnation condensed milk) was placed in a small cup at the 
end of each goal arm. The maze was placed on a table in a room displaying distal visual 
cues. Lighting in the test room was kept dimmed. The maze was cleaned with 70% 
ethanol between each run and each mouse to reduce odour cues. 
 
All mice were habituated to the maze for 4 days, during which time they were placed in 
the maze for 5 minutes, with all arms open for exploration. During the first 2 days drops 
of food reward were placed on the floor as well as the food cups to promote exploration. 
During the last 2 days of habituation, food was restricted to the food wells at the end of 
each arm.  
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The mice were then trained at the task for a total of 3 weeks (5 days a week). For the 
first 2 weeks training was performed once a day. During this time each mouse ran 6 
trials a day, consisting of one sample and one choice run. For the third week, training 
was performed twice a day. For the sample run, the mouse was held in the ‘start’ arm 
with a wooden block preventing entry into one of the goal arms. The start block was then 
raised and the mouse was free to enter the unblocked goal arm to receive its food reward. 
After consuming the reward (20s maximum consumption time), the mouse was then 
placed back into the start arm. Now both goal arms were unblocked. When the start 
block was raised again, the mouse was free to choose which arm to enter. On this choice 
run, only the arm which had been previously blocked contained the food reward. The 
choice made by the mouse was considered correct if the arm not previously visited was 
chosen. Response times were recorded for all runs. The mouse was then placed back into 
its home cage until its next trial.  
 
The goal arms were pseudoramdomly altered, as to which was open on the sample run. 
Each was presented three times out of the 6 trials for each mouse, with no more than 2 
consecutive trials with the same sample location. If the incorrect arm was chosen during 
the choice run, the mouse was confined to that arm for 20 seconds and then returned to 
its home cage. During this training period the choice run immediately followed the 
sample run, with a maximum delay of 30 seconds for cleaning and resetting the maze.  
 
Following this training period, delays were introduced between the sample and choice 
runs. Delay times of 1, 3, 6 and 10 minutes were chosen, during which time the mouse 
was placed back in its home cage. During the fourth week delays of 1, 3 and 6 minutes 
were performed, with delays of 1 and 10 minutes performed the following week. The 
first day of each week began with a day of trials with no delays. Delays of 1, 3 and 6 
minutes were performed over 4 days, with each mouse receiving 2 trials of each delay 
pseudorandomly alternated per day. Delays of 1 and 10 minutes were performed over a 
2-day period. 10-minute delays were pseudoranomly interspersed with 1-minute delays 
to reduce the possibility of the mice becoming unmotivated to perform the task.  
 
Data were averaged across 2-day blocks. Response times for sample and choice runs 
were plotted for all mice. Statistical analyses were performed using Microsoft Excel and 
PRISM v6 (Graphpad Software, Inc). 
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Locomotor and anxiety testing: Open Field  
 
The open field consisted of a circular arena (diameter: 47.5cm), with a white floor and 
walls (36cm high). Lighting in the test room was kept dimmed. Behaviour in the open 
field was recorded using a camera (dacQUSB, Axona, St. Albans, UK) at a sample rate 
of 4 frame/sec, positioned directly above the arena. Mice were placed in the centre of the 
arena and allowed to freely explore for the test time of 15 minutes. The arena was 
cleaned using 70% ethanol after each test.  
 
Mice were tracked within a defined area of interest (optical division of equal areas 
consisting of the central circle vs. peripheral ring) using Image Pro (v7.0). Analysis of 
data was completed using custom functions created using R statistical programming 
(v2.14.1). Data are presented in 5-minute time bins to allow for the evaluation of the 
change in behaviour over time. Statistical analyses were performed using Microsoft 
Excel and PRISM v6 (Graphpad Software, Inc). 
 
Light/Dark Box 
 
The test apparatus consisted of a smaller dark ‘safe’ compartment (20 x 20 x 30cm), and 
a larger light ‘aversive’ compartment (30 x 30 x 30cm). Lighting in the test room was 
bright. Behaviour in the test box was viewed by way of a camera, positioned directly 
above the test box, linked to a computer screen, which was viewed from a position not 
visible to the mice. The test lasted 6 minutes. Mice were placed in the light compartment 
and the parameters of interest recorded in real time. The test box was cleaned with 70% 
ethanol after each test. Statistical analyses were performed using Microsoft Excel and 
PRISM v6 (Graphpad Software, Inc). 
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Electrophysiology 
 
Acute brain slice preparation 
 
Mice were killed by decapitation. The brain was quickly removed (<1 minute) while 
being submerged in ice-cold ‘dissection’ artificial cerebrospinal fluid (dACSF) 
containing: 125mM NaCl, 2.5mM KCl, 1.25mM NaH2PO4, 26mM NaHCO3, 25mM 
glucose, 0.5mM CaCl2 and 3mM MgCl2, 310-320mOsm/kg, pH 7.4. Following this rapid 
removal, the brain was placed into a beaker containing ice-cold dACSF for 
approximately 2 minutes before being dissected. Dissection first involved the removal of 
the cerebellum; following this the brain was hemisected and a dorsal segment removed 
from the brain at an angle of approximately 105° from the midline surface (Edwards et 
al., 1989). The two hemispheres were glued (Henkel Loctite Adhesives, Ltd) onto a 
slicing stage containing ice-cold dACSF. Transverse hippocampal slices of 400µm were 
cut using an Integra-slice 7550 vibratome (Campden Instruments Ltd, Leicestershire 
UK) fitted with a ceramic blade, and placed into an incubation chamber containing 
dACSF for approximately 5 minutes. Slices were heated to 37°C and then transferred 
through 2 incubation chambers (37°C) containing ACSF as above, except with 
increasing CaCl2 and decreasing MgCl2 concentration (0.5mM/1mM, 1mM/1mM 
respectively) for approximately 5 minutes each. The final incubation chamber contained 
standard ACSF (as above except with 2mM CaCl2 and 1mM MgCl2). This final 
incubation chamber was initially heated to 37°C, once all slices had been placed into the 
chamber it was left to cool to room temperature (22-25°C). Slices were left to recover in 
this final chamber for at least 40 minutes before use. The reduction in temperature aimed 
to slow deterioration of the health of the cells. The incubation ACSF was continuously 
bubbled with 95% O2/ 5% CO2 (Carbogen, BOC Medical). 
 
Whole-cell patch clamping and data acquisition  
 
For recording, slices were placed into a submersion-style recording chamber at room 
temperature (22-25°C) where they were perfused continuously with oxygenated standard 
ACSF. Micropipettes were pulled from borosilicate glass: 1.5mm outer diameter, 
0.86mm inner diameter (Harvard Apparatus, Kent UK) to a resistance of 4-6M%. 
Pipettes were filled with a CsCl-based internal solution composed of: 140mM CsCl, 
2mM CaCl2, 5mM HEPES, 10mM EGTA, and 2mM Mg-ATP, pH 7.2-7.3, 280-
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290mOsm/kg. Principle cells were identified by their location and distinctive soma. 
Whole-cell patch clamp recordings were carried out using an Axopatch 1D patch clamp 
amplifier (Molecular Devices Inc, Berkshire UK); holding potential -70mV; x10 gain.  
Access resistance (<50M%) was assessed repeatedly throughout the recording 
through injection of a voltage test-pulse (+5mV, duration 40ms), no difference was 
observed between WT and TauD35 mice (data not shown). All signals were filtered at 
10kHz (low pass Bessel filter; Axopatch 1D patch-clamp amplifier; Molecular Devices 
Inc, Berkshire UK) and subsequently at 2kHz (low pass Bessel filter; Brownlee 
Precision 440) prior to digitization (10kHz, Digidata 1322A; Molecular Devices, Inc). 
Spontaneous and miniature synaptic currents were acquired using Strathclyde 
Electrophysiology Data Recorder (WinEDR v3.2.6), while evoked postsynaptic currents 
were acquired using Strathclyde Whole Cell Analysis Program (WinWCP v4.3.2) 
(University of Strathclyde, Electrophysiology Software). 
 
Spontaneous and miniature excitatory postsynaptic currents 
 
In order to isolate excitatory currents, cells were voltage clamped at -70mV in the 
presence of SR95531 (6#M, GABAzine, Abcam; a gamma-aminobutyric acid type A 
(GABAA) receptor antagonist). To isolate miniature excitatory currents, tetrodotoxin 
(1#M, TTX, Abcam; a voltage-gated sodium channel blocker), was applied in addition 
to SR95531. Appropriate concentration stock solutions were prepared in distilled water 
and stored in aliquots at -20°C. Final concentrations were prepared in ACSF as needed 
and were washed into the chamber for a period of 5 minutes prior to recording. Length 
of the recording time varied between 20 and 50 minutes depending on the frequency of 
events (a minimum of 30 excitatory events were recorded).  
 
Evoked excitatory postsynaptic currents 
 
Evoked (e) EPSCs were recorded in the presence of 6#M SR95531, from both the 
dentate gyrus (DG), via stimulation to the medial perforant path (mPP), and from CA1 
via stimulation to the Schaffer collateral (SC) pathway.   
DG granule cells or CA1 pyramidal cells were patched using the whole-cell 
configuration described above. A glass microelectrode filled with ACSF was placed in 
either the mPP or the SC pathway to evoke presynaptic action potentials using a square 
pulse constant-voltage stimulator (Digitimer Ltd. Constant voltage isolated stimulator. 
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Model DS2A - Mk.II). The stimulus intensity used was determined via visual assessment 
of the size of response when deemed large enough for accurate analysis. Intensities 
ranged from 0.1 to 25V (pulse duration 100µs). For paired-pulse ratios two stimuli were 
applied at 25, 50, 100, 200, 400, 800 and 1500ms intervals. Each pair of stimuli 
constituted one sweep. 10 sweeps were recorded for each inter-pulse interval. Paired-
pulse ratios were calculated as the amplitude eEPSC2/eEPSC1.  
 
For AMPA-R desensitization experiments, cyclothiazide (CTZ) (Tocris) was used at a 
concentration of 100#M. Evoked EPSCs were recorded as above, however, only inter-
pulse intervals of 25 and 50ms were applied. A 20-minute washout period was used for 
washout experiments. 
 
Extracellular field recordings 
 
Recordings were made using an AxoClamp-2B amplifier and acquired using an ITC-16 
digitizer, Instrutech (NY, USA) and WinWCP v4.3.2. Both recording and stimulating 
microelectrodes (1-2M&) were filled with ACSF, and placed in the stratum radiatum of 
CA1. Schaffer collaterals were stimulated using a Grass SD9 stimulator (RI, USA), with 
a stimulus duration of 100#s. For several recordings, the fibre volley could not be 
analysed as it was indiscernible from the stimulus artefact. For these experiments, the 
AMPA-R antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 20#M), was 
applied following experiment completion in order to confirm the response quantified 
was indeed synaptic. The stimulation strength was set to that which evoked 30-50% of 
the maximal field excitatory postsynaptic potential (fEPSP), as determined through use 
of input-output recording. The maximum response was defined as the initiation of a 
population spike or plateau in fEPSP amplitude. Paired-pulse profile recordings were 
then made using inter-pulse intervals of 25, 50, 100, 200 and 400ms. Prior to LTP 
induction, fEPSP slopes were monitored for a minimum of 15 minutes to ensure stable 
synaptic transmission. Two high-frequency stimulus train protocols were used to elicit 
LTP in different experiments. The first, described as ‘weak tetanus’ consisted of 20 
pulses at 100Hz, repeated 3 times at 1.5s intervals. The second, ‘strong tetanus’ 
consisted of 100 pulses at 100Hz, repeated 5 times at 1.5s intervals. Following 
application of the tetanus, fEPSPs were recorded for a further 60 minutes. All fEPSP 
data were obtained using paired stimuli with an inter-pulse interval of 50ms (excluding 
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paired-pulse profile recordings during which the inter-pulse interval was varied) and 
with a 10 sec delay between each sweep.  
 
D-AP5 (Abcam) was used at a concentration of 25#M. Following input-output and 
paired-pulse profile recordings, a 10-minute period of stable fEPSP slopes was 
established. D-AP5 was then infused for a period of 10 minutes. As before, fEPSP slopes 
were monitored to ensure stability for a minimum of 15 minutes before LTP induction. 
D-AP5 washout began 15 minutes after high frequency stimulation.   
 
In order to confirm a synaptic response, for a subset of experiments the AMPA-R 
antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (Abcam), was applied at a 
concentration of 20#M following experiment completion.  
 
Data analyses 
 
All data analyses were performed by the experimenter blinded to genotype. Spontaneous 
and miniature synaptic currents were analysed using WinEDR v3.2.6 and WinWCP 
v4.3.2. The detection thresholds were set such that the recorded signal had to remain 
above 3 pA for 2 ms in order to be detected as a current. In all conditions, dead time was 
set at 20 ms and running mean period at 10 ms. All signals were inspected by eye with 
the criterion that the rise time must be less than the decay time. Rise times were 
measured 20 to 80% of the maximum amplitude and decay times were fitted with a 
single exponential curve to generate the time constant tau (!) (time to reach 1-1/e of the 
asymptote). To obtain an average amplitude and decay time constant value per 
recording, the number of averaged digitized points was set at 10. 
 
Evoked currents were analysed using WinWCP v4.3.2. A minimum of 10 sweeps were 
recorded for all inter-pulse intervals. Sweeps were then averaged to create an average 
trace for each interval and the amplitude (taken as the mean of 10 digitized points) of 
each response was measured. eEPSC2/eEPSC1 was used to determine the paired-pulse 
ratio for each inter-pulse interval.  
Field potentials were also analysed using WinWCP v4.5. Sweeps were averaged 
in blocks of 6, giving an averaged field potential for 1 minute of recording time. For 
input-output and paired-pulse recordings, 6 sweeps were recorded and averaged for each 
stimulus intensity or inter-pulse interval, respectively. Averaged field potential slopes 
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were analysed using a linear fit to the initial portion (10-50%) of the slope (Figure 2.2.). 
Sweeps recorded for 15 minutes prior to LTP induction were taken as the baseline, with 
all following records taken as a percentage of the mean of these baseline recordings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Statistics 
 
Results are expressed as means ± S.E.M. If a data point differed more than two standard 
deviations from the mean for any one of the measured parameters, all parameters for that 
cell were excluded from statistical analysis. In the case of amplitude distributions, the 
data would not be expected to fit a Gaussian curve. Therefore the median amplitude was 
taken for all data sets. As the medians would be expected to be normally distributed 
across animals within each condition, the means of the median amplitude were then used 
for parametric analysis. The sample sizes (n) given throughout the text refer to the 
number of animals used to calculate means; the total number of cells is indicated in 
parentheses. No more than one cell was ever recorded from the same slice. Differences 
between group means were assessed with unpaired two-tailed t-tests (assuming equal 
variances). Analysis of variance (ANOVA) was used to compare multiple parameters. 
Differences were considered significant if p<0.05. All statistical analyses were 
performed using Microsoft Excel, PRISM v6 (Graphpad Software, Inc).  
Population spike 
Fibre volley 
Stimulus artefact 
fEPSP peak 
Linear fit between 10 and 50% of 
rising phase (between red 
markers) 
Figure 2.2. Representative averaged fEPSP traces indicating the stimulus artefact, fibre volley, 
synaptic fEPSP and population spike. A linear slope was fitted to the initial (10-50%) portion of the 
slope as a measure proportional to response amplitude as indicated (dashed red line). Scale: 0.2mV, 
10ms. 
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CHAPTER 3 
 
Introduction: Molecular biology 
 
One of the key factors believed to contribute to the development of pathological tau 
species present in neurodegenerative tauopathies, is the extensive addition of phosphate 
groups to the protein, known as hyperphosphorylation (reviewed in Iqbal et al., 2009). 
This is thought to be one of the key factors in instigating a cascade of events, initially 
leading to the formation of small soluble tau oligomers and culminating in the 
emergence of NFTs and cell death (ibid.). Thus, the detection of these features is 
imperative for a model of tauopathy. 
  
For the novel TauD35 mouse model to be usable, insertion of the human tau transgene 
containing the P301L mutation must be functional, in that it retains the ability to be 
transcribed and translated into protein. In order for this protein then to provide a 
fundamental characteristic of neurodegenerative tauopathies, it must undergo 
hyperphosphorylation, which in time renders it insoluble, resulting in the presence of 
aggregated forms of tau protein. These elements were primarily tested using molecular 
biology techniques, with the characterisation presented within this chapter forming the 
basis for further work with this mouse model. In understanding the genetics and protein 
expression levels, we are able to provide grounding for further investigation and a basis 
for explaining any differences observed compared to WT mice. It also allows the model 
to be placed in the context of published literature on existing transgenic mouse lines.  
 
Through the use of qPCR and Western blot techniques, this chapter provides insight into 
transgene concentration, its consequence on protein expression, and the development of 
phosphorylated and aggregated tau species across 4-, 13- and 24-month-old mice.  
 
Development of the TauD35 mouse model at GlaxoSmithKline 
 
The TauD35 mouse line was developed at the Platform Technology Sciences unit, GSK 
(Stevenage, UK) in order to study the effects of the overexpression of human tau 
containing the P301L mutation. This proline to leucine missense mutation at position 
301 lies within exon 10 (2nd MTBR) of the tau gene, and is one of the most common 
mutations resulting in FTDP-17 (Wszolek et al., 2006).  
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The model was created on the C57Bl/6J background line, via conventional pronuclear 
injection techniques. The transgene construct contains the 0N4R isoform of tau 
encompassing the P301L mutation, under the CaMKII! promoter (Figure 3.1.A)). 
CaMKII! is expressed postnatally in mice, with expression beginning at birth (Parsley et 
al., 2007). Dramatic increases are evident by day 8, by which time expression within all 
hippocampal subregions (as well as the rest of the brain) appears comparable to that 
observed in adult mice (ibid). Such expression removes transgene effects on embryo 
development. CaMKII! is also largely ‘forebrain-specific’ (Figure 3.1.B)), and thus use 
of its promoter avoids motor deficits caused by transgenic tau expression within the 
spinal cord, as is seen in other tauopathy models (Lewis et al., 2000, Terwel et al., 2005).  
 
All mice were genotyped using conventional PCR methods on ear tissue samples prior to 
shipping to the Biological Services Unit, UCL, at 3 months of age. Tail samples were 
collected from all mice post-mortem for re-genotyping and TaqMan® qPCR analysis.  
 
Pathological phenotype present in a subset of transgenic mice between 17 and 20 
months of age 
 
While at UCL, it became apparent that a proportion of the TauD35 transgenic mice 
within the colony developed a moribund phenotype between 17-20 months of age. Of 
the 28 transgenic mice maintained until this age, 8 were seen to develop this pathological 
phenotype. This manifested in piloerection, sunken eyes, hunched posture, decreased 
grooming and difficulties in movement initiation (akinesia) with reduced ambulation. 
A) 
B) 
Figure 3.1.  The CaMKII" promoter 
restricts transgene expression to the 
forebrain. A) Schematic representation of the 
transgene construct harboured by the TauD35 
mice line. The 0N4R isoform of tau, containing 
the P301L mutation within exon 10 lies 
downstream of the CaMKII! promoter. 
MTBRs are represented in orange. B) 
Transverse section from a 24-month-old 
LOWTAU transgenic mouse stained using the 
human specific antibody, HT7. Note the 
presence of pathological human tau in forebrain 
regions. Scale: 1000#m 
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Mice approaching this age were therefore put under close observation and used prior to 
any discomfort or euthanized following veterinary advice. 
 
Similar pathological phenotypes have previously been described for mice harbouring 
transgenic tau containing the P301L mutation. For mice expressing transgenic tau under 
the control of the murine prion protein promoter, motor dysfunction has been attributed 
to spinal cord pathology (Lewis et al., 2000). However, some impairment has been noted 
in mice where expression is under the control of the CaMKII! promoter, excluding 
expression from the cerebellum, brain stem and spinal cord (Ramsden et al., 2005). Here 
dysfunction including decreased ambulation, hunched posture and hind-limb dysfunction 
were attributed to a loss of higher motor input, supported by observations of pathological 
changes in the dorsal corticospinal tracts.  
With transgenic tau expression also confined to the forebrain in TauD35 mice, it is 
possible common dysfunctions such as the hunched posture and reduced ambulation are 
due to degeneration of populations of cortical neurones, resulting in a loss of higher 
motor input. Indeed, gross neurodegeneration and an enlargement of ventricles was 
observed in the TauD35 mice presenting with this moribund phenotype (Figure 4.1., 
Chapter 4 and Figure 7.2., Chapter 7), however, degeneration of neuronal populations 
outside of the hippocampus were not quantified in the present study. Investigations into 
possible spinal and/or muscular pathology, and conformation of degeneration in 
descending motor pathways would be required to comment further.  
 
Genetic characterisation 
 
Primary validation of the TauD35 mouse line at the Platform Technology Sciences unit, 
GSK (Stevenage, UK) consisted of conventional PCR, and protein expression analysis in 
the form of Western blotting and immunohistochemistry. These techniques provide 
information on the stability of the transgene (in detecting possible ‘drop-out’) and the 
levels of protein expressed (indicating possible transgene silencing or copy number 
differences), respectively.  
 
Production of a transgenic mouse model via classical pronuclear injections techniques 
continues to be favoured method since its development in the early 1980s (Ittner and 
Gotz, 2007). However, the nature of the technique means that the transgene is inserted 
randomly into the genome. Expression is therefore subject to the position of integration, 
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as well as the unpredictability of the number of transgene copies inserted, due to DNA 
integrating as concatemers. In some cases, the transgene can insert into more than one 
site within the genome, an event that cannot be detected using conventional PCR 
methods. During subsequent breeding, it is possible for these integration sites to 
segregate, creating variation in the transgene copy number harboured by offspring. 
Genetic recombination events during meiosis may also result in alterations to the 
transgene copy number inherited by offspring.  
 
Following inconsistences observed during pilot studies conducted at the GSK 
Neurosciences Therapeutic Area (Shanghai, China), along with the observation that only 
a proportion of TauD35 mice developed a pathological phenotype in old age, I was 
prompted to further examine the transgene properties of this novel mouse line. In 
collaboration with Stuart Martin, we were able to design a qPCR experiment using 
uniquely designed TaqMan® primers/probe for the CaMKII! promoter sequence in order 
to investigate the transgene copy number. Transgene copy number was determined using 
crude DNA extracts from ear clip tissue samples, or tail tissue samples collected post-
mortem. 
 
Protein characterisation  
 
In order to understand the level of tau protein expression in the TauD35 mice across a 
range of ages, I employed the use of the Western blotting. Developed by Towbin et al., 
(1979), Western blotting has become a common technique for the detection and 
quantification of proteins within a complex sample. The technique works by separating 
proteins based on molecular weight using gel electrophoresis, the proteins can then be 
transferred to a membrane for detection using appropriate antibodies.  
 
Monomeric human tau protein separated using Western blot is characteristically 
observed as a ‘smeared’ triplet of bands, migrating between ~55 and 75kDa. The six 
different isoforms of tau migrate with slightly different molecular weights due to the 
inclusion or omission of exons 2, 3 and 10. Heterogeneous phosphorylation of each of 
these isoforms results in small increases in molecular weight due to the addition of 
phosphate groups, and these factors combine to create the characteristic smear (Buee et 
al., 2000). Upon de-phosphorylation, these isoforms are seen to migrate with reduced 
molecular weights of between ~45 and 65kDa. In this state, the isoforms can be 
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distinguished and correspond to recombinant tau weights (Goedert et al., 1992, Hanger 
et al., 2002).  
 Adult mice express only three of the six isoforms of tau found in humans (Liu 
and Gotz, 2013). These include only the 4R isoforms, migrating with de-phosphorylated 
weights of: ~50kDa (0N4R), ~58kDa (1N4R) and ~65kDa (2N4R) (Buee et al., 2000). 
The transgene construct harboured by the TauD35 mice consists of only the 0N4R 
isoform, and thus this is additive to the murine isoform present. Large variations in the 
degree of phosphorylation of the overexpressed mutant human isoform, possibly due to 
it providing a more amenable substrate for kinases (Alonso Adel et al., 2004), is thought 
to result in its smeared appearance, spanning 50-60kDa, as has often been observed with 
mouse models harbouring the same human isoform (Sahara et al., 2002, SantaCruz et al., 
2005, Berger et al., 2007, Sahara et al., 2013, Petry et al., 2014).   
 
Results: Molecular Biology 
 
TauD35 transgene copy number 
 
Identification of two separate TauD35 transgenic lines determined using TaqMan® 
qPCR 
 
In order to ascertain the number of transgene copies harboured by TauD35 animals, 
qPCR techniques were employed. Due to the insufficient length of conserved human and 
murine tau sequence, transgene copy number could be determined solely through the 
development of a probe to the CaMKII! promoter. Assuming murine homozygosity of 
CaMKII! (and therefore an endogenous gene copy number of two), results gathered 
from transgenic animals were analysed relative to WT copy numbers. Initial results 
revealed that the copy number of the tau transgene in TauD35 mice was high (with an 
estimated minimum of 5 copies), but more importantly, there were two clear groups 
within the transgenic line, one displaying almost double the number of transgene copies 
of the other. The 2 lines present were appointed HIGHTAU and LOWTAU respectively.  
Analysis of this kind only allowed us an idea of transgene copy number, relative 
to WT controls run alongside each set of samples; however, the indication of 2 
transgenic groups prompted more in-depth research.  
 
Transgene copy number is not necessarily correlated to mRNA or protein expression in 
conventional transgenesis, and therefore determining mRNA or protein expression levels 
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provides the only definitive answer as to whether differences in gene copy numbers 
result in an expression effect. In this case, where only copy number of the promoter had 
been determined, conformation of the functionality of the extra gene dose proved even 
more important. In order to investigate whether transgene copy number differences were 
translated to differences in human tau protein levels between HIGHTAU and LOWTAU 
mice, Western blot techniques were employed.  
 
HIGHTAU mice develop pathological phenotype by 17-20 months of age 
 
In order to determine why only a proportion of TauD35 mice develop the pathological 
phenotype described previously, mice displaying this characteristic phenotype were 
investigated with regards to transgene copy number. All tissue samples available from 
these mice were tested. The results showed that all mice belonging to this group were of 
the high copy number mouse line (HIGHTAU). Due to this, HIGHTAU mice were not 
available above 20 months of age for experimentation.  
 
Western Blot Validation 
 
Western blot analysis was performed using total extract hippocampal homogenate, 
except where indicated. All tau antibodies used detected their anticipated tau species, 
migrating between 50 and 70kDa, in WT, LOWTAU and HIGHTAU mice. The smeared 
appearance of the tau species between 50 and 60kDa in transgenic mice is in keeping 
with previous literature, in which a 0N4R tau construct containing the P301L mutation is 
harboured by different mouse models (Sahara et al., 2002, SantaCruz et al., 2005, Berger 
et al., 2007, Sahara et al., 2013, Petry et al., 2014).  
 
Confirming the existence of two transgenic lines:  
Different levels of human tau protein in the hippocampus of LOWTAU vs. HIGHTAU mice 
 
The human-specific antibody, HT7, was used to assess whether tau protein levels reflect 
the differences in transgene copy number between LOWTAU and HIGHTAU mice. HT7 
displays high specificity for human tau, with no non-specific binding observed in WT 
mice. Hippocampal tissue from 4-month-old mice was used as this age is prior to 
observable aggregate formation in both lines (Chapter 4). Human tau levels were 
increased significantly by 170% from LOWTAU to HIGHTAU mice (p=0.0126).  
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To test whether the differences observed in human tau levels between the two transgenic 
lines were maintained with increasing age, and to provide confirmation to previous 
results gained, tissue from 13-month-old mice was also tested. The level of human tau 
protein present in LOWTAU mice was similar to mice of 4 months of age. While still 
highly significant (p=0.0043), the percentage increase of 34% recorded in HIGHTAU mice 
at 13-months was decreased from that seen at the younger age of 4-months. This result is 
likely due to the existence of tau aggregates in 13-month-old HIGHTAU mice (Chapter 4), 
with tau that is incorporated into tangle-like inclusions lost during initial low speed 
centrifugation in the preparation of total extract homogenate (Berger et al., 2007). In 
addition to the large band present between 50 and 60kDa, all transgenic mice also 
exhibit higher molecular weight species (~90kDa), which are discussed further below. 
These results provide validation to the transgene copy number differences seen 
using TaqMan® qPCR. Further validation using Western blot techniques came while 
performing characterisation experiments (see below).  
Figure 3.2.  HIGHTAU mice express significantly more human tau protein within the 
hippocampus compared to LOWTAU animals at 4 (A) and 13 (B) months of age. A)i) and B)i) 
Western blot of total extract, using the human-specific antibody, HT7. No human tau protein is 
observed in WT mice at either age. A)ii) and B)ii)Density values for human tau normalised to HspA9 
loading control are expressed as mean ± SEM. Significance evaluated using 2-tailed Students t-test; 
p<0.05*, p<0.01** 
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Western Blot Characterisation of LOWTAU and HIGHTAU mice 
 
Both LOWTAU and HIGHTAU mice display relatively low levels of mutated human tau  
 
In order to determine the relative levels of tau in LOWTAU and HIGHTAU hippocampus 
compared to endogenous WT murine tau, the pan-tau antibody DA9 was used to assess 
tissue from 4-month-old mice. This age is prior to observable aggregate deposition in 
both lines (Chapter 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WT mice display bands migrating at ~50kDa, ~58kDa and ~67kDa (seen only with high 
overexposure) corresponding to the 3 endogenous monomeric isoforms of tau expressed 
in adult mice (Buee et al., 2000, Adams et al., 2009, Liu and Gotz, 2013), with small 
increases in molecular weight due to endogenous phosphorylation, when compared to 
de-phosphorylated/ recombinant tau (Hanger et al., 2002). At this age, the ~50kDa band 
(representing the 0N4R isoform) constitutes the more prominent species of the three, 
with the 2N4R (~67kDa) isoform constituting the least prevalent isoform, as is 
consistent with previous data using hippocampal samples from young adult mice (Liu 
and Gotz, 2013). 
Figure 3.3.  Comparison of total tau expression in WT, LOWTAU and HIGHTAU mice at 4 (A) and 
13 (B) months of age. A)i) and B)i) Western blot of total extract, using the pan-tau antibody, DA9. 
A)ii) and B)ii) All density values normalised to HspA9 loading control. Total tau in transgenic mice 
normalised to WT, represented by line at 1. Plotted values are expressed as mean ± SEM. 
Significance evaluated using a 2-tailed Students t-test; p<0.05*, p=0.051§ 
A)i)! B)i)!
A)ii)! B)ii)!
0
10
20
30
40
LOWTAU n=3
HIGHTAU n=2
**
50kDa!
60kDa!
90kDa!
50kDa!
60kDa!
90kDa!
(T
ota
l ta
u/ 
Hs
pA
9)/
 !
M
uri
ne
 ta
u!
0
2
4
6
8
*
0
2
4
6
8
LOWTAU n=3
HIGHTAU n=2
§
4 months! 13 months!
WT! LOWTAU! HIGHTAU! WT! LOWTAU! HIGHTAU!
 80 
A large increase in the prominent 50-60kDa tau species is observed in both transgenic 
lines when compared to WT mice. In contrast to WT, only one diffuse band spanning 
50-60kDa is apparent, due to the abundant expression of the 0N4R isoform and indicting 
higher varieties of phosphorylated tau species. Levels of tau in LOWTAU mice at 4 
months of age were found to be approximately 4 times the level of WT murine tau. Tau 
expression in the HIGHTAU line was significantly increased, with these mice displaying a 
6.5 times increase.  
In order to provide validation of this finding, 13-month samples were also 
evaluated for total tau. An apparent increase in the 1N4R (~58kDa) isoform was detected 
in WT mice at this age compared to 4-month-old mice. Despite this increase in murine 
tau, LOWTAU mice presented >3 times the level of tau protein, similar to relative levels 
detected at 4 months. The level of tau relative to endogenous tau at 13 months in 
HIGHTAU mice was decreased when compared to younger samples. As stated earlier, this 
decrease is likely due to the incorporation of tau into large aggregates at 13 months 
(Chapter 4), and their loss during initial low speed centrifugation.  
 
Transgenic mice also display higher molecular weight tau species (discussed further 
below) in addition to the prominent 50-60kDa band. Smaller species are assumed to be 
degradation products of tau, or possibly truncated forms of tau as has been suggested 
previously (Tai et al., 2012). 
 
The relatively small increase in tau protein levels in TauD35 mice, makes both the 
HIGHTAU and LOWTAU lines relatively mild transgenic models, compared to other similar 
lines such as the rTg4510 mouse model, in which tau is expressed 13-fold (SantaCruz et 
al., 2005).  
 
Age-dependent changes in tau phosphorylation 
 
Two phosphorylation dependent antibodies: CP13, which recognises tau phosphorylation 
at S202 and PHF-1, which recognises the phosphorylation sites, S396 and S404, were 
employed to investigate the cardinal feature of pathological tau, hyperphosphorylation. 
Both CP13 and PHF-1 display high specificity when compared to other tau 
phosphorylation dependent antibodies (Petry et al., 2014). Samples from 4, 13 and 24 
month old mice were analysed in order to investigate the age-dependent aspect of tau 
phosphorylation. 
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A similar pattern of age-dependent tau phosphorylation 
was seen with both CP13 and PHF-1, with a low level of 
phosphorylation present in WT mice at all ages observed with both antibodies. Using 
CP13, 4-month-old WT mice display two distinct bands migrating at ~50 and ~58kDa, 
representing S202 phosphorylation of both the 0N4R and 1N4R endogenous isoforms 
respectively. Taken together, overall S202 phosphorylation of endogenous murine tau 
isoforms is not seen to change from 4 – 24 months of age (Figure 3.4.D)). In contrast to 
CP13, the degree of S396/S404 (PHF-1) phosphorylation in WT mice was observed to 
alter with age (Figure 3.5.D)). At 4-months, the 0N4R tau isoform shows as having a 
higher degree of S396 and S404 phosphorylation (Figure 3.5.A)i)). By 13 months, 
phosphorylation of the 0N4R (~50kDa) and 1N4R (~58kDa) isoforms appears equal 
(Figure 3.5.B)i)), resulting in an increase in overall murine tau phosphorylation at S396 
and S404 sites. A significant reduction in overall WT PHF-1 reactivity is seen between 
13 and 24 months (p=0.021)(Figure 3.5.C)i) and D)).  
Figure 3.4. Age- and dose-dependent phosphorylation of tau 
assessed by Western blotting using CP13 (S202) across 4 (A), 
13 (B) and 24 (C) months of age. A)ii),  B)ii) and C)ii) Density 
values for phosphorylated tau normalised to HspA9 loading 
control are expressed as mean ± SEM. D) Comparison of WT 
S202 phosphorylation across 4-, 13- and 24-months. 
Significance evaluated using 1-way ANOVA or 2-tailed 
Students t-test; p<0.05*, p<0.01**, p<0.001*** 
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Indeed, CP13 and PHF-1 reactivity has been shown 
previously in non-transgenic control mice (Adams et 
al., 2009, Petry et al., 2014). A degree of phosphorylation is expected physiologically, 
due to its role in the regulation of tau binding to MTs and the consequential regulation of 
axonal transport (Ballatore et al., 2007).  
 
Transgenic mice display a large amount of both S202 (CP13) and S396/S404 (PHF-1) 
phosphorylation when compared to WT at all ages. In contrast to WT controls, 
phosphorylated species from transgenic mice are more diffuse, particularly those species 
phosphorylated at the PHF-1 epitope, reflecting a more heterogenous degree of overall 
phosphorylation of the human 0N4R isoform, which creates species of slightly altered 
molecular weight.  
Figure 3.5. Age- and dose-dependent phosphorylation of 
tau assessed by Western blotting using PHF-1 (S396/ 
S404) across 4 (A), 13 (B) and 24 (C) months of age. A)ii),  
B)ii) and C)ii) Density values for phosphorylated tau 
normalised to HspA9 loading control are expressed as mean 
± SEM. D) Comparison of WT S202 phosphorylation across 
4-, 13- and 24-months. Significance evaluated using 1-way 
ANOVA or 2-tailed Students t-test; p<0.05*, p<0.01**, 
p<0.001*** 
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In 4 and 13 month old mice, we also observe clear increases in phosphorylation 
in HIGHTAU compared to LOWTAU mice. These increases are most dramatic at 4 months, 
where S202 phosphorylation is increased by 211% from LOWTAU to HIGHTAU mice 
(Figure 3.4.A)), with S396/S404 phosphorylation increased by 117% (Figure 3.5.A)). 
 
Interestingly, as well as increases in the amount of tau phosphorylated, the size of 
phosphorylated tau species was also seen to change in an age- and dose-dependent 
manner, observed with both CP13 and PHF-1. At 4 months, transgenic mice present 
phosphorylated tau species between 50 and 60kDa (Figure 3.4.A)i) and (Figure 
3.5.A)i)). With age, the phosphorylated tau species displayed a higher molecular weight. 
By 24 months, the majority of tau migrated with an apparent molecular weight of 64kDa 
(Figure 3.4.C)i) and (Figure 3.5.C)i)). This age-dependent ‘shift’ from 50-60 to 64kDa is 
characteristic of pathological tau, and is caused by the hyperphosphorylation of tau in 
disease (SantaCruz et al., 2005, Berger et al., 2007, Sahara et al., 2013). Using a protein 
fraction similar to that used in the present study, Sahara et al., (2013) observe an almost 
identical age-dependent phosphorylation of S396 and S404, relative to the different (and 
more pathologically aggressive) mouse model used.  
 
Smaller species of tau migrating below 50kDa in 13 month old HIGHTAU and 24 month 
old LOWTAU are speculated to be degradation products of tau or may possibly represent 
truncated forms of tau as has been suggested previously (Tai et al., 2012) 
 
Sarkosyl-insoluble tau: Western blot analysis of P3 fraction 
 
As we see from Figure 3.2. A)i) and B)i) the detection of human tau from total 
hippocampal homogenate, in both LOWTAU and HIGHTAU mice, results in a large 
‘smeared’ band, from which individual tau species cannot be resolved. This is due to the 
variety of phosphorylation states of normal soluble tau species (Sahara et al., 2002, 
SantaCruz et al., 2005, Berger et al., 2007). It is known that the type of 0N4R isoform 
found in the paired helical filaments of AD migrate with an apparent weight of 64kDa 
due to hyperphosphorylation (Goedert et al., 1992, Buee et al., 2000, Lewis et al., 2000). 
This form of tau is insoluble when incubated with the detergent sarkosyl. Sarkosyl 
incubation is thus often used to remove other non-aggregated/soluble forms of tau, 
allowing for the detection of filamentous forms only. NFTs themselves are also lost 
during initial centrifugation (Greenberg and Davies, 1990, Berger et al., 2007), resulting 
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in the sarkosyl-insoluble (P3) fraction containing only dispersed paired helical filaments 
which, following denaturing, can be run on an SDS-PAGE gel (Greenberg and Davies, 
1990). These filaments are derived from less aggregated populations of paired helical 
filaments, such as neuropil threads or filaments dissociated from NFTs and are 
considered indicative of the severity of aggregated tau pathology (SantaCruz et al., 
2005).  
 
The relative levels of sarkosyl-insoluble tau in LOWTAU and HIGHTAU mice of increasing 
age were compared. In both 4 and 13 month old LOWTAU mice, insoluble tau migrating 
at ~54kDa was observed. The amount of tau of this weight was increased in HIGHTAU 
mice at 4 months. By 13 months of age however, HIGHTAU mice displayed the greater, 
64kDa tau along with continued expression of ~54kDa tau. This apparent dose-
dependency aspect of insoluble tau formation has been noted previously (Sahara et al., 
2002). With increasing age,  ~54kDa tau is reduced, with the 64kDa band becoming the 
more prominent of the two bands by 24 months. These observations are in keeping with 
previous data from a similar mouse model (SantaCruz et al., 2005), in which the 
development of insoluble tau migrating at 64kDa coincides with the development of 
large numbers of NFTs (see Chapter 4).  
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Figure 3.6. Sarkosyl-insoluble tau present 
in the P3 fraction at 4 (A), 13 (B) and 24 
(C) months of age, assessed using the 
human specific antibody, HT7, shows and 
age- and dose-dependent development of 
64kDa insoluble tau. Amido black total 
protein stain was used as a loading control, 
although control data were not used for 
analysis. 
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Due to the fractionation procedure employed, classical loading controls for the sarkosyl-
insoluble fractions cannot be used, often resulting in a lack of loading control 
(SantaCruz et al., 2005, Berger et al., 2007). The total protein stain, Amido Black, 
provided a loading control for the present study, although the quality of stain was not 
sufficient for quantification. Sarkosyl-insoluble tau was thus not quantified; images 
(Figure 3.6) are therefore for qualitative purposes only.  
 
High molecular weight bands detected in transgenic mice of all ages 
 
Along with the prominent band migrating at 50-60kDa, another, higher molecular weight 
band, ~85-100kDa, was found to be present in all transgenic mice, identified with both 
DA9 and HT7 antibodies at 4 and 13 months of age. Phosphorylation dependent 
antibodies CP13 and PHF-1 also detected a higher molecular weight band migrating at 
~90-100kDa, observed in LOWTAU mice only when overexposed (not shown in Figure 
3.4.A)i) and B)i) and Figure 3.5.A)i) and B)i)). It is possible these bands represent 
oligomeric species of tau, as has been suggested for higher molecular weight species 
previously (Berger et al., 2007, Tai et al., 2012). Slight variations in molecular weight 
creating a ‘smeared’ appearance are assumed to represent differences in phosphorylation 
status. While the apparent molecular weights are not quite sufficient to suggest 
multimeric structures (two or more tau molecules) of full-length tau, it is possible these 
species are made up of oligomeric hyperphosphorylated truncated forms of tau.  
 
These higher molecular weight species are also observed in the sarkosyl-insoluble 
fraction of all transgenic mice at 13 months. A small amount of these higher weight 
species are also detected at 24 months and can be seen by overexposure (not shown in 
Figure 3.6.). Unlike the disperse filaments of this fraction that are disassociated by 
boiling with SDS and DTT, these species likely represent higher order aggregates that 
are at least partially resistant to this denaturation process.   
 
 
 
 
 
 
 
 86 
Summary and Discussion: Molecular Biology 
 
Transgene copy number determined using TaqMan® qPCR led to the discovery that in 
fact, the TauD35 mouse model exists as two transgenic lines, with one line harbouring 
approximately double the number of transgene copies than the other, resulting from 
either changes to copy number via recombination events, or two separate transgene 
integration events that became separated during breeding. These lines were appointed 
HIGHTAU and LOWTAU, respectively, and are referred to as such throughout. Differences 
in transgene dose between the two transgenic lines are reflected in the amount of human 
tau protein expressed, indicating that the additional copies of the human cDNA 
harboured by HIGHTAU mice are indeed functional. This is confirmed through observed 
increases in the phosphorylation of tau between LOWTAU and HIGHTAU mice.  
 
Between 17 and 20 months of age, HIGHTAU mice develop a pathological phenotype 
comparable to that described previously in aged mice harbouring a similar transgene 
(Ramsden et al., 2005). Due to this moribund phenotype, HIGHTAU mice over 20 months 
of age were not available for experimentation. 
 
Characterising LOWTAU and HIGHTAU transgenic mice 
 
The characteristic ‘shift’ of the 0N4R isoform of human tau from ~54kDa to 64kDa is 
often used to indicate the development of insoluble tau pathology and thus NFTs. The 
64kDa weight is caused by the hyperphosphorylation of 0N4R tau (Goedert et al., 1992), 
and is a species found in AD and FTDP-17 patients (Buee et al., 2000). The 
development of this species (in both LOWTAU and HIGHTAU mice) is therefore supportive 
of the use of TauD35 mice as a tool to study the development of pathological tau 
relevant in disease.  
 
Sarkosyl-insoluble tau migrating at the lower weight of ~54kDa has been observed 
previously (Sahara et al., 2002, SantaCruz et al., 2005), in particular at younger ages. 
This may represent a form of tau which displays less phosphorylation (as de-
phosphorylated/recombinant tau migrates at 52kDa (Buee et al., 2000)), but which is 
included into tau filaments, possibly as a result of other modifications such as 
ubiquitination and glycation (Buee et al., 2000). By investigating these smaller species 
using electron microscopy, Sahara et al., (2002) show that they are indeed filamentous, 
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albeit with a shorter fibre length than those forms of tau detected in older animals. It is 
therefore possible that insoluble tau migrating at ~54kDa represents a species with a low 
level of phosphorylation in a filamentous form, which may act as a filament precursor/ 
nucleation site for additional aggregation into mature NFTs. Due to the difficulty of 
working with such a small volume of original homogenate (as is provided by a single 
hippocampus), the ~54kDa band may also include a small amount of contamination from 
the sarkosyl-soluble fraction (S2). 
The dispersed filaments under study when looking at sarkosyl-insoluble tau may 
represent an intermediate step (or steps) in the development of mature NFTs (Goedert et 
al., 1992), and thus the apparent decrease at 24 months may be due to the more complete 
development of NFTs and their loss during initial centrifugation. The apparent higher 
presence of overall insoluble tau at 13 months in HIGHTAU mice, compared to LOWTAU 
24 month mice, may reflect their increased capacity for NFT development. Decreases in 
the amount of ~54kDa tau with age/ dose are accompanied by increases in 64kDa 
species. This may reflect the hyperphosphorylation of tau on its way to becoming 
integrated into more mature aggregates/ NFTs.  
 
In addition to hyperphosphorylated 64kDa tau accumulation, higher molecular weight 
(~85-100kDa) human tau species were observed in both LOWTAU and HIGHTAU mice 
from as young as 4 months. Thought to be oligomers of tau (Berger et al., 2007, Tai et 
al., 2012), these species were found to be partly sarkosyl-insoluble and SDS resistant, 
and contain a proportion of tau phosphorylated at S202 and/or S396/S404 in HIGHTAU 
mice. The apparent reduction in the sarkosyl-insoluble forms of these higher molecular 
weight species at 24 months, compared to 13 months, could possibly be due to the more 
complete development of NFTs at 24 months and their loss during centrifugation. 
 
Overall, both LOWTAU and HIGHTAU mice were found to express relatively low amounts 
of human tau (4 and 6.5 times respectively) in comparison to endogenous murine tau. 
This finding makes both models relatively mild transgenic lines in contrast to similar 
mouse models of tauopathy (SantaCruz et al., 2005). Interestingly, the relatively small 
difference in protein level between LOWTAU and HIGHTAU mice is seen to result in large 
differences in the amount of tau that is hyperphosphorylated and insoluble in sarkosyl,  
indicative of large differences in tau pathology. 
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CHAPTER 4 
 
Introduction: Histology 
 
The presence of aggregated tau protein within the brain is a fundamental feature of all 
neurodegenerative tauopathies (including AD and FTDP-17). In AD, the development of 
NFTs follows a stereotypical pattern, beginning in the medial temporal lobe (EC and 
hippocampus) before spreading through limbic structures and finally reaching isocortical 
and associative areas (Braak and Braak, 1991). Indeed, the extent of such pathology has 
been shown to correlate to the severity of cognitive decline in AD patients (Arriagada et 
al., 1992, Giannakopoulos et al., 2003, Guillozet et al., 2003), making the presentation of 
this cardinal feature paramount for a new model of tauopathy. Neuronal loss represents 
another key feature of neurodegenerative tauopathies, and has been shown to possess a 
topographical and hierarchical pattern paralleling that of NFT development. However, 
within the same brain region neuronal loss can exceed the NFT burden (Gomez-Isla et 
al., 1996, Gomez-Isla et al., 1997), making it a superior correlate of cognitive decline.  
 
We therefore investigated the age- and dose-dependent development of both NFT 
pathology and neurone loss within TauD35 mice. As the transgene harboured by the 
TauD35 models is expressed under the CaMKII! promoter, and is thus strongly 
expressed within the hippocampus (www.mouse.brain-map.org (Lein et al., 2007), 
Figure 3.1.B)), and with the obvious vulnerability of the hippocampus to NFT 
development and neurone loss (as displayed in AD), one may expect primary NFT 
pathology and neuronal loss within the hippocampus of TauD35 mice.  
 
Performing pathological tau and cell count analysis also allows these novel transgenic 
lines to be placed in context with existing literature using other transgenic lines 
harbouring the same mutation (Lewis et al., 2000, Ramsden et al., 2005, Terwel et al., 
2005) and makes the interpretation of future results possible. Here, histological 
characterisation also provided further validation of differences in transgene copy 
number.  
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Identification of pathological tau 
 
Western blot data presented in the previous chapter revealed that tau is forming insoluble 
paired helical filaments in both LOWTAU and HIGHTAU mice from 4 months of age. 
However, the nature of the tissue preparation protocol for these Western blot 
experiments means the origins of these filaments are not mature NFTs. At this age, these 
filaments were also not found to be hyperphosphorylated. Thus, while being indicative 
that a process of tau aggregation has begun, histological analysis is essential to 
determine whether mice exhibit full NFT pathology and thus model a key characteristic 
of tauopathies. As well as confirming that NFTs are indeed formed in these models, use 
of a range of ages from both lines means that we are able to characterise pathology in an 
age- and dose-dependent manner.  
 
In order to perform this primary validation and characterisation, good antibody selection 
was vital. Antibodies needed to be specific for tau, recognise common pathological 
epitopes found in both human patients as well as other mouse models, and also cover a 
wide range of pathological species. To this end, a range of both commercial and non-
commercial (kindly provided by Peter Davies, Albert Einstein College of Medicine, 
USA) antibodies were chosen, including: HT7 (human tau), MC1 (misfolded human 
tau), as well as CP13, AT8 and PHF-1 (tau phosphorylated at a variety of serine and 
threonine residues),  
The AT8 epitope (tau phosphorylated at S202/T205) is believed to play a role in 
regulating further phosphorylation of tau at other disease-associated sites (Bertrand et 
al., 2010a), and is therefore likely an epitope phosphorylated early in the cascade of tau 
phosphorylation (Kimura et al., 1996). The antibody CP13 recognises tau 
phosphorylated at S202. As this is one of the sites included in the AT8 epitope it is likely 
CP13 recognises one of the earliest tau sites to be phosphorylated (Su et al., 1994). The 
MC1 epitope is created from the folding of tau into a distinct pathological conformation 
(Jicha et al., 1997), a process also believed to occur early in the development of 
pathological tau (Weaver et al., 2000). Sites thought to constitute those phosphorylated 
later in the disease process include the epitope of PHF-1 (S396/S404) (Su et al., 1994). 
By using the human specific antibody HT7 and co-staining with AT8, we were able to 
identify whether the tau protein forming pathological species was of human origin and 
therefore due to the translation of the transgene. 
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Neuronal cell counts: Cresyl Violet Nissl Stain 
 
As with the development of NFTs, neuronal loss has also been shown to occur prior to 
the presentation of symptoms in AD patients. It has been demonstrated that even in mild 
AD, prior to any significant cognitive decline, substantial reductions in volume are 
visible within the hippocampus (Lehericy et al., 1994, Jack et al., 1997) and EC (Gomez-
Isla et al., 1996) of patients relative to cognitively normal age-matched controls. Indeed, 
the topographical, hierarchical pattern of neuronal loss in AD has been shown to parallel 
the development of NFTs (Gomez-Isla et al., 1996, Gomez-Isla et al., 1997), despite 
neurone loss in some brain areas greatly exceeding NFT burden (Gomez-Isla et al., 
1997). Some have even suggested NFT formation is the principle event associated with 
neuronal loss in the EC and CA1 areas (Giannakopoulos et al., 2003). As well as 
correlating with each other, both NFT load and neuronal loss correlate well with duration 
and severity of illness (Gomez-Isla et al., 1996, Gomez-Isla et al., 1997, Giannakopoulos 
et al., 2003). Due to these data, and the fact that brain atrophy caused by neuronal loss is 
a major feature of many forms of dementia and thus provides further validation of these 
novel lines as models of dementia, neuronal loss within both LOWTAU and HIGHTAU mice 
was also investigated using a Nissl stain.  
 
It is now 120 years ago that work by Franz Nissl first exposed the ability of cationic dyes 
(such as cresyl violet) to label small granules within neuronal (and some glial) cell 
bodies. The method is based on the interaction of such dyes with the DNA and RNA 
within these cells. It is the RNA that creates the so-called granular ‘Nissl bodies’, due to 
its high concentration in the rough endoplasmic reticulum and ribosomes within the 
cytoplasm. The preferable staining of neurones is due to their high concentration of 
rough endoplasmic reticulum, required to meet their need for a high degree of protein 
synthesis. Staining in this way provides a clear depiction of the neuronal cell soma and 
can therefore be used to identify and count the number of principle neuronal cells within 
a given area. 
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Results: Histology 
 
Significant neuronal cell loss in the CA1 region of HIGHTAU mice at 17.5 
months of age 
 
Neuronal loss is a characteristic feature of neurodegenerative tauopathies, and for this 
reason represents one of the desirable traits of a tauopathy model. As the number of 
neurones within a defined area may impact conclusions drawn about the number of tau 
aggregates, initial groundwork consisted of assessing neuronal loss within the 
hippocampus of both HIGHTAU and LOWTAU mice compared to WT controls. Principle 
cells were identified and counted using a Nissl stain. Pyramidal cells of the CA1 and 
CA3 cell layers were investigated in mice ranging from 4 to 24 months. Due to high 
density of cells in the DG, cell numbers could not be reliably obtained for this area and 
therefore have not been quantified. 
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Figure 4.1. Significant neuronal cell 
loss is observed within the 
hippocampus of HIGHTAU mice 
presenting with the pathological 
phenotype characteristic of this line. A) 
Representative images of hippocampal 
regions CA1, CA3 and DG from 17.5-
month-old HIGHTAU and 24-month-old 
LOWTAU mice, stained using cresyl violet. 
Scale bar: 25#m. B) Absolute neuronal 
cell counts analysed using two-way 
ANOVA followed by Sidak’s post hoc 
test i) LOWTAU CA1 ii) HIGHTAU CA1; 
significant difference at 17.5months iii) 
LOWTAU CA3 iv) HIGHTAU CA3; 
significant main effect of genotype 
indicated by bar. p<0.05*, p<0.01**. 
Error bars indicate SEM. C) 
Representative images of whole 
hippocampal sections from 17.5-month-
old mice. (Left) WT, (Right) HIGHTAU. 
Scale bar 200#m. 
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Neuronal cell counts from WT controls were not found to differ across the 20-month age 
range studied, assessed using a one-way ANOVA (WT CA1: 4m 235.0 ± 26.6; 13m 
240.3 ± 9.0; 17.5m 213.8 ± 14.2; 24m 252.6 ± 6.2, p=0.53. WT CA3: 4m 134.0 ± 3.6; 
13m 124.0 ± 8.2; 17.5m 128.0 ± 12.0; 24m 129.2 ± 7.3, p=0.8).  This finding indicates 
neuronal loss in the CA1 or CA3 areas does not occur with normal ageing in mice within 
this time frame. This is analogous to data collected previously from control C57Bl6/J 
mice (Calhoun et al., 1998) as well as healthy human patients (West et al., 1994), which 
indicates there is no neuronal loss with age within the hippocampus, along with other 
brain regions (Gomez-Isla et al., 1996, Gomez-Isla et al., 1997). 
 
No significant differences were found in the number of neurones between WT and 
LOWTAU mice at 24 months of age in either the CA1 or CA3 cell layers (Figure 4.1.B)i) 
and  B)ii)). This finding reveals that up until this time, while extensive tau pathology is 
evident, LOWTAU mice do not exhibit neuronal loss within the hippocampus, and thus do 
not display a fundamental characteristic of neurodegenerative tauopathies.  
 
As no HIGHTAU mice survived until 24 months of age, neuronal loss was assessed in the 
oldest HIGHTAU mice available (17.5-months) using age-matched controls. The mice 
used here already presented with the pathological phenotype typical of HIGHTAU mice of 
this age (piloerection, hunched spine and akinesia) and were culled for ethical reasons.  
Significant cell loss was observed in the CA1 cell layer, with a decrease of 55% from 
WT to HIGHTAU mice (Sidak post-hoc test, p=0.0074, Figure 4.1.B)ii)). Within the CA3 
region, a main effect of genotype was detected (genotype: F(1, 8) = 7.015, p = 0.0293) 
with cell numbers reduced by 23% in HIGHTAU mice at 17.5 months (Figure 4.1.B)iv)). 
An overview of the hippocampus shows the reduction in hippocampal volume along 
with an enlargement of the lateral ventricle in HIGHTAU mice when compared to WT 
animals (Figure 4.1.C)). The large cell loss observed in the CA1 region in the HIGHTAU 
mice bears a resemblance to the degeneration seen in the rTg4510 mouse model, where 
significant neuronal loss (~60%) is apparent in the CA1 region (SantaCruz et al., 2005). 
Indeed, comparable findings have also been reported in human AD cases, where the 
largest and most significant neuronal loss within the hippocampus is found in the CA1 
area (West et al., 1994).  
 
In order to investigate when cell loss begins in HIGHTAU animals, we then compared cell 
numbers in 4- and 13-month LOWTAU and HIGHTAU mice to WT controls. As expected 
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from the results observed at 24-months, LOWTAU mice showed no neuronal cell loss in 
either the CA1 or CA3 cell layers (Figure 4.1.B)i) and iii)). Moreover, no significant cell 
loss was detected at these younger ages in the CA1 or CA3 regions of HIGHTAU mice 
compared to WT controls  (Figure 4.1.B)ii) and iv)).  
 
These data highlight the more pathologically aggressive nature of the HIGHTAU line of 
TauD35 mice. It may be hypothesised that the characteristic pathological phenotype and 
premature mortality seen in this line is the result of substantial neuronal cell loss 
throughout the brain (Figure 4.2.C), see also Figure 7.2., Chapter 7).  
 
Identification of tau pathology with LOWTAU and HIGHTAU mice 
 
In order to validate the novel TauD35 mouse lines as models of tauopathy, it was of 
course imperative to determine whether they do indeed develop the cardinal feature of 
these neurodegenerative diseases: the NFT. The CA1, CA3 and DG regions of the 
hippocampus were examined for the presence and cellular location of pathological tau, 
using a wide range of antibodies including: HT7 (human tau), MC1 (misfolded human 
tau), as well as CP13, AT8 and PHF-1 (tau phosphorylated at a variety of serine and 
threonine residues). This array of antibodies allowed us to determine whether tau present 
in TauD35 mice forms common pathological species detected in human tauopathy cases. 
Employing these antibodies against different forms of tau across 4-, 13- and 24-month-
old mice also allowed us some understanding of the age-dependent development of 
pathological tau. In addition we hypothesised that the presence of higher levels of 
mutated human tau protein in HIGHTAU mice would contribute an earlier onset and more 
severe degree of tau pathology within these mice compared to the LOWTAU mouse line, 
and thus by examining both lines simultaneously we were able to gain insight into the 
dose-dependency of pathological tau accumulation.  
 
Sections from age-matched WT mice were stained in parallel with each of the antibodies 
against pathological tau. No labelling was observed in any WT sections (Figures 4.5., 
4.6., 4.7. and 4.8.). 
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Both LOWTAU and HIGHTAU mice develop characteristic NFTs 
 
For the present study, the specific tau antibodies described were chosen for the detection 
of mature NFTs. Antibody labelling of NFTs provides superior specificity over 
alternative approaches such as Thioflavin-S or Gallyas silver stains. Such detection 
methods do not identify tau exclusively, but rather rely on the presence of "-pleated 
sheets (LeVine, 1999) or affinity for silver ions (Uchihara, 2007) respectively, to expose 
tau aggregates. With small, optimally handled samples, immunohistochemistry provided 
us with the most reliable detection method available for NFT identification. In 
combining primary antibodies with fluorescently conjugated secondary antibodies and 
imaging with an epifluorescent microscope, we are able to visualise pathological tau in 
detail. Further to this, higher resolution confocal imaging (Figure 4.2.B)) allowed us to 
determine that aggregates exhibited the condensed, twisted morphology characteristic of 
mature NFTs (Bancher et al., 1989, Augustinack et al., 2002), and they are thus referred 
to as such throughout. In addition, the morphology of NFTs observed within the present 
study is comparable to both mouse models and human patients harbouring the same, 
P301L, mutation (Figure 4.9.)(Spires et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A)! B)!
C)! Figure 4.2. Intracellular diffuse tau and NFT 
morphology A) Overall image of transverse 
hippocampus from a 13-month HIGHTAU mouse double 
stained using HT7 (human tau) and DAPI. Composite 
image was created using a 20x objective on an EVOS® 
FL Auto Cell Imaging System. Scale: 200#m. B) A 
single CA3 neurone from (A), showing twisted tau 
filaments filling the soma. Scale: 5#m. C) CA3 region of 
a 4-month HIGHTAU mouse double stained using CP13 
(S202) and DAPI. Note diffuse tau staining within all 
cellular compartments, in particular the somatodendritic 
compartment. Scale: 20#m. Images (B) and (C) obtained 
using a Zeiss LSM 510 confocal microscope with 60x oil 
immersion objective. 
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Age and dose-dependent progression of tau pathology 
 
We observe no aggregate pathology throughout the hippocampus in either LOWTAU or 
HIGHTAU mice at 4 months of age. However, some diffuse staining with CP13 is 
observed in the soma and dendrites of cells across the hippocampus of both lines (Figure 
4.2.C) and Figure 4.6.). This pattern of CP13 reactivity within neuronal processes has 
been observed previously in the young mice of other tauopathy mouse models (Ramsden 
et al., 2005, Adams et al., 2009), and may represent tau in a pre-tangle state (Kimura et 
al., 1996, Augustinack et al., 2002). All other antibodies produced no staining except in 
mossy fibres (discussed below). The presence of CP13 reactivity in the absence of other 
phosphorylation-dependent antibody stain at this young age supports the opinion that 
S202 is phosphorylated early in pathological tau development.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Absolute NFT numbers 
detected using HT7/AT8, CP13, 
MC1 and PHF-1 antibodies for 
pathological tau. A-C) Absolute 
NFT numbers detected in the CA1 
(A), CA3 (B) and DG (C) regions 
from 4-24 months. (Inserts) show 
enlarged absolute NFT number of 13-
month-old LOWTAU animals. Two-
way ANOVA, significance indicated 
by p<0.01**, p<0.001***. No 
HIGHTAU animals survive until 24 
months of age. Error bars indicate 
SEM. 
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A substantial difference in tau pathology is observed between the two transgenic lines by 
13 months of age. Here LOWTAU mice present few/ sparse NFTs, whereas HIGHTAU mice 
show severe aggregate numbers in each region of the hippocampus, detected with all 
AT8/HT7, CP13, MC1 and PHF-1  (Figure 4.3.A), B) and C)).  
 
Absolute NFT numbers for HIGHTAU mice at 13-months were compared to LOWTAU mice 
at 24 months of age by way of a two-way ANOVA, providing a comparison between the 
two transgenic lines at ages when each displayed severe NFT pathology. This allowed an 
assessment of whether differences in transgene dose results in the same eventual pattern 
of tau pathology, simply on a different timescale.  
No difference was observed in NFT numbers between 13-month HIGHTAU and 
24-month LOWTAU mice within the DG (Figure 4.3.C)). Within the CA1 region, a main 
effect of antibody was detected, indicating differences in the number of aggregates 
detected with each of the four antibodies used in this region in both transgenic lines 
(antibody: F(3, 12) = 14.71, p=0.0003, Figure 4.3.A)).  The highest number of NFTs in 
both HIGHTAU 13-month and LOWTAU 24-month-old mice were detected using MC1. 
Figure 4.4. The ratio of NFTs detected using HT7/AT8, CP13, MC1 and PHF-1 antibodies for 
pathological tau to the average number of cells per animal. Calculated ratios of the number of 
NFTs to the average number of cells per animal counted in the CA1 (A) and CA3 (B) regions in 13- 
and 24-month-old mice. (Inserts) show enlarged NFT ratios of 13-month-old LOWTAU animals. Two-
way ANOVA, significance indicated by p<0.01**, p<0.001***. No HIGHTAU animals survive until 24 
months of age. Error bars indicate SEM. 
WT
n=3
LOWTAU
n=2
HIGHTAU 
n=2
WT 
n=3
LOWTAU
n=4
HIGHTAU
0
20
40
60
13months 24months
***
**
LOWTAU
0
1
2
3
13months
13months 24months
WT
n=3
LOWTAU
n=2
HIGHTAU 
n=2
WT 
n=3
LOWTAU
n=4
HIGHTAU
0
20
40
60
**
LOWTAU
0
1
2
3
13months
A)! B)!
CA1! CA3!
Nu
mb
er 
of 
NF
Ts
/ m
ea
n n
um
be
r o
f c
ell
s (
24
0x
40
0"
m)
!
***
WT 
n=3
LOWTAU
n=3
HIGHTAU
n=2
WT
n=3
LOWTAU
n=2
HIGHTAU 
n=2
WT 
n=3
LOWTAU
n=4
HIGHTAU
0
50
100
150
4months 13months 24months
AT8/HT7 Double stain
CP13
MC1
PHF-1
LOWTAU
0
1
2
3
13months
 97 
Compared to the antibody that recognised the second highest number of inclusions 
(CP13), MC1 identified 12.5% more tangles in the CA1 region of 13-month-old 
HIGHTAU mice. In 24-month-old LOWTAU mice, MC1 identified 13.6% more NFTs than 
CP13 in the CA1 region. This result supports data collected from AD patients, where the 
conformational change in tau recognised by the MC1 antibody is one of earliest detected 
pathological alterations to the protein (Weaver et al., 2000). The detection of higher 
numbers of NFTs by MC1 may also be contributed to by the nature of NFT maturation, 
such as epitope truncation, obstruction or dephosphorylation (Uchihara, 2007). As MC1 
recognises a conformational change in tau, rather than a specific phosphorylation site, it 
may be that its epitope is preserved throughout the development of a NFT. For both 13-
month HIGHTAU and 24-month LOWTAU mice, PHF-1 detected the lowest number of 
NFTs compared to all other antibodies. This result is in keeping with phosphorylation 
patterns observed in human patients showing S396 is one of later sites of tau to be 
phosphorylated (Kimura et al., 1996), as well as data from similar mouse models 
(Ramsden et al., 2005).  
 
Fewer NFTs were detected within the CA3 area compared to other hippocampal regions 
studied, in both 13-month HIGHTAU and 24-month LOWTAU mice. By comparing absolute 
aggregate numbers in this area, significantly fewer NFTs were detected in 24-month 
LOWTAU animals, with a main effect of genotype detected between this group and 13-
month HIGHTAU animals (genotype: F(1, 4) = 49.22, p=0.0022, Figure 4.3.B)). As no 
neuronal loss is recorded within the CA3 region of 24-month LOWTAU mice, one must 
conclude that the lower transgene copy number of these mice results in the production of 
fewer NFTs in this region.  
 
In order to account for any neuronal cell loss in HIGHTAU 13-month-old mice, where cell 
counts were available for CA1 and CA3, the ratio of NFT numbers to the average 
number of cells in that area per animal were compared. Comparison of the ratio of NFT 
numbers in the CA1 region between 13-month HIGHTAU and 24-month LOWTAU mice 
revealed fewer NFTs in LOWTAU mice, a feature previously masked by a low level of 
cell loss in this area at 13 months of age. In addition to a main effect of antibody 
established using absolute numbers, a main effect of genotype between the two lines at 
the different ages became apparent (antibody: F(3, 12) = 16.77, p=0.0001, genotype: F(1, 4) 
= 22.15, p=0.0093, Figure 4.4.A)). Compared NFT ratio calculations for the CA3 region 
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showed comparable reductions in LOWTAU 24-month-old mice as were seen with 
absolute NFT counts (genotype: F(1, 4) = 53.27, p=0.0019, Figure 4.4.B)).  
 
All inclusions reactive with AT8, and thus phosphorylated at S202/T205, were also 
found to be reactive for the human-specific antibody HT7, at all ages, irrespective of tau 
dose. This finding suggests that no NFTs are formed from purely murine tau 
phosphorylated at S202/T205. This does not, however, exclude the possibility that 
murine tau is incorporated into inclusions along with transgenic human tau.  
 
Thus, the hippocampus of TauD35 mice shows an age- and dose-dependent neuronal 
accumulation of misfolded and abnormally phosphorylated tau associated with AD.  
 
Mossy fibre staining 
 
Tau is modified in axons prior to mislocation 
 
A degree of mossy fibre staining was seen across all ages (4-, 13- and 24-months) with 
each of the antibodies: HT7/ AT8 (Figure 4.5.), CP13 (Figure 4.6.), MC1 (Figure 4.7.) 
and PHF-1 (Figure 4.8.) in all transgenic mice. Staining showed a heterogeneous pattern, 
even within the same age group with each antibody. These variations in mossy fibre 
staining between mice may be expected, due to individual variations and minor 
differences in slicing angle. No staining was observed in age-matched WT controls.  
 
Both transgenic lines displayed a level of mossy fibre reactivity with all tau antibodies at 
4 months of age, prior to the detection of tau aggregates. Mossy fibre reactivity with 
antibodies CP13, MC1 and PHF-1 has been observed previously in young tauopathy 
mice (Harris et al., 2012). Within both the 13- and 24-month groups, a decrease in mossy 
fibre staining was consistently associated with the development of NFTs, possibly due to 
the mislocation of tau into the somatodentritic region decreasing axonal levels.  
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Figure 4.5. Representative images of the CA1, CA3 and DG regions of the hippocampus 
from LOWTAU and HIGHTAU mice at 4, 13 and 24 months of age double stained using AT8 
and HT7. WT sections from 24-month-old mice are included. Sections were double stained HT7 
(human tau, red) and AT8 (S202/ T205, green). Mossy fibre staining is evident from 4 months of 
age in both LOWTAU and HIGHTAU animals. At 13-months, a large discrepancy is observed in the 
number of NFTs between LOWTAU and HIGHTAU mice. Scale: 25#m. 
Figure 4.6. Representative images of the CA1, CA3 and DG regions of the hippocampus 
from LOWTAU and HIGHTAU mice at 4, 13 and 24 months of age stained using CP13. WT 
sections from 24-month-old mice are included. Sections were stained using CP13 (S202). Mossy 
fibre staining is observed from 4-months. Diffuse tau is also evident within the somatodendritic 
compartment from 4 months of age in both LOWTAU and HIGHTAU animals. At 13-months, a 
large discrepancy is observed in the number of NFTs between LOWTAU and HIGHTAU mice. 
Scale: 25#m. 
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Figure 4.7. Representative images of the CA1, CA3 and DG regions of the hippocampus 
from LOWTAU and HIGHTAU mice at 4, 13 and 24 months of age stained using MC1. WT 
sections from 24-month-old mice are included. Sections were stained using MC1 (misfolded 
tau). Mossy fibre staining is observed from 4 months of age. At 13-months, a large discrepancy 
is observed in the number of NFTs between LOWTAU and HIGHTAU mice. Scale: 25#m. 
Figure 4.8. Representative images of the CA1, CA3 and DG regions of the hippocampus 
from LOWTAU and HIGHTAU mice at 4, 13 and 24 months of age stained using PHF-1. WT 
sections from 24-month-old mice are included. Sections were stained using PHF1 (S396/ S404). 
Mossy fibre staining is observed from 4 months of age. At 13-months, a large discrepancy is 
observed in the number of NFTs between LOWTAU and HIGHTAU mice. Scale: 25#m. 
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Summary and Discussion: Histology 
 
Principle cell numbers were evaluated in the CA1 and CA3 regions of the hippocampus 
in both LOWTAU and HIGHTAU mice compared to age-matched WT littermates. No cell 
loss was observed up to 24-months of age in LOWTAU mice, even though extensive 
pathology was evident. In HIGHTAU mice of 17.5-months of age, already presenting with 
the characteristic pathological phenotype associated with this line, significant cell loss in 
the CA1 area had become apparent. The large (>50%) reductions in neuronal cell 
numbers seen in this region are in agreement with similar mouse models (SantaCruz et 
al., 2005) and even human AD cases (West et al., 1994), highlighting the vulnerability of 
the CA1 pyramidal cells to tau dysfunction. The large reduction in hippocampal volume 
(Figure 4.1.C)), while contributed to by the loss of neurones, also likely includes the loss 
of neuropil including synapses. The presentation of one of the cardinal features of 
neurodegenerative tauopathies within their lifespan, brands the HIGHTAU mice line a 
more favourable model compared to LOWTAU mice in this respect. The LOWTAU model 
does, however, provide an increased opportunity to investigate the very earliest effects of 
tau dysfunction, through prolonging the initiation phase of pathology development. The 
ability to study dose-dependent effects of tau through the use of both lines also provides 
a valuable opportunity. 
Immunohistochemistry provided a way to investigate the presence and location 
of pathological tau. Using a common antibody (CP13) for the detection of 
phosphorylated tau frequently thought of as an indicator of ‘early’ pathological changes 
(Ramsden et al., 2005, Adams et al., 2009), we observed diffuse staining of the cell soma 
and processes in both LOWTAU and HIGHTAU mice at the 4-months-old (Figure 4.2.C) and 
Figure 4.6.). This diffuse staining pattern was not observed with any other antibody 
used, supporting the opinion that S202 phosphorylation occurs early on in the temporal 
cascade of pathological tau development.  
 
At 13-months in LOWTAU mice, absolute NFT numbers detected with CP13 and indeed 
all antibodies used, were found to be sparse, affecting only a few hippocampal neurones 
in each section examined. This was in contrast to the extremely large numbers of 
inclusions present throughout the hippocampus of HIGHTAU mice at this age. In the CA1 
region, while absolute NFT numbers were found to be comparable to 24-month LOWTAU 
mice, a main effect of antibody was detected, indicating significant differences in the 
numbers of NFTs detected with each antibody. In agreement with previous data that 
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MC1 and CP13 detect epitopes present in early NFT formation (Ramsden et al., 2005), 
these antibodies were found to identify the highest numbers of pathological inclusions in 
the CA1 region, possibly representing the continued initiation of NFT development at all 
ages. Similarly, PHF-1, a marker of late-stage pathological tau (ibid), detected the lowest 
number of NFTs of the antibodies used.  
 
Where cell counts were available for the CA1 and CA3 regions, the ratio of NFTs to the 
average number of cells of the animal was calculated and compared between HIGHTAU 
13-month-old and 24-month LOWTAU mice. With all antibodies used, a significant effect 
of genotype was detected in both hippocampal areas, representing significantly fewer 
NFTs in 24-month LOWTAU mice compared to 13-month HIGHTAU animals. The 
emergence of an effect of genotype within CA1 when comparing the calculated ratios, 
may be due to a small amount of loss of NFT containing neurones within CA1 in 
HIGHTAU mice at 13-months, resulting in extracellular ‘ghost’ tangles. These ghost NFTs 
are the remnants of tangle-bearing neurones following their death. As they are not 
readily degraded, ghost tangles often present a morphology similar to the intracellular 
NFTs of living neurones (Kril et al., 2002). Thus while cell counts are slightly 
decreased, numbers of NFTs are not seen to differ, resulting in comparable absolute NFT 
numbers between HIGHTAU 13-month and LOWTAU 24-month-old mice. Indeed, double 
staining of phosphorylated tau (AT8) and neuronal cell bodies revealed what appeared to 
be a small minority of extracellular NFTs in 13-month HIGHTAU animals within the CA1 
region (Figure 4.9.); however, such staining was used for qualitative purposes only, with 
the calculation of the ratio of NFTs to the number of cells deemed more reliable for the 
present study.  
 
Some degree of mossy fibre staining was observed in all transgenic mice at all ages. 
Mossy fibre staining has been documented previously (Sydow et al., 2011, Harris et al., 
2012) and reflects the physiological localisation of tau in axons (Trojanowski et al., 
1989, McMillan et al., 2011, Liu and Gotz, 2013), highlighted here due to the density of 
axons in this fibre tract. While staining was not quantified, some qualitative observations 
were made. 
While tau is present in axons physiologically, HT7 reactivity within these fibres 
reveals that human tau is sorted within murine neurones, allowing it to adopt a 
physiological intracellular position. Reactivity with all AT8, CP13, MC1 and PHF-1 
indicates a level of pathological tau modification takes place within axons prior to 
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mislocation to the cell soma and the development of aggregates. These observations 
have been made previously, with CP13, MC1 and PHF-1 reactivity being observed in the 
mossy fibre tract of young tau transgenic mice (Harris et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is suggested that a level of hyperphosphorylation/ misfolding occurs in axons 
before tau is mislocated to the somatodendritic compartment. This development of 
pathological tau, and even its mislocation, can be tolerated by the neurone for some time 
as is seen in hibernating animals (Arendt et al., 2003). The hibernation period in such 
animals is interrupted by arousal periods lasting up to one day (ibid), where tau is de-
phosphorylated and re-sorted to the axonal compartment, meaning that the time a 
neurone spends harbouring large amounts of hyperphosphorylated or misfolded tau is 
limited. Following a prolonged period of exposure of a neurone to hyperphosphorylated 
or misfolded mislocated tau, a cell may loose its ability to reverse this process; and thus 
the tau becomes pathological, forming soluble toxic species which result in deleterious 
effects on the neurone, and finally aggregates, which develop into mature NFTs within 
the soma.   
Figure 4.9. Representative images of the CA1, CA3 and DG regions of the hippocampus double 
stained for pathological tau and neuronal nuclei at 13 months of age reveal occasional 
extracellular NFTs within the CA1 region of HIGHTAU mice. Sections were double stained using 
cresyl violet (neuronal nuclei) and AT8 (S202/ T205) developed using DAB HRP. An extracellular 
NFT (NFT with no associated nucleus) is shown (insert) in the representative image from the CA1 
region of the HIGHTAU mouse. Extracellular NFTs were found to account for only a small minority of 
NFTs, and were only ever observed within CA1. Scale: 50#m.  
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At 13-months, a lower degree of fibre reactivity was observed in HIGHTAU mice when 
compared to LOWTAU animals. It is suggested that a decrease in fibre staining is 
indicative of tau mislocation into the somatodendritic compartment, possibly caused by 
the summation of multiple modifications and overloaded axonal phosphatase activity 
(Bertrand et al., 2010b). The mislocated tau can be observed as NFTs, with the number 
of inclusions appearing to negatively correlate to the degree of mossy fibre staining. It 
has previously been suggested (de Calignon et al., 2012) that a loss of axonal 
immunoreactivity may also signify axonal degeneration prior to neurone loss; however, 
axonal density was not quantified in the present study. 
 
In summary, it is shown that the mutated human tau protein produced in these models is 
processed correctly into the axonal compartment within hippocampal neurones in both 
the LOWTAU and HIGHTAU lines of TauD35 mice. With increasing age we see that this 
tau assumes common pathological conformations, as well as aggregating to form NFTs, 
with increasing transgene dose shown to accelerate this development. In terms of NFT 
development, HIGHTAU mice of 13 months of age are found to be comparable to 4.5/5 
month old rTg4510 mice (Ramsden et al., 2005). In HIGHTAU mice of 17.5 months of 
age, already presenting with the moribund phenotype typical of this line, significant 
neuronal loss is observed within the CA1 region. Such features are characteristic of 
human tauopathies, making both TauD35 models valuable new tools to study tau 
dysfunction. In highlighting the more pathologically aggressive nature of the HIGHTAU 
transgenic line, compared to the LOWTAU model, we also provide conformation of the 
functionality of the extra transgene copies harboured by HIGHTAU mice.  
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CHAPTER 5 
 
Introduction: Behaviour 
 
The degree of both NFT pathology and neuronal loss has been correlated to the cognitive 
decline of AD patients (Arriagada et al., 1992, Gomez-Isla et al., 1997, Giannakopoulos 
et al., 2003, Guillozet et al., 2003). Indeed we see that the selective spatial distribution of 
both of these characteristic pathologies is compatible with the temporal development of 
cognitive symptoms in AD, where an initial impairment of episodic memory is typical 
due to isolation and degeneration of medial temporal lobe structures including the 
hippocampus. As the transgene is expressed under the CaMKII! promoter, and is thus 
strongly expressed in the hippocampus (www.mouse.brain-map.org (Lein et al., 2007)), 
and with the obvious vulnerability of the hippocampus to NFT development and neurone 
loss (as displayed in AD), one may hypothesise that hippocampal-dependent behavioural 
deficits would be among the first to show.  
 
In order to determine if TauD35 mice present with hippocampal-dependent memory 
dysfunction, 12-month-old mice were tested using the T-maze forced alternation task. In 
addition to this memory dependent task, mice were also examined for changes in 
locomotion and anxiety using the open field and light/dark box behavioural tests.  
 
The age of behavioural testing was chosen in order to be sufficiently prior to the 
presentation of the ailing phenotype developed by a proportion of TauD35 mice, later 
discovered to be of the HIGHTAU line. The motor component of the pathological 
phenotype seen in HIGHTAU mice between 17 and 20 months of age would preclude 
behavioural testing. Due to the low sample numbers of HIGHTAU mice included, data 
presented herein is treated as pilot data for further testing.  
 
At the time of behavioural testing, it was not yet known that two transgenic lines existed 
within the TauD35 mouse model. Following post-hoc copy number analysis of all mice, 
data were separated into LOWTAU and HIGHTAU. Unfortunately, this resulted in low 
sample numbers of HIGHTAU mice being included. Behavioural data included within this 
chapter is therefore treated as pilot data for further testing.  
 
 
 106 
T-maze forced alternation task 
 
The present investigation has so far concentrated on the characterisation of tau pathology 
within the hippocampus. Therefore the behavioural task chosen for testing was one that 
shows high sensitivity to hippocampal dysfunction (Dudchenko, 2001, Deacon and 
Rawlins, 2006).  
 
The T-maze forced alternation task tests ‘spatial working memory’, that is, the mouse 
must remember what arm of the maze it has previously visited and alter its choice on the 
second run in order to receive a consumable reward. This type of short-term memory is 
utilised within the one trial, and once used should be forgotten (Dudchenko, 2004).  
 The innate behaviour of rodents means that they will naturally tend to alter their 
choice of goal arm. This instinctive behaviour is necessary for rodents to locate food, 
water, shelter and mates within their natural habitat, and is a tendency encouraged during 
the habituation period using the food reward. This means that even prior to training, WT 
mice will show a ~75% correct response rate in the task, with this increasing to >90% 
correct following the training period (Deacon and Rawlins, 2006, Cacucci et al., 2008). 
Since the early use of the T-maze, it has been observed that rats with damage to the 
hippocampus display clear deficits in their ability to correctly perform within the maze, 
tending instead to perform at the level of chance (50% correct) (Aggleton et al., 1986, 
Dudchenko et al., 2000, discussed in O'Keefe, 1978). This finding demonstrates the high 
sensitivity of the T-maze alternation task to dysfunction within the hippocampus. The 
exact reason for this high dependency on the hippocampus has not yet been fully 
elucidated (Dudchenko, 2001), but is likely due to the complex role of the hippocampus 
in processing spatial information (O'Keefe, 1978).  
 
Adding a short delay between the sample and choice runs can increase the cognitive 
demand of the T-maze; by simply increasing the amount of time the animal must 
remember its previous choice. This method can increase the chance of detecting more 
subtle cognitive deficits. In the present study, delays of 1, 3, 6 and 10 minutes were 
chosen. In order to prevent mice becoming demotivated to perform the task, trials using 
longer delays were always interspersed with trails of the shortest delay period.  
 
The room within which the task was performed contained visible landmark cues on each 
of the 4 walls. Previous work using rats has noted that the presence of such cues is not 
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necessary to performance in the task; however, if present, rats will use the cues to aid the 
correct choice (although they are still not completely reliant on them) (Dudchenko, 
2001).  
 
The protocol used within the present study for testing within the T-maze was adapted 
from that previously published for use on mice (Cacucci et al., 2008).  
 
Locomotor and Anxiety testing 
 
As well as the assessment of hippocampal-dependent memory deficits using the T-maze, 
mice were also evaluated in terms of locomotor activity and anxiety levels. To do this, 
the behaviour of transgenic mice in the open field and light/dark box was compared to 
WT littermates. Both the open field and light/dark box are based on the approach-
avoidance conflict. This conflict is established by the contradiction of the innate 
behaviour of a mouse, such as its natural exploratory behaviour, with the aversive 
properties of a large open space or brightly lit environment.  
 
Open field 
 
The open field test was first developed in the early 1930s by Calvin Hall, and consists 
simply of an inescapable open arena. Despite its development using rats, the test has also 
been shown to be successful for use on mice (Prut and Belzung, 2003). Its simplicity and 
ability to quickly measure many clearly defined behaviours led to its huge popularity. 
Even today, some 80 years after its first use, the open field provides one of most 
common tests for locomotor activity, exploration and anxiety-related behaviours (ibid).  
For the present study, the open field has been used for testing two main 
parameters: time spent in centre, taken as an indicator of anxiety; and total distance 
travelled, as a measure of overall exploratory/locomotor activity. Both parameters are 
examined in 5-minute time bins, giving an idea of changes in anxiety-related behaviour 
and exploratory behaviour, respectively, over time.  
 
Light/dark box 
 
Another common test used to assess anxiety-related behaviour in mice is the light/dark 
box. First developed by Crawley and Goodwin (1980), the light/dark box consists of an 
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aversive (light) compartment and safe (dark) compartment. Mice will naturally favour 
the dark enclosed compartment; however, an urge to explore the enclosure will drive the 
mouse to enter the light compartment. Measurements for evaluating anxiety include: 
latency to enter the dark compartment and latency to return to the light compartment, the 
number of transitions between the two compartments, as well as the total time spent in 
either compartment.  
 
Results: Behaviour 
 
Hippocampal-dependent memory 
 
No memory deficit in either LOWTAU or HIGHTAU mice at 12 months 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hippocampal-dependent memory was assessed using the T-maze forced alternation task 
in mice of 12 months of age. Correct responses were pooled into 2-day blocks for 
analysis. The percentage of correct trials initially following habituation for both 
transgenic lines were not found to differ from WT mice. Over the following 7 training 
blocks, both transgenic lines were seen to learn the task as well as WT littermates. With 
all groups reaching >90% correct by the end of training (training block: F(7, 126) = 8.348, p 
< 0.0001) (Figure 5.1.A)).  
Figure 5.1. No deficit in 
hippocampal-dependent 
memory in LOWTAU or 
HIGHTAU mice 
compared to WT 
controls. A) Percent 
correct responses across 
training block (2 days).  
B) Response time of 
sample (1st) run across 
training block. C) 
Response time of choice 
(2nd) run across training 
block. Error bars indicate 
SEM. 
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For both sample and choice runs, each mouse was timed from the point of placement 
into the start arm, until all four feet were over a specified line at the entry point to each 
goal arm. These values were recorded as ‘response times’. Prolonged response times for 
choice runs effectively introduce a delay to the trial, increasing the amount of time the 
mouse must remember its previous choice, and thus must be monitored. Mice that 
completed the trial with a response time of over two standard deviations from the mean 
response time of that genotype for two or more consecutive training blocks, for either the 
sample or choice run, were excluded from all analyses. One WT mouse fulfilled this 
criterion and was subsequently excluded from the analyses of all testing. Response times 
were not found to differ significantly for either the sample or choice runs for transgenic 
mice compared to WT, however, faster response times, particularly during the sample 
run, were noted for both HIGHTAU animals tested (Figure 5.1.B)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Varying delays were then introduced between the sample and choice runs. Delays of 1, 3 
and 6 minutes were chosen initially in the hope of detecting more subtle cognitive 
deficits. While the performance of WT and both transgenic lines was seen to decrease 
slightly with increasing delay, changes were not found to be significant. Therefore, to 
further increase cognitive demand, a delay time of 10 minutes was introduced. To 
prevent the mice becoming demotivated to perform the task, these trials were run 
interspersed pseudorandomly with the shortest delay time of 1 minute. All trials 
including a delay time of 1 minute were grouped for analysis (Figure 5.2.A)). For both 
Figure 5.2. No deficit in 
hippocampal-dependent 
memory in LOWTAU or 
HIGHTAU mice compared 
to WT controls with 
increasing delay. A) 
Percent correct responses 
with increasing delays of 1, 
3, 6 and 10 minutes. All 1-
minute delays have been 
averaged. B) Response 
times of sample (average of 
all sample runs during the 
testing period) and choice 
runs with increasing delay 
time. Error bars indicate 
SEM. 
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WT and LOWTAU mice, performance in trials using a 10-minute delay were again slightly 
decreased, however, accuracy remained above chance (50%). The slight reduction in the 
percentage of correct choices made by WT mice with increasing delay time excludes the 
possibility of contamination of the choices made by ‘intra-maze’ factors such as 
olfactory cues. In contrast, HIGHTAU mice did not display a consistent reduction in 
performance with the longest delay time. These results confirm an absence of a deficit in 
hippocampal-dependent memory in LOWTAU mice at this age, while also suggesting no 
impairment in HIGHTAU animals.   
 
Response times for delay trials were again recorded, all sample run times were grouped 
for analysis (Figure 5.2.B)). No significant differences were detected between transgenic 
and WT mice for either sample or choice runs, however, as was observed during 
training, HIGHTAU mice displayed extremely fast response times for sample runs.  
 
While firm conclusions about the status of hippocampal-dependent memory in HIGHTAU 
mice are prevented due to the low sample number, the similar behaviour within the T-
maze of the 2 mice tested certainly suggests that HIGHTAU mice are unimpaired in this 
memory task, as well as displaying a more rapid response time on the first sample run, 
possibly reflecting disinhibitory behaviour.   
 
Locomotor and anxiety testing 
 
Open field! 
 
In order to assess overall locomotor activity in the transgenic cohorts compared to WT 
mice, total distance travelled within the open field arena was measured. As expected, the 
total distance travelled over time decreased in WT mice, seeing a reduction of 37% from 
the first 5-minutes to the last 5 minute period, reflecting habituation to the environment. 
The behaviour of LOWTAU mice was seen to follow that displayed by WTs, with the total 
distance travelled over the 15-minute test period decreasing by 35%. Interestingly, 
HIGHTAU mice displayed a significantly different pattern of behaviour (genotype ' time: 
F(4, 38) = 4.562, p = 0.0042) (Figure 5.3.A)). The distance travelled by HIGHTAU mice in 
the first 5 minutes of being placed within the arena was lower than that seen in WT and 
LOWTAU animals, however, mice continued to explore at the same rate throughout the 
test period, displaying no habituation to the environment. In calculating the total path 
 111 
length of the three genotypes, it is seen that in fact all groups travelled the same total 
distance during the open field test (Figure 5.3.D)); HIGHTAU mice, however, were 
initially less active, suggesting increased anxiety, and then did not habituate to the 
environment staying moderately active throughout.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As initial levels of activity differed between genotypes, the activity change ratio was 
calculated to assess habituation. Using this score (outlined by Bolivar (2009), in which 
the distance travelled in the final 5 minute period is divided by the sum of the distance 
travelled in the first and final 5 minute blocks; a score of 0.5 indicates unchanged 
activity), we see that HIGHTAU mice do not habituate, in comparison to significant 
habituation displayed by the WT and LOWTAU groups (activity change ratio, 1-sample t-
test against a defined value of 0.5; WT: 0.39, p=0.0001; LOWTAU: 0.39, p=0.0002; 
HIGHTAU: 0.53, p=0.365) (Figure 5.3.B)).  
Figure 5.3. HIGHTAU mice display a lack of habituation to a novel environment in the open field. 
A) Distance travelled across 15 minutes, binned in 5-minute blocks. Two-way ANOVA reveals a 
significant interaction between genotype and time (p=0.0042).  B) Activity change ratio, representing 
the amount of activity in the 3rd period relative to the summed activity in the 1st and 3rd periods. One-
sample t-test with a hypothesised mean of 0.5 (no change in activity), significance indicated by 
p<0.001***. C) The relative time spent within a defined central region compared to time spent in the 
periphery of the arena (area equal between centre and periphery), binned in 5 minute blocks. D) Total 
distance travelled within the 15 minute testing period. Error bars indicate SEM. 
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Time spent within a defined central region (equal area within centre and surround) 
relative to the periphery of the arena was taken as a general marker of anxiety-like 
behaviour. All mice displayed some increase in the relative time spent within the centre 
throughout the time of the trial (time in centre: F(2, 38) = 8.592, p = 0.0008), reflecting a 
decrease in anxiety with habituation (Figure 5.3.C)). For WT mice, this saw relative 
centre-time increase from 31±3.5% in the 1st period to 49±4% in the 3rd period, a trend 
mirrored by LOWTAU mice (1st period: 31±3%, 3rd period: 46±4%). HIGHTAU mice, 
however, displayed a slightly different pattern of behaviour, with the amount of time 
they spent within the centre of the arena increasing to a lesser extent from 32±7% 
initially, to only 38±6% in the final 5 minutes. This final increase in HIGHTAU centre-
time also took longer to achieve, again suggesting a deficit in habituation in these mice. 
In spite of this, analysis of variance did not reveal significant differences between 
genotypes likely due to low sample numbers of HIGHTAU mice.  
 
Light/dark box 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Tendency towards a reduction in anxiety-like behaviour in HIGHTAU animals. A) 
Latency to first enter the dark compartment following placement within the light box. One-way 
ANOVA; §p=0.059 B) Latency to re-enter the light compartment. C) Percentage time spent within the 
dark compartment. Axis has been cut at 40%, the percentage of time that would be predicted for a 
mouse to spend within the dark compartment based on the relative sizes of each box. D) The number 
of transitions between the light and dark compartments. Error bars indicate SEM. 
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In addition to the open field, mice were also tested using the light/dark box. During this 
6-minute assessment, 6 parameters were measured including: latency to enter the dark 
compartment and latency to return to the light compartment, the number of transitions 
between the two compartments, as well as the total time spent in either compartment.  
 
WT mice behaved in a manner comparable to previous work using C57Bl/6 animals in 
all parameters measured (Costall et al., 1989). Neither LOWTAU nor HIGHTAU mice 
displayed significantly different behaviour from WT littermates in all elements of the 
test (Figure 5.4.); however, analysis of variance did reveal a tendency towards a 
difference between WT and HIGHTAU animals in the amount of time taken to first enter 
the dark compartment (p=0.059) (Figure 5.4.A)). Here, WT mice displayed a typical 
latency time to enter the dark compartment of 12.27 ± 2.93s. The longer latency of 
HIGHTAU mice (29.5 ± 6.5s) to enter the safety of the dark box may be interpreted as 
reduced anxiety in this line leading to an increase in exploration time of the light 
compartment in the first instance (Costall et al., 1989). However, one may therefore 
anticipate an increase in the percentage of time spent in the light compartment 
throughout the course of the test. By predicting the amount of time a mouse would spend 
in each compartment based on random activity, we would expect just 40% of the 6 
minutes to be spent in the dark box, a forecast based on the relative sizes of each section 
(3/5 light, 2/5 dark). In fact, WT mice stayed within the dark compartment for 69 ± 3.5% 
of their time, highlighting their natural aversion to open and bright spaces. HIGHTAU 
mice, however, spent only 53 ± 3% within the dark box. Although not significantly 
different, one may argue that HIGHTAU mice do show a leaning towards a reduction in 
time spent within the dark compartment, a measurement considered the most 
consistently useful in the assessment of the anxiolytic action of drugs (Bourin and 
Hascoet, 2003).  
Original work by Crawley and Goodwin (1980) on the anxiolytic effects of 
benzodiazepines, described that rather than the total amount of time spent within each 
compartment, the essential feature of anxiolytic action was an increase in the number of 
transitions between compartments. The number of transitions performed by WT mice in 
the present study averaged a characteristic 14.8 ± 1.3, with this value rising to 20.0 ± 2.0 
for HIGHTAU animals. While not significant, again one may conclude these results 
indicate potentially interesting differences in the anxiety-like behaviour of HIGHTAU 
mice. 
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Summary and Discussion: Behaviour 
 
In order to assess possible deficits in hippocampal-dependent spatial working memory 
within our tauopathy model, the T-maze forced alternation task was chosen, due to its 
high sensitivity to dysfunction within the hippocampus (O'Keefe, 1978).  
During training, both LOWTAU and HIGHTAU mice were seen to learn the maze as 
well as their WT counterparts, with all mice reaching over 90% correct by the final 
training block. In a bid to uncover more subtle deficits, a delay of 1, 3, 6 or 10 minutes 
was then introduced between the sample and choice runs, increasing the length of time 
during which the mouse must remember its previous choice. Again the performance of 
both LOWTAU and HIGHTAU mice did not differ from WT controls. These data show that 
LOWTAU mice do not display detectable impairment of hippocampal-dependent memory 
at 12 months of age using the T-maze forced alternation task. While sample numbers for 
HIGHTAU mice are extremely low, data collected thus far certainly does not suggest the 
presence of a deficit in spatial working memory in this line. Thus, it would seem that the 
large NFT load (Chapter 4) present within the hippocampus of HIGHTAU mice of this age, 
does not affect this form of hippocampal-dependent memory.  
 
Behavioural data collected from rTg4510 mice at 4.5 months (an age showing 
comparable pathology to HIGHTAU mice of 12/13-months) revealed a deficit in the 
retention of spatial reference memory by way of a decrease in search bias for the target 
quandrant in the Morris water maze (SantaCruz et al., 2005, Hoover et al., 2010). While 
not a test of working memory, the hippocampal-dependency of this task does indicate 
deficits in hippocampal function due to tau dysfunction, a feature not detected within the 
present study.  
 
For WT and LOWTAU mice during both the training and testing (delay) phases, response 
times were seen to be highly variable for the sample run, with an overall mean of 
approximately 10 seconds recorded for both groups. During the choice run, however, 
response times were found to be more consistent, with the average run time for each 
genotype consistently recorded as less than 5 seconds. Differences in the averaged 
response times between the sample and choice runs are attributed to the fact that prior to 
each sample run, a long period has ensued in which the mouse has been away from the 
maze, be that either the approximate 1 hour inter-trial interval, or overnight. The sample 
runs therefore include a time in which the mouse is re-familiarising itself with the maze, 
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resulting in higher variability. Choice runs, however, occur with a maximum of 10-
minutes (during delay trials) away from the maze, therefore producing more consistent 
response times.  It is of note, however; that the two HIGHTAU mice tested both displayed 
extremely fast response times on both the sample and choice runs, with response times 
of less than 3 seconds commonly recorded.  
 Despite the low sample number of HIGHTAU animals included within this test 
(n=2), both mice were seen to display these extremely fast response times on the first 
sample run with great consistency. It is thus possible that this finding may reflect 
reduced anxiety or disinhibition of the HIGHTAU line. As the mice perform well on the 
task, it negates the possibility that these particularly fast response times are the result of 
abnormal repetitive behaviour.  
 
Patients of FTDP-17 often display a range of behavioural disturbances earlier in the 
disease process, including disinhibition, with memory deficits manifesting only late in 
the disease (Wszolek et al., 2006). Data gathered through use of the T-maze forced 
alternation task therefore supports use of the HIGHTAU mouse line as a model for this 
neurodegenerative tauopathy.  
 
In contrast to the T-maze forced alternation task, results gathered from open field and 
light/dark box testing are somewhat harder to interpret. Primarily used within the present 
context to provide control testing for T-maze results, the open field and light/dark box 
are often simply described as assessing anxiety-related behaviours, which have been 
attributed to alterations within the amygdala (Cook et al., 2014). Use of these tests 
within the present study, however, exposed interesting changes in the behaviour of 
HIGHTAU mice compared to other genotypes, results that may in fact fit better with the 
earliest clinical symptoms of personality and behavioural changes presented by patients 
with FTDP-17 (Wszolek et al., 2006).  
  
Within the open field test, differences in the behaviour of HIGHTAU mice compared to 
both WT and LOWTAU animals were evident. While the total path length of each of the 
three genotypes was found to be comparable, analysis of the distance travelled plotted 
against time exposes that HIGHTAU mice achieve this overall distance through a different 
pattern of behaviour. WT and LOWTAU animals are seen to begin their time within the 
open field arena with a relatively high level of ambulation, which shows a characteristic 
decrease over the 15-minute test period as mice become habituated with their 
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environment (Bolivar, 2009). HIGHTAU mice, however, travel a shorter distance within 
the first 5 minutes than WT or LOWTAU mice, but then maintain this level of ambulation 
for the duration of the test. As all mice travel comparable total distances within the 15-
minutes, this result seems to reflect higher initial anxiety, with reduced habituation to the 
environment, rather than hypo- or hyperactivity. In calculating the activity change ratios 
outlined by Bolivar (2009), in which the initial level of activity is considered, we 
confirm an absence of habituation in HIGHTAU mice. Previous work with the similar 
mouse model, rTg4510, also revealed reduced habituation to an open field environment 
at an age displaying similar pathology to that studied in the present experiments 
(SantaCruz et al., 2005).  
 
All genotypes displayed an increase in the time spent within the central region of the 
open field during the 15-minute testing period, reflecting a decrease in anxiety due to 
habituation to the environment. While not significant, HIGHTAU mice did display a 
tendency to spend less time within the centre compared to both WT and LOWTAU mice. 
Again this result agrees with previous data from rTg4510 mice, in which a reduction in 
the time spent within the centre of an open field arena was seen at an age corresponding 
pathologically to that used presently (Cook et al., 2014). A reduction in time spent 
within the centre is typically taken as a marker of increased anxiety, however, results 
gathered through use of the light/dark box (discussed below) conflict with this 
conclusion. Conflicting results were also gathered by Cook et al., (2014) using separate 
anxiety testing, possibly leading one to conclude that rather than an increase in anxiety, a 
reduction in the amount of time P301L mutant tauopathy mouse models spend within the 
centre of an open field, may instead indicate a reduced ability to habituate to a novel 
environment.  
 
Testing using the light/dark box was used to assess simple anxiety-like behaviours of 
transgenic mice compared to WT controls. Neither LOWTAU nor HIGHTAU mice displayed 
significantly changed behaviour compared to their WT littermates in any of the six 
parameters considered; however, a tendency towards an increase in the time taken for 
HIGHTAU mice to first enter the dark compartment was noted. As is discussed by Bourin 
and Hascoet (2003), the meaning of this measure is somewhat difficult to determine and 
is thus rarely discussed. Potential deficits in the general locomotor activity of HIGHTAU 
mice resulting in simply slower ambulation (and therefore an increased latency to enter 
the dark box) are disregarded, due to the observation of a high number of transitions 
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between the two compartments throughout the test.  This is supported by the fact 
HIGHTAU mice travelled an equal overall distance to WT and LOWTAU mice within the 
open field test, as well as their extremely fast response times during both the sample and 
choice runs of the T-maze forced alternation task; thus demonstrating the ability of 
HIGHTAU mice to run quickly, and to continue moving for a time period exceeding the 
duration of the light/dark box test (6 mintues).  
It may be that a longer delay to enter the ‘safety’ of the dark box is a result of 
decreased anxiety, resulting in a longer period of exploration of the light compartment in 
the first instance, as is seen after administration of anxiolytic drugs such as Diazepam 
and GR38032F to WT C57Bl/6 mice (Costall et al., 1989). In addition, HIGHTAU mice 
show a leaning towards a reduced amount of total time spent within the light 
compartment and an increase in the number of transitions between compartments, both 
also indicative of a reduction in anxiety. Similarities between these data from HIGHTAU 
mice and similar rTg4510 mice in the light/dark box are again noted. Cook et al., (2014) 
describe an increase in the amount of time spent within the light compartment in 
rTg4510 mice, which agrees with the trend recorded in HIGHTAU animals. 
 
Overall, neither transgenic line exhibits a change in hippocampal-dependent spatial 
working memory compared to WT controls at 12 months of age, assessed using the T-
maze forced alternation task. This finding demonstrates the resilience of hippocampal 
memory networks to the tau dysfunction present in these lines, in particular within 
HIGHTAU animals, which already present with a high NFT load at this age (Chapter 4). 
Interestingly, HIGHTAU mice were seen to display extremely fast response times during 
the first, sample run within the T-maze, suggestive of disinhibitory behaviour. Indeed, 
both the open field and light/dark box tests also revealed interesting differences in the 
behaviour of HIGHTAU mice, including deficits in habituation to a novel environment and 
potential reductions in anxiety-like behaviour. In this respect, the pilot data presented 
suggests the HIGHTAU model emulates human FTDP-17, in that behavioural and 
personality changes, such as disinhibition, are among the first to show, with memory 
only loss occurring much later in the disease process (Wszolek et al., 2006).  Such 
results are also found to be somewhat comparable to data from tau-/- animals, suggesting 
that these behavioural changes are due to a loss of normal tau function (Ikegami et al., 
2000). 
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CHAPTER 6 
 
Introduction: Electrophysiology  
 
Due to the consensus that synaptic dysfunction is likely one of the first indicators of AD 
(Scheff et al., 2006), it followed that an electrophysiological characterisation be 
undertaken in the attempt to identify the earliest synaptic changes, prior to the 
development of NFT pathology. Extensive electrophysiological studies were completed 
at 4 months of age. This age corresponds to further work within the lab (Cummings et 
al., 2015) on the APPswexPS1M146V double transgenic (TASTPM) (Howlett et al., 2004) 
and the single APPswe transgenic (TAS10) (Richardson et al., 2003) mouse models of 
amyloid-" dysfunction, allowing for comparison, as well as being prior to the 
development of NFTs within TauD35 mice (Chapter 4). Some electrophysiological 
recordings were also conducted in 13- and 24-month-old mice to allow for an 
understanding of electrophysiological changes with age.  
 
At the time of electrophysiological testing, there was yet no indication that two 
transgenic lines existed within the TauD35 mouse model. Data from transgenic animals 
is therefore grouped within this chapter. Tail samples were, however, kept for post hoc 
genotyping and following copy number determination, data were plotted as scatters with 
LOWTAU and HIGHTAU indicated as can be seen throughout. For rare cases where copy 
number could not be determined, data has been presented in grey. Where potential 
differences between transgenic lines were noted all attempts were made to increase the 
sample numbers for both transgenic lines if mice were available.  
 
Within this chapter, I will discuss both whole-cell patch clamp experiments and 
extracellular recordings of synaptic transmission, performed using 400#m thick acute 
slices, cut transversely with respect to the hippocampus (Figure 6.1.A)). An introduction 
to the electrophysiological techniques employed is given in Appendix 1. Previous work 
within the lab has identified large changes in excitatory transmission within the 
hippocampus of the double transgenic TASTPM model of amyloid-" dysfunction 
(Cummings et al., 2015). In addition, the recent discovery of the postsynaptic role of tau, 
in the targeting of Fyn to dendritic spines and subsequent effects on NMDA-Rs (Chapter 
1) also fuelled the decision to concentrate solely on excitatory synaptic transmission 
within the hippocampus for this initial characterisation.  
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The acute transverse hippocampal slice (Figure 6.1.A)) provided the optimal 
experimental system for electrophysiological characterisation. Developed in 1971 
(Skrede and Westgaard), the acute slice typically describes a 300-500#m thick slice of 
hippocampus, which is kept alive in vitro. Acute slices made from mice, under the 
present conditions, can be kept healthy for up to 8 hours. The excitatory trisynaptic 
circuit of the hippocampus is preserved well in the transverse plane, exposing the 
extremely well defined and densely packed principle cell layers creating the circuit 
described in Chapter 1 (as can be seen as darker bands in Figure 6.1.A)).  This 
preparation provides the stability and clarity of cell layers needed for electrophysiology, 
with the lamina structure of the dendritic and cell body layers ideal for extracellular 
recordings.  
Figure 6.1. A) (Left) Pseudo-Normarski (or 
differential interference contrast (DIC)) 
image of an acute transverse hippocampal 
slice, obtained using the transmission settings 
on an Olympus Fluoview confocal microscope 
mounted on an upright Olympus BX50WI 
microscope and 5X water immersion objective. 
Scale: 400#m. 
Figure 6.1. B) (Right) Simplified schematic of 
the hippocampal network as presented in 
Figure 1.3. The network is principally 
unidirectional. Input from the entorhinal cortex 
connects to the DG and CA3 regions via the 
medial and lateral perforant paths. CA3 cells 
receive input from the dentate gyrus via mossy 
fibres (MF). CA3 connects to CA1 via the 
Schaffer collateral (SC) pathway. CA1 also 
receives direct input via the perforant path. CA1 
neurones provide input to the subiculum, which 
in turn forms the main output of the 
hippocampus.  
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!
CA1!
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SC!
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um!
From EC layer III 
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Cortex!
Fimbria!
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Two hippocampal regions were chosen for electrophysiological study: the CA1 and DG 
(Figure 6.1.B)). The CA1 region possesses some of the most vulnerable cells to the 
effects of tau dysfunction, as is demonstrated through their considerable NFT 
development and extensive loss in human AD patients as well as animal models of 
tauopathy (West et al., 1994, SantaCruz et al., 2005). The CA1 also provides a well-
characterised and accessible area, with the SC-CA1 synapses by far the most studied 
with regards to LTP.  
 
As is presented in Figure 6.1.B), in mice, the granule cells of the DG receive their 
principle input from layer II of the EC (ECII). This input comes in the form of two main 
pathways arising from the medial and lateral EC. Axons from the former, medial EC, 
project via the medial perforant path (mPP), which terminates in the middle third of the 
DG molecular layer (Hjorth-Simonsen and Jeune, 1972). The lateral EC in turn projects 
via the lateral perforant path (lPP), which is found to terminate on granule cell dendrites 
in the outer third of the molecular layer (Hjorth-Simonsen, 1972).  
In AD, it is the pyramidal neurons of the EC that are first affected by tau 
pathology (Braak and Braak, 1991), as well as seeing substantial neurone loss even 
during the early stages of the disease (Gomez-Isla et al., 1996). Therefore, along with the 
CA1, it appears that EC pyramidal neurones (in particular the large neurones of layer II 
(Morrison and Hof, 1997)) show a specific vulnerability to tau dysfunction. 
Consequently, in order to assess possible changes in neurotransmitter release from ECII, 
synaptic transmission was recorded from the postsynaptic DG granule cells. Whole-cell 
patch clamp techniques were used to investigate both spontaneous and evoked 
transmission, with paired-pulse ratio (PPR) recordings made following stimulation to the 
mPP.  
 
The mice presently under study express mutated tau under the CaMKII! promoter and 
thus, as expression levels within these vulnerable neurones is high (www.mouse.brain-
map.org (Lein et al., 2007)), one may predict degeneration of synaptic transmission 
within the EC and CA1 as an early event within the disease progression of this model.  
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Results: Electrophysiology  
 
Spontaneous excitatory postsynaptic currents 
 
Excitatory currents have been isolated within the present study through use of the 
gamma-aminobutyric acid (GABAA) receptor antagonist, SR95531 (also known as 
gabazine). Using whole-cell patch clamp techniques without application of exogenous 
stimulation, spontaneous excitatory postsynaptic currents (EPSCs) were investigated in 
both CA1 and the DG.  
 
Spontaneous postsynaptic currents can result from either the stochastic fusion of a single 
vesicle of neurotransmitter with the presynaptic membrane, therefore representing 
release at a single synapse (known as miniature (m) EPSCs); or from spontaneous action 
potentials (APs) within a presynaptic neurone triggering the release of neurotransmitter 
from a single axon, therefore representing release from either a single, or multiple 
presynaptic sites (known as spontaneous (s) EPSCs). These mEPSCs and sEPSCs can be 
separated from each other pharmacologically via application of the voltage-gated sodium 
channel blocker, tetrodotoxin (TTX), which inhibits the generation of APs and thus 
isolates mEPSCs. 
 
CA1 at 4 months of age 
 
Electrophysiological data from the hippocampus was initially collected at 4 months of 
age. This age is prior to the development of NFTs within TauD35 mice (Chapter 4), and 
thus investigates possible functional deficits prior to the development of one of the 
cardinal features of neurodegenerative tauopathies. 
 
No difference in the membrane resistance of CA1 pyramidal cells at 4 months 
of age 
 
Using whole-cell patch clamp techniques allows one to document certain properties 
about the patched cell. The membrane resistance of individual CA1 pyramidal cells was 
obtained from examination of a test-pulse (+5mV, 40ms), applied immediately after 
achieving whole-cell configuration and stabilization of the cell. Analysis of variance 
revealed no difference between genotypes in the presence or absence of TTX at 4 
months of age (Figure 6.2.).  
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Basal synaptic transmission within the CA1 region: No difference between 
genotypes for either spontaneous or miniature EPSCs 
 
The frequency of sEPSCs and mEPSCs within the CA1 region of the hippocampus were 
not found to differ significantly between genotypes, indicating that the number of release 
sites (n), release probability (Pr) and AP generation are not affected by the presence of 
the transgene at this young age (Figure 6.3.A)). A significant main effect of TTX was 
detected (TTX: F(1, 39) = 4.393, p<0.05), signifying the contribution of spontaneous AP-
driven release in the absence of TTX.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. No difference in the 
membrane resistance of CA1 pyramidal 
neurones recorded in the presence 
(mEPSC) and absence (sEPSC) of TTX 
at 4 months of age. Bar graphs represent 
data per animal, with statistical analysis run 
on these data. Error bars indicate SEM. 
Scatter plots represent results from 
individual cells from WT, LOWTAU and 
HIGHTAU animals. Sample numbers are 
given per cell, with sample numbers per 
animal given in parentheses.  
Figure 6.3. No difference 
between genotypes in 
spontaneous excitatory 
currents recorded in the 
presence (mEPSC) and 
absence (sEPSC) of TTX 
from CA1 pyramidal 
neurones at 4 months of 
age. A) Frequency of 
excitatory currents. A 
significant effect of TTX 
was detected using a two-
way ANOVA, significance 
indicated by p<0.05*. B) 
Representative current 
traces recorded in the 
presence and absence of 
TTX. C) Mean of the 
median amplitude. A 
significant effect of TTX 
was detected using a two-
way ANOVA, significance 
indicated by p<0.001***. 
D) No difference detected 
in the decay time of 
excitatory currents. Scale: 
10pA, 50ms. Error bars 
indicate SEM. Scatter plots 
indicate LOWTAU and 
HIGHTAU data.  
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TTX treatment was seen to result in a significant reduction in the median amplitude of 
EPSCs recorded from both WT and TauD35 mice (TTX: F(1, 37) = 19.25, p<0.0001) 
(Figure 6.3.C)). As sEPSCs are the result of spontaneous APs within the presynaptic 
neurone, it is likely this result reflects the AP-driven simultaneous release of 
neurotransmitter from multiple axonal boutons in the absence of TTX. The decay time of 
EPSCs was not seen to differ between genotypes or with TTX treatment (Figure 6.3.D)), 
indicating that neither the presence of the transgene nor TTX affects AMPA-R kinetics. 
 
Dentate Gyrus at 4 months of age 
 
No differences in the membrane resistance of DG granule cells at 4 months of 
age 
 
The membrane resistance of individual DG granule cells was obtained from examination 
of a test-pulse (+5mV, 40ms), applied immediately after achieving whole-cell 
configuration and stabilization of the recording. As was observed previously in data 
from CA1 pyramidal neurones, at this age, no differences were observed in granule cell 
membrane resistance between WT and TauD35 mice (Figure 6.4.).  
 
 
 
 
 
 
 
 
 
 
 
 
No differences in basal synaptic transmission within the DG  
 
Only sEPSCs were recorded from DG granule cells at 4-months. At this age, no 
differences were observed in the frequency, median amplitude or decay time constant of 
sEPSCs between WT and transgenic animals (Figure 6.5.).  
Figure 6.4. No difference in the 
membrane resistance of DG granule cells 
recorded at 4 months of age. Bar graphs 
represent data per animal, with statistical 
analysis run on these data. Error bars 
indicate SEM. Scatter plots represent 
results from individual cells from WT, 
LOWTAU and HIGHTAU animals. Sample 
numbers are given per cell, with sample 
numbers per animal given in parentheses.  
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CA1 at 13 months of age 
 
In order to investigate changes in spontaneous activity with increasing age and 
development of NFTs, sEPSCs were recorded within the CA1 region at 13 months of 
age. As was discovered later, this age corresponds to a time of large disparity in tau 
pathology between LOWTAU and HIGHTAU mice. Scatter plots presented throughout allow 
insight into potential differences in the electrophysiological properties between the two 
lines, with the transgenic lines discussed separately at points of interest.  
 
A significant difference in the membrane resistance of CA1 pyramidal cells at 
13 months of age 
 
The membrane resistance of CA1 pyramidal cells were obtained as described previously, 
from examination of a test-pulse (+5mV, 40ms), applied immediately after achieving 
whole-cell configuration and stabilization of the patch. In contrast to results observed at 
4-months, a significant difference (p=0.03) in the membrane resistance of these neurons 
was observed between WT and TauD35 mice at this older age (Figure 6.6.). An increase 
in the membrane resistance of layer III cortical pyramidal neurons has been noted 
previously in the rTg4510 mouse model at both early and advanced stages of pathology 
development (Crimins et al., 2012).  
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Figure 6.5. No difference in spontaneous 
excitatory currents recorded from DG 
granule cells at 4 months of age. A) No 
difference was detected in the frequency of 
spontaneous excitatory currents between WT 
and TauD35 animals. B) No difference in 
the mean of the median amplitude between 
genotypes. C) No difference detected in the 
decay time of excitatory currents between 
WT and TauD35 mice. Error bars indicate 
SEM. Scatter plots indicate LOWTAU and 
HIGHTAU data.  
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Basal synaptic transmission within the CA1 region: A trend toward an increase 
in median EPSC amplitude in TauD35 mice  
 
The frequencies of sEPSCs recorded from the CA1 region of the hippocampus were not 
found to differ significantly between genotypes (F(2, 17) = 0.6978, p=0.5) (Figure 6.7.A)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. Increased membrane 
resistance of TauD35 CA1 pyramidal 
neurones recorded at 13 months of 
age. Bar graphs represent data per 
animal, with an unpaired Student’s t-
test analysis run on these data (p=0.03). 
Error bars indicate SEM. Scatter plots 
represent results from individual cells 
from WT, LOWTAU and HIGHTAU 
animals. Sample numbers are given per 
cell, with sample numbers per animal 
given in parentheses.  
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Figure 6.7. A trend towards an 
increased spontaneous excitatory 
current amplitude recorded from 
CA1 pyramidal neurones of TauD35 
mice at 13 months of age. A) No 
difference was detected in the frequency 
of spontaneous excitatory currents 
between WT and TauD35 animals. B) A 
trend toward an increase in the mean of 
the median amplitude in TauD35 mice 
was observed. Unpaired Student’s t-test, 
p<0.05§. C) No difference detected in 
the decay time of excitatory currents 
between WT and TauD35 mice. Error 
bars indicate SEM. Scatter plots indicate 
LOWTAU and HIGHTAU data.  
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Comparison of the median amplitude of sEPSCs recorded at this age revealed a trend 
toward a significant increase in sEPSC amplitude in TauD35 animals compared to WT 
(p=0.051) (Figure 6.7.B)). No difference in the decay time of sEPSCs was detected 
between genotypes, indicating no change in AMPA-R receptor kinetics (Figure 6.7.C)). 
It is noted, however, that the frequency, amplitude and decay time constant of 
sEPSCs recorded from the 2 HIGHTAU mice included in this data set were low in 
comparison to data obtained from LOWTAU animals. This suggests that excitatory 
synaptic transmission at the SC-CA1 synapse is altered by the development of mature 
tau pathology in these mice; however, due to the age of the animals, unfortunately 
sample numbers could not be increased for HIGHTAU mice prior to the completion of this 
thesis. 
 
Evoked excitatory activity  
 
In addition to assessing basal excitatory synaptic transmission, more specific synaptic 
properties can be evaluated through evoking activity within particular axonal pathways 
and recording the responses of recipient neurones. Using whole-cell patch clamp 
techniques to record the responses of CA1 pyramidal and DG granule cells, activity was 
evoked within the SC and mPP pathways, respectively, using 2 closely time stimuli. The 
interval between the 2 stimuli can been varied, and the PPR calculated. As is discussed 
in Appendix 1, this allows one to infer certain information about the Pr of the synapses 
under study. As before, excitatory transmission has been isolated through use of the 
GABAA receptor antagonist, SR95531 (gabazine). 
 
CA1 at 4 months of age  
 
No difference in PPR at SC-CA1 synapses at 4 months of age 
 
The responses of CA1 pyramidal neurones to stimulation of the SC pathway were 
recorded, and the PPR calculated with varying inter-pulse interval. Both WT and 
TauD35 mice were found to display characteristic facilitation of the second response 
(Wu and Saggau, 1994) with a loss of stimulus interaction occurring with an inter-pulse 
interval of (400ms. Analysis of variance confirmed a main effect of inter-pulse interval 
(interval: F(6, 96) = 17.87, p<0.0001), with no differences detected between genotypes 
(Figure 6.8.). 
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Dentate Gyrus at 4 months of age 
 
Decrease in Pr of mPP-DG synapses in TauD35 mice at 4 months of age 
 
In order to investigate the possibility of tau dysfunction within ECII affecting the Pr of 
mPP synapses, we recorded responses from granule cells in response to paired-pulse 
stimulation of the mPP.  
The mPP synapses respond to paired stimuli by displaying characteristic 
depression, commonly thought to be due to an inherently high Pr, as reducing external 
Ca2+ eliminates this depression (McNaughton, 1980). WT mice in the present study were 
observed to display this typical feature, showing paired-pulse depression (PPD) in 
response to paired stimuli with intervals up to 800ms (Figure 6.9.A)). Interestingly, 
TauD35 mice exhibited a different pattern of behaviour, with a two-way ANOVA 
revealing a significant interaction of genotype with increasing inter-pulse interval 
(interval x genotype: F(6, 180) = 2.600, p=0.02). Sidak’s post hoc analysis exposed a 
significant increase in the PPR of TauD35 mice only at an interval of 100ms (p=0.04), 
despite paired-pulse facilitation (PPF) occurring at intervals of 50, 100 and 200ms in this 
line (Figure 6.9.A)). An increase in PPR here likely represents a decrease in the Pr of 
these synapses in TauD35 mice of 4 months of age.  
Figure 6.8. No difference in 
the paired-pulse ratio 
recorded at the SC-CA1 
synapse at 4 months of age.  
A) PPRs obtained from CA1 
pyramidal cells in response to 
stimulation of the Schaffer 
collateral pathway. No 
difference was detected between 
genotypes at inter-pulse 
intervals of 25-1500ms. Error 
bars indicate SEM. Scatter plots 
indicate LOWTAU and HIGHTAU 
data.  B)i) Representative traces 
of CA1 responses to paired 
stimulation at an inter-pulse 
interval of 25ms. Scale: 10pA, 
10ms B)ii) Representative 
traces of CA1 responses to 
paired stimulation at an inter-
pulse interval of 400ms. Scale: 
10pA, 20ms. WT (black), 
LOWTAU (orange), HIGHTAU 
(red).  
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AMPA-R desensitisation does not contribute to PPD 
 
While the PPD of mPP synapses is generally thought to be the result of an inherently 
high Pr (McNaughton, 1980), desensitisation of AMPA-Rs may play a role. AMPA-Rs 
mediate fast excitatory synaptic transmission within the central nervous system, opening 
and desensitising within a few milliseconds. The role of desensitisation is essential to 
ensure a brief postsynaptic current even if the time course of glutamate clearance from 
the synapse is not optimal. Colquhoun et al., (1992) showed that paired fast application 
(1ms) of glutamate to outside-out patches of DG granule cells resulted in depression of 
the second response. The removal of the presynaptic element in these experiments 
demonstrates an inherent property of granule cells (as well as pyramidal cells to a 
Figure 6.9. An increase in the paired-
pulse ratio recorded from TauD35 
DG granule cells in response to 
stimulation of the medial perforant 
pathway at 4 months of age. A) A 
significant increase in PPR was 
recorded at an inter-pulse interval of 
100ms in TauD35 mice compared to 
WT animals. Two-way ANOVA, with 
Sidak’s post hoc comparison, 
significance indicated by p<0.05* B) 
The shortest inter-pulse intervals of 25 
and 50ms recorded in the presence of 
AMPA-R desensitisation inhibitor, 
CTZ, revealed no contribution of 
AMPA-R desensitisation in causing 
PPD at these short intervals. Error bars 
indicate SEM. Scatter plots indicate 
LOWTAU and HIGHTAU data.  
25 50 100 200 400 800 1500
0.5
1.0
1.5
2.0
WT n=15
LOWTAU n=10
HIGHTAU n=7
TauD35 n=17
*
25 50 100 200 400 800 1500
0.5
1.0
1.5
2.0
WT n=15
LOWTAU n=10
HIGHTAU n=7
TauD35 n=17
*
A)!
Pa
ire
d-p
uls
e r
ati
o!
Inter-pulse interval (ms)!
25 50 25 50 25 50 25 50
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
WT n= 10
LOWTAU n=8
HIGHTAU n=2
WT n=5 
HIGHTAU n=2
LOWTAU n=4
TauD35 n=11
TauD35 n=6
Copy number 
not determined n=1
25 50 25 50 25 50 25 50
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
WT n= 10
LOWTAU n=8
HIGHTAU n=2
WT n=5 
HIGHTAU n=2
LOWTAU n=4
TauD35 n=11
TauD35 n=6
Copy number 
not determined n=1
25 50 25 50 25 50 25 50
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
WT n= 10
LOWTAU n=8
HIGHTAU n=2
WT n=5 
HIGHTAU n=2
LOWTAU n=4
TauD35 n=11
TauD35 n=6
Copy number 
not determined n=1B)!
Pa
ire
d-p
uls
e r
ati
o!
Inter-pulse interval (ms)!
SR DMSO CTZ DMSO 
wash-out 
 129 
slightly lesser extent) to show depression of the second of two responses, a property 
likely caused by the desensitisation of AMPA-Rs. It is possible that the pre- and 
postsynaptic elements combine in producing the characteristic PPD of mPP synapses.  
In order to examine whether AMPA-R desensitisation contributed to the PPD 
recorded at the shortest inter-pulse intervals tested, as well as examine any possible 
differences in desensitisation between genotypes, PPRs were obtained using 25 and 
50ms inter-pulse intervals, in the presence of the AMPA-R desensitization inhibitor, 
cyclothiazide (CTZ, 100#M). Control experiments were performed using the vehicle, 
dimethyl sulfoxide (DMSO, 0.025%) on each slice prior to the application of CTZ. This 
allowed for the exclusion of possible side effects on synaptic transmission caused by 
presence of the solvent, as has been reported previously (McLarnon et al., 1986).  
 
AMPA-R desensitisation was not found to contribute to the PPD depression observed in 
WT mice at the shortest inter-pulse intervals of 25 and 50ms. In addition, the PPRs 
calculated for transgenic mice at these shortest inter-pulse intervals were not affected by 
the inhibition of AMPA-R desensitisation (Figure 6.9.B)). 
 
CA1 at 13 months of age 
 
No difference in PPR at SC-CA1 synapses at 13-months 
 
Both WT and TauD35 mice were found to display the PPF characteristic of this synapse 
(Wu and Saggau, 1994) at inter-pulse intervals below 400ms. A main effect of interval 
was detected assessed using a two-way ANOVA (interval: F(6, 66) = 46.06, p<0.0001) 
(Figure 6.10.). Unfortunately, it was later discovered that no HIGHTAU mice had been 
included within this data set, and thus scatter plots of transgenic data are not included.  
 
 
 
 
 
 
 
 
 
Figure 6.10. No difference 
in the paired-pulse ratio 
recorded from CA1 
pyramidal cells in response 
to stimulation of the 
Schaffer collateral 
pathway at 13 months of 
age. No difference was 
detected between WT and 
LOWTAU mice at inter-pulse 
intervals of 25-1500ms. 
Error bars indicate SEM. 
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Extracellular field recordings  
 
In order to assess various properties of synaptic transmission from a population of SC-
CA1 synapses, extracellular recording techniques were employed. Stimulation of CA3 
axons was used to evoke dendritic responses from a population of CA1 pyramidal 
neurone apical dendrites, recorded using an electrode placed within the stratum radiatum 
of CA1. Further details of the theory and analysis of extracellular field recordings can be 
found in Appendix 1. 
 
This recording technique was used to assess: 1) overall synaptic efficiency (input-output 
relationship), 2) release probability (PPR recordings) and 3) synaptic plasticity (long-
term potentiation (LTP) experiments) from a population of SC-CA1 synapses. As is 
described in Appendix 1, LTP experiments have been split temporally for analysis, into 
post-tetanic potentiation (PTP, 1st minute post-tetanus), short-term potentiation (STP, 8-
12 minutes post-tetanus) and LTP (51-60 minutes post-tetanus).  
 
4 months of age 
 
No difference in basal synaptic transmission of SC-CA1 synapses 
 
Extracellular field recordings from SC-CA1 synapses at 4 months of age were contributed to 
by undergraduate students, Kenrick Yap and Emma Spowart under my supervision.  
 
The input-output relationship with increasing stimulus strength was used as a measure of 
overall synaptic efficacy, as well as providing a measure by which to determine the 
stimulus strength for subsequent recording. As one would expect, the fEPSP size 
(determined using initial fEPSP slope) was seen to increase with increasing stimulus 
strength for both genotypes, with a main effect of input voltage identified (voltage: F(7, 
280) = 208.7, p<0.0001) (Figure 6.11.A)). No difference in input-output relationship was 
detected between WT and TauD35 animals. It was noted that the fEPSP response 
recorded from LOWTAU mice appeared consistently smaller compared to WT and 
HIGHTAU animals. Data were therefore separated for analysis using a two-way ANOVA 
with Tukey’s post hoc test. A significant reduction in LOWTAU fEPSP response was seen 
for input voltages exceeding 60V (60V: p=0.05; 70V: p=0.032; 80V: p=0.031). A 
reduction in input-output relationship has been observed previously in female rTg4510 
mice, at an age prior to the development of detectable tau pathology (Dalby et al., 
2014).  
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As whole-cell patch clamp recordings of PPR at SC-CA1 synapses only examine 
synapses impinging on that one cell, PPR over increasing inter-pulse intervals was also 
examined using extracellular field recordings, allowing synapses onto numerous CA1 
neurones to be investigated simultaneously. As observed using patch, the PPR calculated 
displayed facilitation for inter-pulse intervals <400ms (interval: F(4, 164) = 194.9, 
p<0.0001), with no differences detected between WT and transgenic mice (Figure 
6.11.B)).  
 
No difference in long-term synaptic plasticity 
 
In order to investigate long-term synaptic plasticity at SC-CA1 synapses in 4-month-old 
mice, an extracellular stimulating electrode was used to apply high-frequency tetanic 
stimulation to the SC axons. Two protocols were employed; one, referred to as ‘weak’ 
stimulation consisted of 3 trains of 20 pulses at 100Hz, repeated three times with an 
interval of 1.5 seconds. The other, referred to as ‘strong’ stimulation consisted of 5 trains 
of 100 pulses at 100Hz, repeated 5 times with an interval of 1.5 seconds. These two 
protocols aimed at overcoming any differences that may lie in the ability to induce LTP, 
such as changes in induction threshold (Schneider et al., 2001). fEPSP responses were 
monitored for 60 minutes post-tetanus.  
Figure 6.11. Basal synaptic transmission recorded at the SC-CA1 synapse at 4 months of age. 
A) Input-output relationship showed increased fEPSP amplitude in response to increasing stimulus 
intensity applied to SC axons for both WT and TauD35 mice. No difference was detected between 
genotypes. (Insert) shows separated LOWTAU and HIGHTAU data (Two-way ANOVA, Tukey’s post hoc 
comparison, p=0.05§, p<0.05   ).  B) PPR obtained from a population of CA1 neurones in response 
to stimulation of SC axons. No difference was detected between genotypes at inter-pulse intervals of 
25-400ms. (Insert) shows separated LOWTAU and HIGHTAU data. Error bars indicate SEM. Scatter 
plots indicate LOWTAU and HIGHTAU data.  
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The responses to both weak (Figure 6.13.A)i)) and strong (Figure 6.12.A)) tetanic 
stimulation were compared between WT and TauD35 mice. No differences were 
detected in PTP, STP or LTP between genotypes, using either stimulation. As one may 
expect, LTP induction using the strong high frequency tetanus resulted in a larger 
magnitude LTP (WT: 167.2 ± 12.3%) than was produced following weaker stimulation 
(WT: 139.5 ± 5.8%). The absence of a difference between genotypes implies that 
TauD35 mice at 4 months of age are capable of sustaining extremely strong tetanic 
stimulation at the SC-CA1 synapse and that mechanisms of LTP induction are in place.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All LTP experiments were monitored using paired stimuli, applied with a constant inter-
pulse interval of 50ms. This allowed for PPR calculation and thus an indication of the 
site of LTP expression, be it pre- or postsynaptic (McNaughton, 1982). The PPR 
recorded from WT mice during LTP was compared to 100% using a one-sample t-test. 
Transgenic data was then compared to WT by was of an unpaired Student’s t-test. This 
method of analysis provided an indication of what is typical for a WT C57Bl/6J mouse, 
while subsequently determining whether the presence of the transgene in TauD35 mice 
altered this.  The PPR recorded during LTP in WT mice was not found to differ 
significantly from 100% following weak stimulation, with no differences detected 
between genotypes (Figure 6.13.A)ii). These data indicate the source of the LTP 
Figure 6.12. No difference in LTP 
recorded at the SC-CA1 synapse at 4 
months of age via ‘strong’ tetanic 
stimulation. A) No difference was 
observed in PTP, STP or LTP between 
genotypes. B) PPR calculated throughout 
field recording. WT mice showed a 
significant increase from 100 in PPR 
during LTP. No difference was detected 
between WT and TauD35 mice. C)i) 
Averaged fEPSP during LTP (51-60 
minutes). C)ii) Averaged PPR obtained 
during LTP. Scatter plots indicate 
LOWTAU and HIGHTAU data. Error bars 
indicate SEM. 
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recorded to be postsynaptic. Interestingly, strong stimulation was seen to produce a 
significant increase in WT PPR recorded during 51-60 minutes (p=0.002), indicating a 
reduction in Pr, with no difference detected between WT and TauD35 mice (p=0.2) 
(Figure 6.12.B)). This reduction in Pr would work to oppose potentiation, possibly 
acting as a compensatory mechanism to the strong high frequency stimulation, indicating 
that the observed potentiation has a large postsynaptic component.  
 
WT mice exhibit NMDA-R independent synaptic plasticity at 4-months 
 
In using the NMDA-R antagonist, AP5, we aimed to investigate whether the P301L 
mutation harboured by the TauD35 model affects the NMDA-R-dependence of LTP at 
SC-CA1 synapses. As discussed in Appendix 1, while NMDA-R-dependent LTP is 
believed to provide the primary mechanism of potentiation at this synapse (Collingridge 
et al., 1983), other forms, namely voltage-gated Ca2+ channel (VGCC)-dependent LTP, 
have been also described here (Grover and Teyler, 1990).  
 
The more active D- isomer of AP5 was bath applied at a concentration of 25#M for 15 
minutes prior to the commencement of baseline recording to allow for equilibration. 
Following establishment of a stable baseline and application of the tetanus, AP5 was 
maintained within the bath for a further 15 minutes prior to washout. Theoretically, by 
blocking NMDA-Rs during the high frequency tetanus, the postsynaptic influx of Ca2+ 
required for the induction of LTP (Appendix 1) is prevented, thus inhibiting synaptic 
potentiation. Responses were recorded for a further 60 minutes without the presence of 
AP5 before the application of a second tetanus to ensure the slices were viable and 
potentiation could be established (Figure 6.13.A)i)).  
  
Analysis of variance revealed that AP5 caused a significant reduction of both PTP (AP5: 
F(1, 47) = 79.30, p<0.0001) and STP (AP5: F(1, 47) = 79.34, p<0.0001) (Figure 6.13.B)i) and 
C)i), supporting original work using the NMDA-R antagonist (Collingridge et al., 1983). 
However, between 5 and 25 minutes post-tetanus, a potentiation of the fEPSP was seen 
to develop to some degree in both genotypes (Figure 6.13.A)i). Analysis revealed that in 
the presence of AP5, 4-month-old WT mice do not display a significant reduction of 
LTP. This result is in contrast to data collected from TauD35 mice, where AP5 was seen 
to significantly reduce the magnitude of LTP at this age (p=0.002) (Figure 6.13.D)i).  
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Figure 6.13. PTP, STP and 
LTP recorded at the SC-CA1 
synapse in the absence and 
presence of NMDA-R 
antagonist, AP5 at 4 months of 
age via ‘weak’ tetanic 
stimulation. A)i) Field 
recordings form WT and TauD35 
mice in the presence and absence 
of AP5. While not included in 
analysis, a second tetanus was 
performed to ensure viability of 
slices. A)ii) PPR obtained (50ms 
inter-pulse interval) in the 
presence and absence of AP5. 
B)i) PTP (1st minute) recorded in 
the presence and absence of AP5. 
B)ii) PPR obtained during PTP in 
the presence and absence of AP5. 
C)i) STP (8-12 minutes) recorded 
in the presence and absence of 
AP5. C)ii) PPR obtained during 
STP in the presence and absence 
of AP5. D)i) LTP (51-60 
minutes) recorded in the presence 
and absence of AP5. D)ii) PPR 
obtained during LTP in the 
presence and absence of AP5. 
Two-way ANOVA with Sidak’s 
post hoc comparison, 
significance indicated by 
p<0.05*, p<0.01**, p<0.001***. 
Error bars indicate SEM. Scatter 
plots indicate LOWTAU and 
HIGHTAU data.  
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The lack of NMDA-R-dependent LTP at this synapse in WT mice contradicts the 
previous long held opinion that the form of LTP expressed here is dependent upon the 
NMDA-R (Collingridge et al., 1983, Malenka, 1991). It is possible that this may 
represent species differences, as earlier work was completed using rats instead of mice.  
Present data indeed suggest, that under certain conditions, murine SC-CA1 synapses can 
potentiate without Ca2+ influx through postsynaptic NMDA-Rs at 4 months of age.  
 
Analysis of the PPR calculated during PTP, revealed that the reduction in PTP observed 
in the presence of AP5, was likely due to a decrease in Pr during this first minute. 
Analysis of variance of PPR during this time exposed a main effect of AP5 (AP5: F(1, 47) 
= 6.625, p=0.013) (Figure 6.13..B)ii). No change in PPR was detected during either STP 
or LTP (Figure 6.13.C)ii) and D)ii), implying that any effects of AP5 during these 
periods are not the result of presynaptic changes.  
 
Due to the atypical timing of LTP onset (over 5-25 minutes post-tetanus) control 
experiments were performed in order to rule out any effects of AP5 washout (Figure 
6.14.). During these experiments, AP5 was washed out of the bath solution immediately 
following tetanic stimulation. Data revealed a similar increasing synaptic potentiation 
over time, with a significant LTP developing by 51-60 minutes in WT slices (one-
sample t-test, compared to 100%, p=0.021). This slowly developing LTP was also 
witnessed by Grover and Teyler (1990) following high frequency stimulation with AP5 
present throughout the experiment, supporting the conclusion that the washout of AP5 
does not contribute to the increasing potentiation seen in the present experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14. LTP recorded 
from the SC-CA1 synapse 
of WT mice at 4 months of 
age in the presence of AP5. 
AP5 was washed out 
immediately following tetanic 
stimulation in order to rule 
out any effect of AP5 
washout in causing the slowly 
developing LTP witnessed in 
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13 months of age 
 
Extracellular field recordings of SC-CA1 synapses at 13-months 
 
No difference in basal synaptic transmission of SC-CA1 synapses 
 
The input-output relationship between increasing stimulus strength and fEPSP amplitude 
was assessed at 13-months (Figure 6.15.A)). As expected, both genotypes displayed an 
increase in fEPSP size with increasing stimulus strength, with a main effect of voltage 
detected (voltage: F(7, 112) = 79.47, p<0.0001). In contrast to data collected at 4-months, 
no difference was observed in the input-output relationship between WT, LOWTAU and 
HIGHTAU animals. Only a single HIGHTAU sample was included in this data set.  
 
PPR was assessed via field recordings in 13-month-old animals (Figure 6.15.B)). As we 
have observed previously at SC-CA1 synapses, the PPR decreased with increasing inter-
pulse stimulus, with the two stimuli ceasing to interact by an inter-pulse interval of 
400ms (interval: F(4, 124) = 97.44, p<0.0001). No difference was observed between WT 
and TauD35 mice. At the shortest interval of 25ms, it was noted that HIGHTAU samples 
(n=4) appeared to display an increase in PPR, suggestive of a reduction in Pr. Upon 
data separation, Tukey’s post hoc analysis revealed a significant difference between 
LOWTAU and HIGHTAU animals, at this 25ms interval (p=0.03).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.15. Basal synaptic transmission recorded at the SC-CA1 synapse at 13 months of age. A) 
Input-output relationship showed increased fEPSP amplitude in response to increasing stimulus 
intensity applied to SC axons for both WT and TauD35 mice. No difference was detected between 
genotypes. B) PPR obtained from a population of CA1 neurones in response to stimulation of SC 
axons. No difference was detected between genotypes at inter-pulse intervals of 25-400ms. (Insert) 
shows separated LOWTAU and HIGHTAU data recorded using 25 and 50ms inter-pulse intervals (Two-
way ANOVA, Tukey’s post hoc comparison, p<0.05  ).  Error bars indicate SEM. Scatter plots indicate 
LOWTAU and HIGHTAU data.  
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No difference in long-term synaptic plasticity 
 
LTP was assessed at 13 months of age using the weak stimulation protocol. No 
difference was detected in PTP, STP or LTP between WT and TauD35 mice (Figure 
6.16.A)i)). Analysis of the PPR calculated during LTP, exposed a significant decrease 
from 100% in WT mice (one-sample t-test, p=0.03), revealing a presynaptic contribution 
to LTP in the form of an increase in Pr. TauD35 data did not differ from WT, suggesting 
an increase in Pr during LTP in both genotypes (Figure 6.16.A)ii)).  
 
Both WT and TauD35 mice exhibit a significant amount of NMDAR-dependent 
synaptic plasticity 
 
Experiments using the NMDA-R antagonist, AP5, were conducted at 13-months to study 
possible changes in the NMDA-R-dependence of LTP with age, as has previously been 
suggested to occur at SC-CA1 synapses in rats (Shankar et al., 1998).  
 
As was observed at 4 months of age, analysis of variance revealed a significant effect of 
AP5 in reducing the magnitude of PTP (AP5: F(1, 55) = 186.1, p<0.0001) and STP (AP5: 
F(1, 55) = 122.5, p<0.0001) (Figure 6.16.B)i) and C)i). However, in contrast to data 
collected at 4-months, at 13 months of age, AP5 was seen to cause a significant 
reduction of LTP in both WT and TauD35 animals (AP5: F(1, 55) = 27.01, p<0.0001) 
(Figure 6.16.D)i)). This reduction in LTP in WT mice indicates that at this age, WT mice 
possess LTP induction mechanisms dependent on NMDA-Rs. It is however of note, that 
despite a significant overall effect of AP5, a proportion of potentiation does remain 
within these mice, implying induction through NMDA-R-independent processes occurs 
to some extent (Figure 6.16.A)i)).  
 
Analysis of the PPR obtained during both PTP and STP revealed an effect of AP5 
treatment on Pr compared to control (no AP5) (AP5: PTP: F(1, 55) = 11.82, p=0.001; STP: 
F(1, 55) = 4.471, p=0.039) (Figure 6.16.B)ii) and C)ii)). This AP5-dependent change in the 
PPR calculated during STP contrasts with 4-month data, where the reduction in fEPSP 
response size was found to be due to postsynaptic mechanisms. These data instead imply 
a presynaptic component, in that the decrease in STP magnitude may be in part due to a 
reduced Pr. The effect of AP5 on LTP, however, did not appear to be due to changes in 
Pr (Figure 6.16.D)ii)).  
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Figure 6.16. PTP, STP and 
LTP recorded at the SC-CA1 
synapse in the absence and 
presence of NMDA-R 
antagonist, AP5 at 13 months 
of age via ‘weak’ tetanic 
stimulation. A)i) Field 
recordings form WT and 
TauD35 mice in the presence 
and absence of AP5. A)ii) PPR 
obtained (50ms inter-pulse 
interval) in the presence and 
absence of AP5. B)i) PTP (1st 
minute) recorded in the 
presence and absence of AP5. 
B)ii) PPR obtained during PTP 
in the presence and absence of 
AP5. C)i) STP (8-12 minutes) 
recorded in the presence and 
absence of AP5. C)ii) PPR 
obtained during STP in the 
presence and absence of AP5. 
D)i) LTP (51-60 minutes) 
recorded in the presence and 
absence of AP5. D)ii) PPR 
obtained during LTP in the 
presence and absence of AP5. 
Two-way ANOVA with 
Sidak’s post hoc comparison, 
significance indicated by 
p<0.05*, p<0.01**, 
p<0.001***. Error bars 
indicate SEM. Scatter plots 
indicate LOWTAU and HIGHTAU 
data.  
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24 months of age 
 
In addition to 4- and 13-month-old data, extracellular recordings were also completed at 
24 months of age. While this old age presents some difficulty in obtaining patch clamp 
recordings, extracellular field recordings can be made with ease, allowing insight into 
the properties of synaptic transmission at this age. Unfortunately, due to the advanced 
age of the animals, sample numbers at 24-months were low for both WT and TauD35 
groups. Due to the development of a pathological phenotype between 17- and 20-months 
and consequent obligation to cull these animals, HIGHTAU mice were not available for 
experimentation at 24 months of age.  
 
Extracellular field recordings at 24-months 
 
No difference in basal synaptic transmission 
 
An increase in the fEPSP amplitude with increasing stimulus intensity was observed in 
both WT and TauD35 mice at 24 months of age (voltage: F(7, 98) = 155.5, p<0.0001). As 
was seen at 13-months, no differences were detected in the input-output relationship 
between WT and transgenic animals (Figure 6.17.A)).  
 
Both WT and TauD35 mice displayed similar PPR across all inter-pulse intervals. As 
was observed at younger ages, a decline toward a ratio of 1 was seen with increasing 
inter-pulse interval (interval: F(4, 56) = 81.34, p<0.0001) (Figure 6.17.B)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17. Basal synaptic transmission recorded at the SC-CA1 synapse at 24 months of age. 
A) Input-output relationship showed increased fEPSP amplitude in response to increasing stimulus 
intensity applied to SC axons for both WT and TauD35 mice. No difference was detected between 
genotypes. B) PPR obtained from a population of CA1 neurones in response to stimulation of SC 
axons. No difference was detected between genotypes at inter-pulse intervals of 25-400ms. Error bars 
indicate SEM.  
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No difference in long-term synaptic plasticity 
 
The weak tetantic stimulation protocol produced consistent potentiation within both WT 
and TauD35 mice at 24 months of age. No differences were detected in the levels of 
PTP, STP or LTP between the genotypes (Figure 6.18.A)i)), with analysis of PPR during 
LTP revealing the postsynaptic locus of LTP expression (Figure 6.18.A)ii)).  
 
Both WT and TauD35 mice display NMDAR-independent synaptic plasticity 
 
The addition of AP5 at 24-months led to the now characteristic reduction of PTP and 
inhibition of STP, seen at previous ages, in both WT and TauD35 animals (AP5: PTP: 
F(1, 20) = 75.51, p<0.0001; STP: F(1, 20) = 38.40, p<0.0001) (Figure 6.18.B)i) and C)i)). No 
effect of AP5 was detected during LTP (Figure 6.18.D)i)), indicating the development of 
an NMDA-R-independent form of potentiation over the 60-minute recording time 
(Figure 6.18.A)i)).  
 
As recognized previously, AP5 had a significant effect on the PPR calculated during 
PTP (AP5: F(1, 20) = 6.430, p=0.02) (Figure 6.18.B)ii)), suggesting a reduced Pr compared 
to control (no AP5) as the cause of the reduction in fEPSP response size during the first 
minute post-tetanus in the presence of the antagonist. PPR during both STP and LTP did 
not display an effect of AP5 (Figure 6.18.C)ii) and D)ii)), suggesting postsynaptic 
mechanisms are responsible for the inhibition of STP and development of LTP.  
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Figure 6.18. PTP, STP and 
LTP recorded at the SC-CA1 
synapse in the absence and 
presence of NMDA-R 
antagonist, AP5 at 24 months 
of age via ‘weak’ tetanic 
stimulation. A)i) Field 
recordings form WT and TauD35 
mice in the presence and absence 
of AP5. While not included in 
analysis, a second tetanus was 
performed to ensure viability of 
slices. A)ii) PPR obtained (50ms 
inter-pulse interval) in the 
presence and absence of AP5. 
B)i) PTP (1st minute) recorded in 
the presence and absence of AP5. 
B)ii) PPR obtained during PTP in 
the presence and absence of AP5. 
C)i) STP (8-12 minutes) recorded 
in the presence and absence of 
AP5. C)ii) PPR obtained during 
STP in the presence and absence 
of AP5. D)i) LTP (51-60 
minutes) recorded in the presence 
and absence of AP5. D)ii) PPR 
obtained during LTP in the 
presence and absence of AP5. 
Two-way ANOVA with Sidak’s 
post hoc comparison, 
significance indicated by 
p<0.05*, p<0.001***. Error bars 
indicate SEM. Scatter plots 
indicate LOWTAU and HIGHTAU 
data.  
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No change in WT SC-CA1 properties with ageing 
 
Interestingly, extracellular field recordings revealed remarkable consistency at SC-CA1 
synapses in WT mice with ageing. In comparing select elements such as half-maximal 
fEPSP response size (Figure 6.19.A), PPRs obtained using 25ms inter-pulse interval (Figure 
6.19.B), LTP (Figure 6.19.C) and PPR calculated during LTP (Figure 6.19.D), we expose 
how CA3-CA1 connectivity, CA3 Pr, as well as the SC-CA1 long-term plasticity together 
with the postsynaptic locus of its expression, remain consistent (one-way ANOVA) in 
WT animals between 4 and 24 months of age.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.19. Extracellular field data collected from SC-CA1 synapses, compared across 4-, 13- 
and 24-months. A) Half maximal response to increasing stimulus voltage collected using an input-
output protocol. B) 25ms inter-pulse interval data collected during PPR experiments. C) Average LTP 
(51-60 minutes post-tetanus). D) PPR obtained during LTP. Error bars indicate SEM. 
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Summary and Discussion: Electrophysiology 
 
Unfortunately, at the time of electrophysiological testing it was not yet known that two 
transgenic groups existed within the TauD35 line. Thus, electrophysiological 
experiments were not designed to accommodate this fact, resulting in inconsistent 
sample sizes frequently too small for the analysis of LOWTAU and HIGHTAU data 
separately. Data from transgenic animals has therefore been grouped within this chapter. 
Following post-hoc copy number analysis of all mice, data from LOWTAU and HIGHTAU 
mice were separated and represented as scatter plots. For many experiments, 
electrophysiological data gathered from both transgenic lines were comparable. For 
those data where possible differences were observed, data were separated and all effort 
made to increase sample numbers for the individual transgenic lines. Where mice of the 
correct age/genotype were not available and thus sample numbers could not be 
increased, results are treated as pilot data for further experimentation, with caution 
exercised in the interpretation of such results.  
 
 A summary of the central data recorded has been tabulated within the following 
discussion according to the type of experiment. Data is then discussed only where 
significant differences are observed between WT and TauD35 animals.  
 
Spontaneous Excitatory activity 
 
 
 
 
Spontaneous Excitatory Activity 
 Membrane 
resistance Frequency Amplitude Decay 
4m 
CA1 
mEPSC sEPSC mEPSC sEPSC mEPSC sEPSC mEPSC sEPSC 
-- -- -- -- -- -- -- -- 
DG 
sEPSC 
-- 
sEPSC 
-- 
sEPSC 
-- 
sEPSC 
-- 
13m CA1 
sEPSC sEPSC sEPSC sEPSC 
         TauD35* --     TauD35§ -- 
Table 6.1. Summary table of spontaneous excitatory activity recorded from the CA1 and DG at 
4- and 13 months of age. Differences indicated are between WT and TauD35 mice. (--) indicates no 
significant difference observed between genotypes. Arrows indicate direction of the change. 
Significance of difference given by *p<0.05, §p=0.051. 
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Embedded within the lipid bilayer are ion channels, which provide a route for ions to 
cross the membrane. The fewer ion channels that are open, the higher the membrane 
resistance. Membrane resistance is therefore a measure of membrane permeability, or 
how many ion channels are open; as well as being related to cell surface area, as 
(assuming constant channel density) smaller cells express fewer ion channels.  
At 13 months of age, a significant increase in membrane resistance is observed 
in the CA1 pyramidal neurons of TauD35 mice. At this age, transgenic animals (both 
LOWTAU and HIGHTAU) exhibit NFT pathology. It is therefore hypothesised that 
intracellular tau mislocation/aggregation may affect ion channel trafficking at this age. It 
is also possible that the detachment of tau from MTs and relocation to the 
somatodendritic compartment within these neurons could possibly result in MT severing 
and disassembly (discussed in Jean and Baas, 2013), leading to a reduction in MT 
scaffold support of the neurone and thus axonal or dendritic retraction.  
 
In addition to this increase in membrane resistance, 13-month-old TauD35 mice display 
a trend towards an increase in the amplitude of sEPSCs compared to WT. An increase in 
sEPSC amplitude may suggest the possibility of alterations to postsynaptic glutamate 
(AMPA-Rs) receptors in TauD35 animals, such as the insertion of new receptors or 
alterations in the conductance of existing receptors; however, the difference here is 
small, and may possibly be influenced by an increase in membrane resistance improving 
the clamp of the cell.  
 
Inspection of the scatter of 13-month transgenic sEPSC data (Figure 6.7.A),B) and C)) 
revealed that despite very low sample numbers, currents recorded from HIGHTAU mice 
consistently displayed a lower frequency and decay time compared to data collected 
from WT and LOWTAU animals.  
 A reduction in sEPSC frequency suggests either a reduction in n, Pr or a 
decrease in AP-driven spontaneous release of glutamate from SC afferent terminals in 
HIGHTAU animals at this age. The extracellular PPR recordings at 13-months did not 
reveal a significant interaction between genotypes; however, a reduction in Pr was seen 
at the shortest inter-pulse interval of 25ms (Figure 6.15.B)). This observation suggests a 
possible contribution of reduced Pr to the lower sEPSC frequencies recorded at this age 
in HIGHTAU mice. The seemingly lower decay time constants of the HIGHTAU sEPSC 
currents suggest possible changes in AMPA-R kinetics. 
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Paired-pulse ratio 
 
 
 
 
 
The responses of WT CA1 pyramidal cells to paired-pulse stimulation of the SC axons 
displayed characteristic facilitation of the second response at inter-pulse intervals 
<400ms. This characteristic PPF is explained through the residual Ca2+ hypothesis 
(discussed in Appendix 1), as has been demonstrated previously by the work of Wu and 
Saggau (1994). As one may expect, the PPRs obtained from a single CA1 neurone 
mirrored those from a population of CA1 cells, at both 4 and 13 months of age.  
 
PPR data obtained though extracellular field recordings at 13 months of age, show a 
significant difference between LOWTAU and HIGHTAU animals at the shortest inter-pulse 
interval of 25ms. As we have seen, this age corresponds to a time of large disparity in 
the severity of tau pathology (Chapter 4). While sample numbers for HIGHTAU mice are 
low in this case (n=4), compared to data from WT and LOWTAU animals, this result 
implies a reduction in the Pr of glutamate from CA3 neurones at an age corresponding 
to high NFT load. This would be consistent with a hypothesis that the development of 
pathological tau, and its mislocation from the axon to somatodendritic compartment, 
results in the disruption of axonal transport of vital components necessary for 
neurotransmitter release. This may lead to a lower release probability in HIGHTAU mice 
at the shortest interval of 25ms.  
 
The PPR of the mPP-DG synapses was recorded only at 4 months of age using whole-
cell patch clamp techniques. Unfortunately, older animals were not available to follow-
up this line of experiments prior to completion of this thesis. Analysis revealed a 
Evoked Excitatory Activity 
 Paired-pulse ratio (PPR) 
4m 
CA1 -- 
DG TauD35* (100ms interval) 
13m CA1 -- (NOTE: No HIGHTAU incl.) 
Table 6.2. Summary table of evoked excitatory activity recorded from the CA1 and DG at 4- and 
13 months of age. Differences indicated are between WT and TauD35 mice. (--) indicates no 
significant difference observed between genotypes. Arrows indicate direction of the change. 
Significance of difference given by *p<0.05. 
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significant increase in the PPR of TauD35 animals compared to WTs at an inter-pulse 
interval of 100ms. At all other inter-pulse intervals <400ms, TauD35 animals displayed 
a higher PPR, seeing PPF at intervals between 50 and 200ms, compared to the PPD 
witnessed in WT mice. This finding indicates a decrease in the Pr of these mPP boutons 
even at this young age.  
 Despite the opinion that the characteristic mPP PPD is the result of an inherently 
high Pr (McNaughton, 1980), studies by von Engelhardt et al., (2010) suggest a possible 
role for postsynaptic AMPA-R function in creating this depression in response to paired 
stimuli. More specifically, they suggest that the strong interaction between synaptic 
AMPA-Rs and a novel auxiliary protein, CKAMP44, within granule cells of the DG 
increases the desensitisation of AMPA-Rs. CKAMP44 knock-out mice display a switch 
from PPD to PPF in the mPP compared to control animals, in a manner comparable to 
results gathered from PPR experiments from TauD35 mice. Due to the possibility that 
decreased AMPA-R desensitisation may contribute to the increase in PPR in transgenic 
animals, its occurrence was investigated in all genotypes. Studies concluded that AMPA-
R desensitisation does not contribute to the PPD seen at mPP-DG synapses with the 
shortest inter-pulse intervals of 25 and 50ms, leading us to conclude that the 
characteristic mPP PPD is due to the high Pr of mPP synapses, and that transgenic mice 
display a reduction of this Pr at a relatively young age.  
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Extracellular Field recordings 
 
 
 
 
 
 
 
Input-output relationship 
 
At the youngest age of 4-months, LOWTAU mice displayed a significantly reduced fEPSP 
slope at the highest stimulation intensities of 60-80V, compared to WT and HIGHTAU 
animals. A similar result has been observed previously in female rTg4510 mice, at an 
age prior to detectable tau pathology (Dalby et al., 2014). Interestingly, this deficit was 
not observed in data collected from HIGHTAU animals, and was no longer observed at the 
older ages of 13- and 24-months, suggesting this reduction in input-output to be an early 
occurrence in the progression of tauopathy that has already been compensated in 
HIGHTAU mice at 4-months of age.  
Extracellular Field Recordings 
 
Input-output PPR LTP 
LTP in presence of 
AP5 (NMDAR-
LTP) 
‘Weak’ TET 
4m SC-CA1 -- 
(LOWTAU*     ) 
-- 
‘Strong’ TET 
-- 
   TauD35** ‘Weak’ TET 
-- 
13m SC-CA1 -- 
-- 
(HIGHTAU*             
25ms interval) 
‘Weak’ TET 
-- 
Main effect of AP5,  
WT  +    
  TauD35*** 
24m 
(ONLY LOWTAU 
TRANSGENICS) 
SC-CA1 -- -- 
‘Weak’ TET 
-- -- 
Table 6.3. Summary table of extracellular field recordings, obtained from the SC-CA1 synapse at 
4-, 13- and 24 months of age. Differences indicated are between WT and TauD35 mice, with the 
exception of LTP recorded in the presence of AP5, in which data is compared to that obtained in the 
absence of the drug. (--) indicates no significant difference observed between genotypes. Arrows 
indicate direction of the change. Significance of difference given by *p<0.05, ***p<0.001. WT (black 
arrow), TauD35 grouped (dark red arrow), LOWTAU (orange arrow), HIGHTAU (bright red arrow).  
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A reduced input-output relationship is indicative of reduced connectivity between CA3 
and CA1 neurones. This may be caused by fewer SC axons/fewer synapses, a decrease in 
Pr, fewer postsynaptic receptors or a reduction in either afferent or postsynaptic 
excitability. By measuring slope of the EPSP response, however, we can disregard 
alterations in postsynaptic excitability. The PPR obtained at 4-months at the same 
synapse, also did not reveal any changes in LOWTAU animals, suggesting that a reduction 
in Pr is not the cause of the decrease in input-output relationship. Looking to mEPSCs 
recorded from CA1 neurones at 4-months, we see that the frequency of mEPSCs is not 
changed in LOWTAU animals compared to WT, which along with PPR data, implies that a 
reduction in synapse number is not the cause for the decrease in input-output 
relationship. Likewise, the amplitudes of mEPSCs were not seen to differ between 
genotypes, suggesting this difference is also not the result of changes in postsynaptic 
receptors. One must, however, bear in mind, that SC synapses do not account for all 
synaptic connections onto CA1 neurones. Nonetheless, in order to mask changes present 
in SC terminals, synapses originating in alternative areas (such as the EC) would have 
to display a change in the opposite direction. We thus conclude that this deficit of 
LOWTAU mice at 4 months of age is likely the result of changes in CA3 axonal 
excitability.  
 
This deficit is also not observed in older animals, suggesting (as was proposed for 
HIGHTAU animals) that any deficits are compensated for by this time. No change in PPR 
at 13- and 24-months, however, suggests any compensation is not accomplished via 
changes in Pr, and thus changes in postsynaptic receptors, or the excitability of axons 
may be implemented at a pivotal point in tau-induced dysfunction. Recording mEPSCs at 
these advanced ages would provide an indication of whether an increase in the number 
of postsynaptic AMPA-Rs contributes to compensating for this deficit. The difficulties of 
performing patch clamp recordings in older animals, however, may lead to a decrease in 
resolution, limiting the recording of small amplitude currents such as miniatures.  
 
Potentiation of the SC-CA1 synapse and its dependence on NMDA-Rs 
 
It has previously been suggested that despite a lack of change in overall LTP with ageing 
(Figure 6.19.C)), age-related differences may occur in separate elements composing the 
total magnitude of potentiation (Shankar et al., 1998). These ideas prompted us to 
examine the NMDA-R-dependency of LTP across age.  
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NMDA-R-dependence of short-term potentiation: PTP and STP 
 
While no differences were detected between genotypes, the reduction in PTP amplitude 
in the presence of AP5 is intriguing. This reduction has been seen previously in the 
presence of AP5 (Grover and Teyler, 1990, 1992, Stevens et al., 1994, Grover and 
Teyler, 1995) however, the reasons behind such an observation have not been speculated 
upon.  
During the present experiments, PPR was calculated throughout the entire 
recording period, allowing insight into whether changes in Pr contributed to LTP. These 
data recorded during PTP were separated, and plotted in the presence and absence of 
AP5 for each genotype. As predicted, the PPR recorded during the first minute was 
greatly reduced in all recordings, indicating an increase in Pr as responsible for PTP 
(McNaughton, 1982), and thus exposing its presynaptic locus. However, results showed 
that in the presence of AP5, PPR was decreased to a lesser extent for all genotypes at all 
ages. This suggests that NMDA-Rs contribute to the increase in Pr following tetanic 
stimulation at the SC-CA1 synapse.   
 Although classically thought of as postsynaptic receptors, the role of presynaptic 
NMDA-Rs, in particular their role in regulating the release of neurotransmitter, is 
gaining acceptance (Duguid and Smart, 2009). In 2010, McGuinness et al., elegantly 
showed the presence of NMDA-Rs on CA3 axonal boutons of rat organotypic cell 
cultures. Using a range of techniques, they exposed that the activation of these NMDA-
Rs was dependent on AP-evoked release of glutamate, and that once activated, these 
receptors contributed to the Ca2+ influx into the bouton along with voltage-gated Ca2+ 
channels (VGCCs), increasing Pr. While these presynaptic receptors may not contribute 
significantly to the rise in intracellular Ca2+ concentration during the 100Hz induction 
protocol (McGuinness et al., 2010), they may play a specific role in aiding intracellular 
Ca2+ concentration to remain elevated over the first minute post-tetanus, perhaps through 
promoting the loading of mitochondria with Ca2+ during tetanic stimulation (Lee et al., 
2007), or by further increasing the activation of PKC (Brager et al., 2003).  
 
Despite this speculation, it is proposed that the reduction in both WT and TauD35 fEPSP 
amplitude immediately following tetanus (PTP) in the presence of AP5, is due to the 
inhibition of presynaptic NMDA-Rs, removing their contribution to the increase in Pr.  
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The inhibition of STP by AP5 observed across all genotypes and ages was perhaps more 
striking. These data indicated a component of STP that displayed an unwavering 
dependence upon NMDA-Rs. This component could be separated from the rapidly 
decaying early STP that was seen to lead on from PTP, and the later developing LTP. 
This pattern of inhibition mirrors experiments conducted by Gover and Teyler 
throughout the 1990s (Grover and Teyler, 1990, 1992, 1995), in which STP was blocked 
following high frequency stimulation in the presence of AP5 (these experiments are 
discussed further below). 
 In 2014, Park et al., reviewed data from their lab in which they describe two 
separate components of STP. Termed STP1 and STP2, they propose that these 
components contribute the rapidly decaying and slower decaying elements of STP, 
respectively; with different combinations of NMDA-Rs contributing these two separate 
components. The present study supports the idea that STP is formed from two separate 
elements. It appears that under our conditions, the existence of the slower STP2 is 
wholly dependent upon NMDA-R activation during induction, whereas the earlier, 
rapidly decaying STP1 can be produced to some extent by other factors, possibly 
VGCCs.  
 
NMDA-R-dependence of long-term potentiation 
 
The induction of LTP at the SC-CA1 synapse has long been thought to be dependent on 
the activation of postsynaptic NMDA-Rs (Collingridge et al., 1983, Malenka, 1991, 
Bliss and Collingridge, 1993). For this reason, the existence of a level of potentiation 
within WT animals of all ages in the presence of the competitive NMDA-R antagonist, 
AP5, was unexpected. To understand these data, we looked to experiments conducted 
during the 1990s in which an NMDA-R-independent form of LTP was demonstrated at 
SC-CA1 synapses by Grover and Teyler (Grover and Teyler, 1990, 1992, 1995). Grover 
and Teyler demonstrated that application of an extremely high frequency tetanus (4 
trains of 100 pulses at 200Hz, 5s interval) in the presence of 50#M D, L-AP5 produced a 
slowly developing LTP, resembling that observed during present experiments. Their 
studies concluded that this potentiation was the result of frequency-dependent activation 
of postsynaptic VGCCs, as application of the L-type VGCC blocker, nifedipine, 
abolished the LTP. Using the same protocol used by Grover and Teyler, Onuma et al., 
(1998) later demonstrated that this VGCC-dependent LTP (VGCC-LTP) could occur at 
the SC-CA1 synapse within young male C57Bl/6 mice.  
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The stimulus protocol used in our experiments was weaker than that originally 
deemed necessary by Grover and Teyler to establish VGCC-LTP. However, in 1996, 
Cavus and Teyler demonstrated that LTP induced using a 100Hz frequency tetanus (2 
trains of 100 pulses at 100Hz, 20s interval) produced a compound LTP, composed of 
both VGCC-LTP and NMDA-R-dependent LTP (NMDAR-LTP). This, along with the 
comparable characteristics of the EPSPs post-tetanus, including a reduced maximum 
PTP amplitude, inhibited STP and the gradual development of LTP over 5-25 minutes 
all indicate that similar mechanisms involving VGCCs are operating during the current 
experiments; although investigations using nifedipine or a similar VGCC antagonist are 
essential for confirmation. Also the lack of change in PPR during LTP suggests that 
presynaptic mechanisms are not involved in generating the potentiation observed, further 
pointing toward postsynaptic VGCCs being accountable for the LTP we observed.  
 
If LTP induced at the SC-CA1 synapse using a 100Hz stimulation protocol is in fact the 
compound product of both NMDAR-LTP and VGCC-LTP (Cavus and Teyler, 1996), it 
would appear that despite possible variations in the contributions of each component, 
these mechanisms work to keep the level of overall potentiation constant from 4-24 
months of age. Interestingly, previous studies using WT rats have suggested that the 
contribution of NMDAR-LTP and NMDAR-independent LTP do differ with ageing. 
Shankar et al., (1998) proposed that the contribution of NMDAR-independent LTP to 
the overall compound potentiation increased as the rats aged from 2 to 24-months.  
Results from WT mice within the present study appear to contradict this finding, instead 
displaying a trend towards a decrease in NMDAR-independent LTP contribution across 
age, with the highest involvement of NMDAR-independent LTP at the youngest age of 4 
months. This contribution is then seen to decrease slightly by 24 months of age (Figure 
6.20.A) grey squares) (one-way ANOVA, p=0.08). It is, however, of note that due to low 
sample numbers of 24-month-old recordings it is not possible to draw firm conclusions 
from these data; although species differences between mice and rats may result in 
variation.  
The pattern of NMDAR-independent LTP contribution across age in TauD35 
mice significantly contrasts that of WT mice (interaction: (F(2, 47) = 4.337, p=0.019). 
Transgenic data tend in the other direction, increasing slightly from 4- to 24 months of 
age, although no significant change in the contribution of NMDAR-LTP is recorded over 
this time (one-way ANOVA, p=0.1) (Figure 6.20.A) blue squares).  
 
 152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the low number of HIGHTAU animals tested for NMDA-R-dependency, separation 
of transgenic data revealed that LOWTAU and HIGHTAU mice displayed a similar increase 
in NMDA-R-independent LTP with age (LOWTAU % LTP in AP5 4m: 110.3 ± 6.5%; 13m: 
116 ± 6.9%; 24m: 139.7 ± 10.6%; HIGHTAU % LTP in AP5 4m: 107.5 ± 6 %; 13m: 133 ± 
27 %). The increase in NMDA-independent LTP appeared to occur somewhat faster in 
HIGHTAU animals, possibly reflecting dose-dependent effects. Collectively these data 
prompt further work in aged animals, as well as work to increase the number of HIGHTAU 
samples. HIGHTAU animals are now being bred for this purpose, and will be at the 
correct age in early 2016.  
 
 
 
 
 
Figure 6.20. Age-dependent changes in the contribution of different components of LTP at 4-, 
13- and 24-months. A) The level of NMDA-R-independent LTP in WT mice tends toward a decrease 
with increasing age, one-way ANOVA p=0.08. NMDA-R-independent LTP recorded from TauD35 
mice appears to rise with increasing age, however, analysis reveals no significant change from 4- to 
24 months of age (p=0.1). Analysis using a two-way ANOVA reveals a significant interaction 
between WT and TauD35 NMDAR-independent LTP (p=0.019). Overall LTP levels have been 
included for reference. Error bars indicate SEM. B) Percent of LTP dependent on NMDA-Rs in WT 
and TauD35 animals of increasing age.  
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Conclusion 
 
In conclusion, TauD35 mice are not seen to differ considerably from WT mice in terms 
of the electrophysiological parameters tested within the hippocampus in the present 
study, including no differences in LTP even up to very advanced ages. The use of AP5 
has, however, revealed possibly very interesting results regarding the NMDAR-
dependency of LTP at the SC-CA1 synapse in WT mice, suggesting other mechanisms 
may indeed be capable of inducing potentiation at this synapse, in particular at younger 
adult ages. This work highlights the potential for species differences between rats and 
mice, and raises important considerations with regard to the increased use of mice in 
LTP experiments in recent years. The age-dependent contribution of NMDAR-LTP to 
overall potentiation was significantly different in WT and TauD35 mice, suggesting that 
the role of NMDA-Rs in inducing LTP may be altered by the development of tau 
pathology. It is feasible that increased tau dysfunction and mislocation with ageing 
within the neurone results in disruption of NMDA-R trafficking or anchoring within the 
synapse, as has been suggested previously (Hoover et al., 2010), leading to an 
upregulation of NMDA-R-independent mechanisms to compensate.  
  Apart from these interesting differences in the NMDA-R-dependency of LTP, 
very few changes were observed in the synaptic transmission of TauD35 mice compared 
to controls. Of note, were significant changes within the mPP-DG synapses at 4 months 
of age, prior to NFT development within the hippocampus, suggesting the possible 
dysfunction of the pyramidal cells of the medial EC as one of the earliest alterations in 
TauD35 mice. Unfortunately, due to the timing of electrophysiological experimentation 
within the DG, older mice were not available to follow-up this finding prior to 
completion of this thesis.  
 
 
 
 
 
 
 
 
 154 
CHAPTER 7 
 
Discussion 
 
Within this thesis I present a novel transgenic mouse model of tauopathy known as 
TauD35, developed to further aid understanding of the aetiology of neurodegenerative 
tauopathies and provide an additional system with which to test novel therapeutics. This 
mouse line expresses human tau, carrying the familial FTDP-17 mutation, P301L. 
Following initial functional investigations, the TauD35 model was in fact found to exist 
as two separate lines, termed LOWTAU and HIGHTAU, differing genetically by transgene 
copy number and thus protein expression level. The HIGHTAU line harbour approximately 
double the number of tau transgene copies and ~1.6 times the level of human tau protein 
when compared to LOWTAU animals. Together, the LOWTAU and HIGHTAU models 
provide an opportunity to study dose-dependent effects of tau dysfunction, as well as 
allowing the dissociation of tau pathology and ageing. 
 
The detection of these two lines late in the course of this PhD resulted in low sample 
numbers for many functional experiments, particularly for the HIGHTAU model, which 
was seen to decline in numbers due to a lack of selective breeding. For the purpose of 
the following discussion, however, results will be reviewed and hypotheses postulated 
based on the data available.  
 
The hippocampus was chosen for this initial characterisation due to its particular 
vulnerability to pathology and neurone loss in AD (the most prevalent tauopathy) (Braak 
and Braak, 1991, Scahill et al., 2002), as well as tau aggregate formation in cases of 
FTDP-17 carrying the P301L mutation (Spillantini et al., 1998, Mirra et al., 1999). It is 
of course of note, that the specific neuronal vulnerability deduced from human patients 
may be modified through the use of non-physiological promoters to drive transgene 
expression in animal models. Interestingly, however, CaMKII! and endogenous tau 
display relatively similar spatial expression throughout the brain, as is seen in Figure 
7.1., making use of the CaMKII! promoter a reasonable choice for models transgenic for 
tau. This was supported by the fact that TauD35 mice, in particular the HIGHTAU line, 
exhibited a high vulnerability of CA1 pyramidal neurones to the development of tau 
pathology and neuronal loss, mirroring the cellular vulnerability observed in AD patients 
(West et al., 1994).  
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Molecular and histological characterisation: validation of LOWTAU and 
HIGHTAU lines 
 
The relatively small (~1.6 times) increase in mutated human tau protein expressed by 
HIGHTAU mice compared to their LOWTAU counterparts was seen to result in substantial 
differences in the timing and extent of tau pathology development. This was particularly 
evident at 13 months of age, when LOWTAU mice were seen to display only occasional 
NFTs within the hippocampus, 
compared to the extensive NFT load 
observed in HIGHTAU animals. At this 
age, the ratio of NFTs (detected using a 
human tau-specific antibody, HT7) to 
number of cells, within the CA1 area of 
the hippocampus in HIGHTAU mice was 
63 times the ratio of NFTs calculated in 
LOWTAU animals in the same 
hippocampal region.  This non-linear 
relationship between protein expression 
level and NFT development has been 
observed previously (SantaCruz et al., 
2005), suggesting a dependence on 
protein concentration for aggregation 
initiation, as well as a role for seeding in 
pathology progression.  
CaMKII! expression" Tau expression"
Figure 7.1. Gene expression of CaMKII" and tau within the mouse brain. Sagittal sections from 
1.8-month-old C57Bl6/J mice showing the similar regional expression of CaMKII! and tau within the 
brain, including high cortical and hippocampal expression. Note the forebrain neurone specific 
expression of CaMKII!.  
Images taken from the Allen Brain Atlas (www.mouse.brain-map.org (Lein et al., 2007)) 
Figure 7.2. Representative whole transverse 
sections from 17.5-month-old WT (A) and 
HIGHTAU (B) animals, stained with cresyl 
violet. A) WT control section. B) HIGHTAU 
animals show significant neuronal loss within 
the hippocampus, along with cortical thinning 
and enlargement of the lateral ventricle. Note the 
comparable size of the cerebellum between WT 
and HIGHTAU animals, compared to the overall 
shrinkage of the forebrain. Scale bar: 500#m.  
A)!
B)!
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It is likely that this considerably elevated pathology development in HIGHTAU mice is a 
contributing factor on the path to the severe pathological phenotype displayed by these 
animals in later life. Analysis of neuronal loss in those mice already displaying these 
pathological symptoms showed extensive neurodegeneration, particularly within the 
CA1 region of the hippocampus (>50% loss of neurones), with additional examination of 
overall transverse sections exposing substantial cortical thinning and ventricle 
enlargement (Figure 7.2.). It is thus presumed, that within HIGHTAU mice, the increase in 
mutated human tau protein expression leads to elevated toxic species of tau evidenced by 
an increase in pathology. This increased toxicity causes widespread neuronal loss, 
eventually leading to sickness and death of the animal. The observation that the timing 
of the final neurodegenerative phenotype of the HIGHTAU mice occurs within a relatively 
short time window (17-20 months) will be a useful feature of this model allowing 
detailed analysis of the factors leading to this phenotype in the preceding months. The 
HIGHTAU mice are now being bred for this purpose for future studies. 
 
Molecular and histological characterisation: development of pathological tau 
 
The pathological species of tau developed by LOWTAU and HIGHTAU animals were 
investigated by both molecular and histological techniques, using antibodies including 
the phosphorylation dependent CP13 (S202) and PHF-1 (S396/S404). Data obtained 
using Western blotting techniques revealed physiological levels of S202 and S396/S404 
phosphorylated tau in WT mice of 4- and 13 months of age. Using 
immunohistochemistry, however, phosphorylated tau was not detected in WT mice at 
any age. This difference is likely due to the fact that the protein of interest is denatured 
and concentrated into a thin band for Western blotting, making this technique more 
sensitive to low concentrations of protein. The low concentration of phosphorylated tau 
is likely too diffuse throughout the cellular compartment to be observed using 
immunohistochemistry.  
Similarly, at 4 months of age, prior to the development of NFTs detected by 
immunohistochemistry in either the LOWTAU or HIGHTAU transgenic lines, a significant 
degree of phosphorylated tau was identified using both CP13 (Figure 7.3.) and PHF-1 
through use of Western blotting. At this relatively young age, all transgenic mice did 
exhibit a degree of axonal mossy fibre staining, detected with all antibodies used. The 
presence of S396/S404 phosphorylated tau in Western blot data therefore likely reflects 
the existence of phosphorylated tau within the axonal compartment, while the diffuse 
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staining of S202 phosphorylated tau within the somatodendritic compartment of both 
transgenic lines would have contributed to the level of protein detected by Western blot.  
 
With age, both transgenic lines were seen to develop a high quantity of twisted 
intracellular NFTs, an observation that correlated to the appearance of a sarkosyl-
insoluble 64kDa tau band in Western blots. It is established that this band is created from 
the hyperphosphorylation of the 0N4R isoform of tau (Goedert et al., 1992), however, 
due to the protocol employed to prepare samples for Western blot, it is not aggregated 
into mature NFTs (Greenberg and Davies, 1990). This band thus represents a 
hyperphosphorylated, insoluble species, assumed to be aggregated to some extent.  
 In addition to the presence of sarkosyl-insoluble tau migrating at 64kDa in older 
animals, insoluble tau was also observed at 4 months of age and at 13-months in 
LOWTAU animals, migrating with a lower molecular weight of ~54kDa. The 
dephosphorylated 0N4R isoform of tau migrates with an approximate weight of 50kDa 
(Buee et al., 2000), thus suggesting that the sarkosyl-insoluble tau observed at these 
younger ages displays a low level of phosphorylation. Sahara et al., (2002) studied this 
lower weight insoluble fraction from younger mice using electron microscopy, and 
determined that this tau does indeed have a fibrous appearance, but is shorter in length 
than those fibres observed from older animals. It therefore seems that the insoluble tau 
migrating at ~54kDa contains a low level of phosphorylation and is aggregated into short 
low order filaments, possibly representing the early stages of further, more mature 
aggregate formation.  
 
In summary, phosphorylated tau is detected in both LOWTAU and HIGHTAU animals at 4 
months of age. While some of this protein is insoluble in sarkosyl, it is not seen to form 
aggregates detectable by immunohistochemistry. At 13-months, LOWTAU animals 
display a very low number of NFTs, along with a small decrease in the amount of 
phosphorylated protein detected by Western blot. HIGHTAU animals, however, display a 
heavy NFT load at 13-months, corresponding to the appearance of insoluble tau 
migrating at 64kDa, despite an overall decrease in phosphorylated tau species detected 
by Western blot, owing to the loss of NFTs during homogenate sample preparation. This 
situation is mirrored in LOWTAU animals of 24 months of age (Figure 7.3.). 
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Functional characterisation: consequences of pathological tau 
 
Behaviour  
 
For investigations into behavioural changes at 12 months of age, data from the HIGHTAU 
mice available displayed a high level of consistency. Within the T-maze forced 
alternation task, HIGHTAU mice performed extremely well, finishing the testing phase 
with a correct response rate of 100%. This finding indicates that in spite of the high NFT 
load present within the hippocampus of these mice at this age, hippocampal-dependent 
spatial working memory was not affected. This supports observations from AD patients, 
in which substantial hippocampal degeneration is observed prior to the onset of the first 
clinical symptoms including deficits in declarative memory (Lehericy et al., 1994, Jack 
et al., 1997), indicating that severe cell loss is required to produce detectable symptoms. 
HIGHTAU animals displaying the characteristic pathological phenotype developed by 
these mice between the ages of 17- and 20-months develop a significant level of 
neurodegeneration, including >50% cell loss within the CA1 region of the hippocampus. 
It would, however, be unfeasible to complete behavioural testing during this time due to 
Figure 7.3. Visual comparison of the 
absolute number of NFTs detected 
using CP13 (S202) via 
immunohistochemistry to the amount 
of S202 phosphorylated tau protein 
detected within the whole hippocampus 
by Western blotting at 4-, 13- and 24 
months of age in LOWTAU and HIGHTAU 
mice. NFT data were obtained by 
averaging the absolute number of NFTs 
counted within a defined area 
(240x400#m) within the CA1, CA3 and 
DG regions. At 4-months, no NFTs had 
developed, despite a large amount of 
S202 phosphorylated tau protein being 
present within the hippocampus of both 
transgenic lines. Following the 
development of a significant NFT load in 
HIGHTAU mice of 13-months, the amount 
of S202 protein appears decreased, owing 
to the loss of NFTs during homogenate 
preparation. 13-month HIGHTAU and 24-
month LOWTAU mice display similar 
absolute numbers of NFTs and S202 
protein within the hippocampus. No 
HIGHTAU animals survive until 24 months 
of age. Error bars indicate SEM. 
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the significant reductions in movement initiation and ambulation displayed by these 
animals. On the other hand, it is hoped that with the continued breeding of this line and 
the predictability of pathological phenotype onset, it will be possible to assess 
behavioural alterations immediately preceding the development of moribund symptoms.  
  
Assessment of changes in anxiety and locomotion using the open field and light/dark 
box revealed interesting differences in the behaviour of HIGHTAU animals. Despite their 
unaffected spatial memory, HIGHTAU mice were seen to show a deficit in habituation to a 
novel environment, as well as displaying a potential reduction in anxiety-like behaviour. 
The nature of these tests, however, does not provide sufficient specificity to attribute 
these changes to dysfunction within a particular brain region. Interestingly, during T-
maze testing HIGHTAU mice also exhibited extremely fast response times on the first, 
sample run, suggestive of disinhibition. Together, these changes to the behaviour of 
HIGHTAU animals more closely mimics the initial symptoms of FTDP-17, in which 
patients exhibit complex and heterogenous personality and behavioural changes, 
including disinhibition (Wszolek et al., 2006).  
 
Synaptic transmission 
 
The majority of electrophysiological testing concentrated on the young age of 4 months. 
At this time, NFTs were not observed in either LOWTAU or HIGHTAU animals, although 
diffuse staining was observed throughout the intracellular compartments of all 
hippocampal neurones using the ‘early’ CP13 antibody, which recognises tau 
phosphorylated at S202. Concentrating electrophysiological analysis at this young age 
aimed to detect the very earliest changes in the functioning of neurones resulting from 
tau dysfunction. Neither the membrane resistance nor basal synaptic transmission of 
CA1 pyramidal neurones or DG granules cells in either LOWTAU or HIGHTAU animals 
was altered at 4-months, indicating that the phosphorylation of tau at S202 and 
mislocation into the somatodendritic compartment does not change these parameters. 
 Examination of PPRs at this age did, however, expose a reduction in the Pr of 
mPP synapses (originating in the medial EC) onto DG granules cells in both transgenic 
lines. The neurones of the EC were not analysed histologically or using molecular 
biology within the present study, and thus detailed conclusions regarding pathological 
tau species harboured by these cells are not known. It is of note, however, that the 
formation of NFTs was not noted in any brain region at this age (data not shown), 
implying that this change in Pr is the result of soluble pathological tau species. This 
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result is interesting as the EC is an area known to show particular vulnerability to tau 
dysfunction in AD (Braak and Braak, 1991, Gomez-Isla et al., 1996), supporting the use 
of both the LOWTAU and HIGHTAU lines as models of tauopathy.  
 
By 13 months of age, the two transgenic lines had developed a significantly different 
NFT burden within the hippocampus, with mice of the HIGHTAU line exhibiting an 
extremely high NFT load compared to their LOWTAU counterparts. This divergence in 
pathology corresponds to an apparent separation of basal synaptic transmission and PPR 
data obtained from both transgenic lines. At this age, HIGHTAU animals display changes 
indicative of a reduction in Pr, as well as possible changes to AMPA-R density/kinetics 
compared to WT and LOWTAU animals, suggesting that a more mature development of 
tau pathology is required to disrupt these parameters. 
At this age, the CA3 neurones of HIGHTAU animals contain significant numbers 
of NFTs, although no cell loss is observed. In terms of the reduction in Pr, it is proposed 
that NFTs inflict a detrimental effect on Pr. It is possible that disruptions in axonal 
transport created through a loss of physiological tau function, as well as the physical 
barrier created by the large intracellular aggregate, may impede the passage of the 
materials needed for neurotransmitter release from these neurones, such as mitochondria 
(Eckert et al., 2014). Indeed, alterations in MT-dependent transport have been recently 
observed to occur in vivo, correlating to the development of pathological tau species in 
two separate mouse models of tauopathy (rTg4510, Majid et al., 2014; JNPL3, Bertrand 
et al., 2013).  
 
However, not all alterations in synaptic transmission occurred following an increase in 
tau pathology, as was demonstrated by the reduction in input-output only in LOWTAU 
animals of 4-months of age. The input-output relationship recorded extracellularly 
measures the postsynaptic potential in response to increasing stimulus strength applied to 
the presynaptic axons. At 4-months, when both LOWTAU and HIGHTAU mice display only 
diffuse staining of S202 phosphorylated tau, the input-output relationship of LOWTAU 
mice at the SC-CA1 synapse is significantly reduced at the highest stimulation 
intensities of 60, 70 and 80V. As is discussed within Chapter 6, a reduction in input-
output at this synapse is indicative of reduced connectivity between the CA3 and CA1 
neurones, possibly caused by a variety of factors. Examination of other 
electrophysiological features including PPR and mEPSCs led to the conclusion that such 
a decrease in input-output is the result of a reduction in CA3 axonal excitability. A 
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similar reduction in input-output at this synapse has been reported previously in the 
rTg4510 tauopathy model at an age showing comparable pathology, i.e. very limited 
phosphorylated tau staining, detected using an antibody recognising tau phosphorylated 
at S202/T205, described as a model of a pretangle stage (Dalby et al., 2014). The authors 
go on to show that this deficit is also present in mice at an age displaying considerable 
tau pathology but still in the absence of neurodegeneration. This was not the case within 
the present study, however, with no deficit observed in either transgenic line at 13-
months or in LOWTAU animals of 24-months. Thus, results gathered from LOWTAU and 
HIGHTAU mice, appear to show a reduction in SC-CA1 connectivity at only the very 
earliest stages of tau dysfunction, with no difference detected at a higher dose of 
pathological tau or with increasing age. It is proposed that the reduced excitability of 
CA3 neurones is compensated in those mice experiencing an increased level of tau 
dysfunction. At the youngest age of 4-months, it may be that the increased 
overexpression of tau in the HIGHTAU line compensates for the loss of tau function 
experienced by both transgenic animals. By 13 and 24 months of age, the longer 
exposure to tau dysfunction endured by those animals initiates compensatory mechanism 
resulting in an increase in excitability of CA3 neurones. An alternative hypothesis is that 
TauD35 mice exhibit a delayed maturation of the SC-CA1 pathway, which is masked in 
HIGHTAU animals at 4 months of age by the increased overexpression of human tau. By 
13-months, the pathway has matured, and thus displays similar excitability to that of WT 
mice.  
 
Synaptic plasticity 
 
One intriguing finding of the present study revealed that in both WT and transgenic 
lines, at all ages studied, the LTP expressed at the SC-CA1 synapse was not wholly 
NMDA-R-dependent, as is often assumed from previous work using rats (Collingridge et 
al., 1983). Instead, all mice showed some level of potentiation 60 minutes following 
tetanus application, presumed to be dependent on voltage-gated calcium channels. 
Interestingly, however, the contribution of these two forms of LTP was seen to alter with 
age. Moreover, this age-dependent adjustment in NMDA-R-dependency was different in 
WT and transgenic mice. Due to the advanced age, small numbers of both WT and 
LOWTAU mice were included at 24-months, leading to a larger error at this age and 
possibly preventing detection of a significant change in NMDA-R-dependency across 
age for both WT and transgenic animals. Even so, we observe an overall trend towards 
an increase in the NMDA-R-dependency of LTP in WT mice with increasing age 
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(Figure 7.4.). This increase contrasts data collected from WT rats, in which the NMDA-
R-dependent component of LTP was decreased in mice of 24-months compared to 
young animals of 2 months of age (Shankar et al., 1998), possibly representing important 
species differences between rats and mice. 
Data obtained from transgenic mice revealed that at 4-months, when LOWTAU 
and HIGHTAU animals displayed a similar level of diffuse S202 phosphorylated tau 
within CA1 neurones, both lines exhibited similar levels of NMDA-R-dependency at the 
SC-CA1 synapse (Figure 7.4.). The contrast to data from WT counterparts indicates that 
the rise in tau S202 phosphorylation, and its relocation into the somatodendritic 
compartment results in an increase in the contribution of NMDA-R-dependent LTP. This 
may be due to an increase in postsynaptic Fyn localisation and the resultant 
phosphorylation of NMDA-Rs anchoring them to PSD-95 (Ittner et al., 2010). With the 
added contribution of NMDA-Rs, NMDA-R-independent LTP may be down regulated 
to compensate, keeping the overall LTP magnitude constant.  
At 13 months of age, both 
transgenic lines then displayed a tendency 
towards a decrease in the percentage of 
NMDA-R-dependency, with this decrease 
possibly more exaggerated in data from 
HIGHTAU mice (Figure 7.4.). With further 
ageing (and progression of tau pathology), 
the dependency of LTP on NMDA-Rs 
continued to decline in LOWTAU animals 
(Figure 7.4.). From these data it is 
hypothesised that as tau pathology 
matures, there is a reduction in the number 
of postsynaptic NMDA-Rs, lowering the 
NMDAR-dependent component of LTP 
and thus causing independent mechanisms 
to be up regulated in response, 
maintaining the overall level of LTP. A 
decrease in postsynaptic AMPA- and 
NMDA-R numbers has previously been 
linked to the accumulation of pathological 
tau within the insula cortex and ventral 
Figure 7.4. The dependence of LTP on 
NMDA-Rs at the SC-CA1 synapse in 
LOWTAU, HIGHTAU and WT animals across 4-, 
13- and 24-months of age. The degree of NFT 
load within the hippocampus in both transgenic 
lines is represented below (number of arrows 
represents the severity of pathology). Error bars 
indicate SEM. 
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striatum of a mouse model of tauopathy, which harbours all isoforms of human tau 
carrying the V337M mutation (Warmus et al., 2014). Notably, the pathology described 
by Warmus et al., was at a pretangle stage rather than a point of mature NFT 
accumulation, although differences in the tau mutation and brain area studied could 
affect the point at which tau pathology decreases NMDA-R function. The authors 
attribute the observed decrease in synaptic glutamate receptors to a tau-dependent 
depletion of the receptor scaffolding protein, PSD-95, which was found to occur in the 
absence of any neurodegeneration or even synapses loss. A reduction in synaptic 
glutamate receptors has also been reported in hippocampal neurones cultured from 
rTg4510 mice (Hoover et al., 2010), indicating a similar phosphorylated tau-dependent 
reduction in the synaptic localisation of both AMPA- and NMDA-Rs in the absence of 
synapse loss.  
 
Taken altogether, the evidence suggests that tau phosphorylation and mislocation to the 
somatodendritic compartment (and possibly into dendritic spines (Hoover et al., 2010)) 
in both LOWTAU and HIGHTAU animals affects the function of NMDA-Rs. Initially, the 
effects manifest as an increase in NMDA-R function, possibly through increased 
anchoring of the NMDA-R to the scaffolding protein, PSD-95 (Ittner et al., 2010). 
Following further phosphorylation and the initiation of aggregation, this mislocated tau 
begins to disrupt the insertion and/or anchoring of NMDA-Rs to the PSD (Hoover et al., 
2010), potentially through contributing to the depletion of PSD-95 (Warmus et al., 
2014). Interestingly, gene-expression analysis of TauD35 mice (discussed further below, 
data adapted from Matarin et al., 2015), reveals a significant reduction in the expression 
of GluN1, an obligatory subunit of the NMDA-R, in both LOWTAU and HIGHTAU animals 
by 18 months of age (Figure 7.5). It may therefore be suggested that the development of 
pathological tau species brings about a reduction in NMDA-Rs through altering the 
expression of genes encoding the receptor.  
 
 
 
 
 
 
 
 
Figure 7.5. Significant reduction in the 
expression of Grin1 (GluN1) at 18-months 
in transgenic animals. At 18-months of age, 
TauD35 mice display a significant decrease 
in the expression of GluN1, an obligatory 
subunit of the NMDA-R. (One-way 
ANOVA, Tukey’s multiple comparison test, 
p=0.002**) compared to WT controls.  
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Gene expression increases in LOWTAU and HIGHTAU animals at 18-months  
 
Analysis of separated transgenic data at 18 months of age was completed by Dr Dervis 
Salih. Immunohistochemistry completed for publication (Matarin et al., 2015) was 
performed by Dr Marina Yasvoina. Consequently these data have been included here for 
discussion, rather than within the results chapters.  
 
A recent collaborative project including members of my current laboratory produced 
genome-wide gene-expression data from TauD35 mice at 2-, 4-, 8- and 18 months of age 
(Matarin et al., 2015). At the time of this study by Matarin et al., it was not yet 
confirmed that the TauD35 mouse model existed as two separate lines, however, as data 
was analysed correlating individual mouse pathology to gene-expression, these data 
stand. In fact, post hoc copy number analysis revealed that the majority of animals 
included in Matarin et al., were of the HIGHTAU line. Additional microarray analysis has 
been completed since publication, increasing the numbers of LOWTAU animals included. 
Here I present further analysis of all data obtained from 18-month animals, with 
LOWTAU and HIGHTAU animals of this age separated. These gene expression changes 
were only completed within the hippocampus in keeping with the hippocampal 
characterisation presented within this thesis.  
 
As is described in Matarin et al., TauD35 mice did not display substantial changes in 
gene expression until relatively late in the disease process, lagging months behind the 
appearance of NFTs, with the majority of significant changes not detected until 18 
months of age (see www.mouseac.org for changes in individual gene expression). It 
therefore followed that the additional analysis presented here be completed at 18-
months. At this age, 85% of genes that showed differential expression in the TauD35 
animals were increased, with only 15% being significantly decreased (Matarin et al., 
2015), fuelling our decision to concentrate only on those genes displaying an increase in 
expression for the current analysis. Of those genes showing a significant reduction in 
expression at 18-months many fell into categories relating to synapses and 
neurotransmission, likely reflecting the loss of synapses and cells (ibid).  
At this advanced age, both LOWTAU and HIGHTAU mice display NFT pathology 
within the hippocampus, although substantial differences in pathology load between the 
two lines exist, as was presented at other ages in Chapter 4. In separating the NFT counts 
completed for publication (Matarin et al., 2015) into LOWTAU and HIGHTAU animals, it is 
established that within the hippocampus HIGHTAU mice exhibit approximately 14 times 
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the NFT number detected with the tau phosphorylation-dependent antibody, AT8 
(S202/T205), when compared to LOWTAU animals. Cell counts were not completed on 
animals used for publication. Despite this, it is predicted that the HIGHTAU mice used for 
gene-expression analysis displayed substantial neurodegeneration as all were noted as 
presenting with the pathological phenotype characteristic of this line at this age. As is 
presented in Chapter 4, mice displaying this moribund phenotype exhibit >50% loss of 
CA1 pyramidal cells, with substantial degeneration also observed within the DG. 
 
 
 
 
 
 
 
 
 
 
Genes that displayed >20% (P<0.01) increase compared to WT within the hippocampus 
were extracted for both LOWTAU and HIGHTAU animals. Any genes that were increased in 
both transgenic lines were subtracted from HIGHTAU data to give those genes ‘exclusive 
 
 
 
 
 
 GO No. LOWTAU HIGHTAU 
Exclusive to 
HIGHTAU 
Immune system 
process 0002376 >0.05 1.04x10
-49 1.22x10-44 
Intracellular 
protein kinase 
cascade 
0007243 >0.05 7.69x10-18 2.89x10-17 
Programmed cell 
death 0012501 >0.05 6.05x10
-9 4.19x10-8 
Mitochondrion 0005739 2.28x10-13 >0.05 >0.05 
Ribosome 0005840 1.45x10-10 >0.05 >0.05 
Figure 7.6. Genes increased >20%in 
LOWTAU and HIGHTAU mice 
compared to WT at 18-months. A) 
Venn diagram depicting the overlap 
between genes increased >20% 
(ANOVA, p<0.01) within the 
hippocampus of LOWTAU and HIGHTAU 
animals of 18 months of age. B) Table 
of representative gene ontology (GO) 
categories identified using WebGestalt 
displaying a significant increase in 
either LOWTAU or HIGHTAU mice. 
Representative categories are similar to 
those identified using Ingenuity.  
Significant increases (p-values) are 
highlighted in red. 
A) 
B) 
LOWTAU n=4! HIGHTAU n=2!
1237!
genes!
549!
genes!
72!
genes!
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to HIGHTAU’ (Figure 7.6.B)).  Detected genes for each genotype were examined using 
WebGestalt and Ingenuity, with representative gene ontology (GO) categories presented 
for each genotype (Figure 7.6.B)). For LOWTAU animals, the majority of genes exhibiting 
significant increases in expression were categorised into relatively unspecific GO 
categories, including ‘intracellular’, ‘cytoplasm’ and ‘cell’. Of more interest, were the 
high number of genes detected showing increased expression relating to mitochondria 
and ribosomes. Such genes were not common to HIGHTAU mice of the same age (Figure 
7.6.B)), indicating that mitochondrial and ribosomal dysfunction occurs prior to the 
development of a severe NFT load and onset of neurodegeneration. It is possible, that 
this genetic overexpression pattern is present within only a subset of neurones, and is a 
prerequisite for subsequent NFT development, or even cell death.  
 
In contrast, HIGHTAU animals exhibited a rise in the expression of genes involved in the 
immune system and inflammation, apoptosis, as well as more general categories 
revolving around protein binding.  
The increase in the expression of genes relating to apoptosis corresponds to the 
neurodegeneration present within the hippocampus of HIGHTAU animals at this age, 
implying a role for apoptosis in producing the cell loss associated with 
neurodegenerative tauopathies. More specifically, a rise in the expression of genes such 
as the initiator and executioner caspases 8 (p=0.0006) and 6 (p=0.02) (McIlwain et al., 
2013) is observed only within this transgenic line compared to WT animals (Figure 
7.7.A) and B)). Both caspase 6 (Guo et al., 2004, Albrecht et al., 2007) and caspase 8 
(Rohn et al., 2001) have been shown to be increased in an active form within the brains 
of AD patients, as well as both being increased in primary hippocampal cultured 
neurones following transfection with a truncated form of tau (Chung et al., 2003). 
Caspase 8 mRNA is also increased in the hippocampus and cortex of rTg4510 mice from 
5.5months (Spires-Jones et al., 2008), an age corresponding to significant cell loss in this 
mouse line (Spires et al., 2006).  
There is, however, a growing body of evidence that dissociates caspase activation 
and cell death. In particular, the executioner caspase 6 has also been linked to the 
formation of NFTs in AD, rather than acute apoptosis. Guo et al., (2004) demonstrated 
that active caspase 6 is associated with pretangles, implying it is associated with the 
initial stages of NFT formation. This is in line with later work by de Calignon et al., 
(2010), who revealed caspase activation prior to NFT formation, suggesting that 
caspases may have a role in initiating NFT formation rather then the other way around. 
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Interestingly, caspase 6 activation has also been observed in the brains of some non-
cognitively impaired individuals, at which time it was mostly confined to the EC and 
CA1 (Albrecht et al., 2007), two areas which, as has been discussed, show particular 
vulnerability to the development of tau pathology and cell loss in AD. In 2008, Spires-
Jones et al., demonstrated that the caspase activation associated with NFT pathology in 
tauopathy disorders does not cause acute cell death, suggesting that activation of 
caspases is not the cause of neurodegeneration. They propose that NFT formation is 
protective, sequestering caspases and thus limiting proteolytic damage. This idea was 
supported by their later work (de Calignon et al., 2010), with others (Wang et al., 2014) 
suggesting that the initiation of tau hyperphosphorylation is employed by cells to aid 
them in escaping from acute apoptosis, however, this later leads to the accumulation of 
hyperphosphorylated tau, which is not reversed, leading to chronic neurodegeneration. 
Despite this previous evidence for caspase involvement in NFT formation, we did 
not observe an increase in the gene expression of caspases in LOWTAU animals, which at 
this age continue to develop NFTs but do not display neurone loss. Thus, from the 
results presented here, it is suggested that instead the upregulation of caspase 6 and 8 
expression may be associated with neuronal death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It was reported previously, that TauD35 mice of 18 months of age displayed elevated 
expression of immune-related genes (Matarin et al., 2015). We now reveal that this 
previous observation was true only of HIGHTAU mice, with significant changes not 
apparent in LOWTAU animals.  
Figure 7.7. HIGHTAU animals show a significant increase in the gene expression of caspase 6 (A) 
and 8 (B) at 18-months of age. At 18-months of age, HIGHTAU mice display a significant increase in 
the expression of caspase 6 (A) (One-way ANOVA, Tukey’s multiple comparison test, p=0.02*), and 
caspase 8 (B) ) (One-way ANOVA, Tukey’s multiple comparison test, p=0.0006***) compared to WT 
controls.  
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In 2014, Wes et al., completed gene-expression analysis on 4 and 6 month old 
rTg4510 mice. The results from this experiment were very interesting in terms of the 
data presented here. They revealed that rTg4510 mice at 6 months displayed a significant 
increase in the expression of genes relating to the immune system. At this age, rTg4510 
mice show a significant NFT load within the hippocampus, as well as significant 
neurodegeneration (Spires et al., 2006), comparable to the situation at 18-months in 
HIGHTAU animals. However, this is a different mouse model, expressing a different level 
of the transgene, different integration site, on a different background strain. Moreover, 
the mice used for the study by Wes et al., were female. The fact that the results in these 
mouse lines are so similar, despite these differences support that the upregulation of 
genes involved in the immune system and inflammatory response within the 
hippocampus is a common consequence of tau dysfunction. More specifically, Wes et 
al., reveal a substantial increase in the expression of genes involved in the complement 
cascade, a finding mirrored in HIGHTAU animals (Figure 7.8.A), B) and C)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Remarkably, this finding is not solely common to tauopathy models. As was 
reported in Matarin et al., a significant rise in immune gene expression has also been 
observed in a model of amyloid-" dysfunction (TASTPM). Again, the expression of 
genes involved in the complement cascade were found to be increased significantly 
within the hippocampus of these animals. This model of amyloid-" dysfunction does not 
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Figure 7.8. HIGHTAU animals exhibit a 
significant increase in the gene expression 
of C1qa (A), C1qb (B) and C1qc (C) at 
18-months of age. At 18-months of age, 
HIGHTAU mice display a significant increase 
in the expression of the C1qa, C1qb and 
C1qc, components of the complement 
cascade (One-way ANOVA, Tukey’s 
multiple comparison test, p<0.0001***) 
compared to WT controls.  
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show neurodegeneration, demonstrating that the rise in immune genes is independent of 
cell death; instead seeming to correlate significantly with the development of pathology 
in the form of amyloid-" plaques. We therefore looked to 13-month-old HIGHTAU mice, 
to see if there was evidence for a change in microglial status prior to neurodegeneration, 
as it is these cells that constitute the principle cellular component of the immune system 
within the brain (Heneka et al., 2014).  
We see from Figure 7.9. that HIGHTAU animals display a clear rise in the number of 
microglia within all subregions of the hippocampus. In HIGHTAU mice displaying a heavy 
NFT load, microglia are seen to infiltrate the cell layers in high numbers, an event not 
observed in LOWTAU animals at a stage of early NFT formation. This finding indicates 
that the inflammatory response may be upregulated prior to degeneration, rather than in 
response to cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9. Microglia appear increased within the hippocampus of HIGHTAU animals at 13 
months. Double immunostaining with CP13 (S202 phosphorylated tau, red) and Iba1 (microglia, 
green). Dashed white lines indicate the cell body layers of each subregion of the hippocampus. The 
mossy fibre pathway is also outlined in LOWTAU and HIGHTAU animals. White arrows indicate the 
infiltration of the CA1 and DG cell body layers by microglia in HIGHTAU animals. Blue arrows indicate 
the infiltration of microglia into the mossy fibre pathway in both LOWTAU and HIGHTAU mice. MF: 
Mossy fibre pathway. Scale bar: 100#m.  
Double CP13 and Iba1 staining was completed by Wenfei Lui. 
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As tau aggregate formation has begun in LOWTAU animals of 13-months, but microglia 
have not yet been upregulated, it is suggested that it is the development of tau pathology 
that initiates the rise in microglia. Indeed, misfolded protein aggregates, including tau 
(Morales et al., 2013), have been shown to activate microglia (Heneka et al., 2014). In 
terms of tau, this activation may only occur following the neuronal release of tau, an 
event on the pathway to tau pathology propagation (discussed in Chapter 1).  
 
In addition to analysing gene-expression changes within the whole hippocampus, Wes et 
al., also examined gene changes in the cellular layers of subregions of the hippocampus, 
using microdissected samples. This work revealed that the majority of gene changes at 
6-months in rTg4510 mice occurred within the CA1 region, including an increase in 
immune genes. This is an interesting finding considering the apparent vulnerability of 
this region to tau pathology development and neurone loss in both rTg4510 (SantaCruz 
et al., 2005) and HIGHTAU animals, as well as AD patients (West et al., 1994). Very few 
gene-expression changes, however, were observed within this region at the earlier age of 
4-months in rTg4510 mice. The authors attribute this relative lack of gene-expression 
changes at this younger age to the enrichment of neurones and low numbers of glial cells 
contained within these samples. Yet as we see in Figure 7.9., microglia do infiltrate the 
cell body layers of the hippocampus following the development of substantial tau 
pathology, prior to neurodegeneration.   
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Overall summary of the LOWTAU and HIGHTAU transgenic lines 
 
Table 7.1. summarises existing transgenic models of tauopathy harbouring a single 
isoform of human tau carrying the P301L mutation. Included are the novel LOWTAU and 
HIGHTAU lines presented within this thesis, allowing for easy comparison of background 
strain, promoter and transgenic tau level. Below, the positive and negative aspects of 
both these transgenic lines are reviewed. 
 
 
 
 
 
 
 
Positive aspects of the HIGHTAU and LOWTAU lines: 
 
• Molecular and histological characterisation confirmed that the human tau 
transgenes harboured by LOWTAU and HIGHTAU mice are functional, resulting in 
an ~1.6 times increase in human tau protein expression in HIGHTAU animals, 
compared to the LOWTAU line. 
Line Background 
Strain 
Tau 
Isoform/
Mutation 
Promoter Transgenic 
Tau Level 
Ref 
JNPL3 C57Bl/DBA2/SW 4R0N/ 
P301L 
mPrP 1x (Lewis et al., 
2000) 
pR5 C57Bl/6 4R2N/ 
P301L 
mThy-1.2 0.7x (Gotz et al., 
2001a) 
Tau-4R/2N-
P301L 
FVB/N 4R2N/ 
P301L 
mThy-1.2 4x (Terwel et 
al., 2005) 
rTg4510 FVB/N 4R0N/ 
P301L 
CaMKII!-
Tet-Off 
13x (SantaCruz 
et al., 2005) 
LOWTAU C56Bl/6J 4R0N/ 
P301L 
CaMKII! 4x Unpublished 
HIGHTAU C56Bl/6J 4R0N/ 
P301L 
CaMKII! 6.5x Unpublished 
Table 7.1. Comparison of LOWTAU and HIGHTAU animal models with common transgenic 
mouse models harbouring a single isoform of human tau carrying the P301L mutation. 
Transgenic tau levels are given as the level of transgenic human tau compared to endogenous 
murine tau. References are given for publications in which the line is first described. mPrP 
(murine prion protein). 
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• Use of the CaMKII! promoter removes complications caused by tau pathology 
within the spinal cord, as has been seen in other tauopathy models (Lewis et al., 
2000), as well as producing a relatively similar spatial expression pattern as 
endogenous tau, with high expression in the cortex and hippocampus. 
• The transgenic tau expressed in both lines is seen to form pathological species 
observed in human tauopathies, including conformationally altered (Weaver et 
al., 2000) and specifically phosphorylated species (Su et al., 1994) 
[http://cnr.iop.kcl.ac.uk/hangerlab/tautable (Hanger et al., 2009)].  
• Both lines see the mislocation of pathological tau into the somatodendritic 
compartment in an age-dependent manner, going on to develop mature 
intracellular NFTs, which display a twisted, filamentous appearance. 
• The pattern of pathology development and neurodegeneration within the 
hippocampus of LOWTAU and HIGHTAU animals is what may be predicted 
considering the overlapping spatial expression pattern of CaMKII! and 
endogenous tau within the brain, and the specific neuronal vulnerability observed 
in tauopathies such as AD. In particular, the vulnerability of CA1 pyramidal 
neurones is modelled well in the HIGHTAU line.  
• Use of both LOWTAU and HIGHTAU animals concurrently provides an opportunity 
to study the dose-dependent effects of pathological tau development independent 
of age. 
• While both the LOWTAU and HIGHTAU lines exhibit a less aggressive 
development of pathology and neurodegeneration compared to the rTg4510 
model of tauopathy (for example, rTg4510: tau pathology 4.5/5m, 
neurodegeneration in CA1 (60%) 5.5m. HIGHTAU: similar level of pathology 
within the hippocampus 13m, similar level of degeneration in CA1 (50%) 
17.5m), this provides a longer time window in which to study the very earliest 
changes associated with tau dysfunction.  
• Lastly, the LOWTAU and HIGHTAU models provide an alternative in a research 
area dominated by the use of the rTg4510 mouse model. There are of course 
disadvantages to the use of mouse models of disease, including: the use of non-
physiological promoters to drive expression, uncertainty of the transgene 
integration site and often the high overexpression of the protein of interest. The 
existence of these disadvantages, however, means that the power of animal 
models lies in the use of multiple different lines and the identification of 
common dysfunctions.  
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Negative aspects of the HIGHTAU and LOWTAU lines: 
 
• The development of pathology and neurodegeneration occur relatively slowly, 
even within the HIGHTAU line. Due to the expense and time investment needed to 
age mice to the required level of pathological tau development, a more 
aggressive model may be preferred. 
• The LOWTAU and HIGHTAU lines do not harbour the Tet-Off sequence required 
for the control of transgene expression, as is the case in other models of 
tauopathy (SantaCruz et al., 2005). Transgenic tau is thus continually expressed 
throughout development in these lines preventing experiments investigating the 
reversal of deficits following transgene suppression. 
 
Conclusion 
 
Within tauopathy research, and indeed dementia research in general, the common use of 
mouse models has been undeniably vital in extending our understanding of the aetiology 
of disease. The existence of a variety of models is however essential, particularly with 
regards to the development and testing of new treatments due to the heterogeneity of the 
human population and the limitations of individual models. Here I present two novel and 
complimentary transgenic mouse models of tauopathy. Both the LOWTAU and HIGHTAU 
transgenic lines are functional, producing dose- and age-dependent development of 
common pathological species of tau. The LOWTAU line exhibits an extensive NFT burden 
within the hippocampus by 24 months of age, with no neurodegeneration observed up 
until this age. The HIGHTAU line presents an extensive NFT load by 13 months of age, at 
which point the very first indications of cell loss within the CA1 region are noted. 
During the following 4 to 7 months HIGHTAU animal pathology advances rapidly, 
culminating in the presentation of a moribund phenotype common to transgenic 
tauopathy models carrying the P301L mutation (Lewis et al., 2000, Ramsden et al., 
2005, Terwel et al., 2005). At this point these mice exhibit significant neurodegeneration 
within the hippocampus, with >50% loss of CA1 pyramidal neurones. This cell loss is 
likely the consequence of a rise in programmed cell death, as indicated by the increase in 
expression of genes relating to apoptosis.  
It is unfortunate that the HIGHTAU line was found to represent only a small 
proportion of the total TauD35 transgenic animals, and that without prior knowledge of 
two separate transgenic lines and thus selective breeding, HIGHTAU numbers continued to 
decline. This resulted in a disappointingly low sample number of HIGHTAU mice for 
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many experiments, complicating the ability to draw definitive conclusions. Despite this, 
particular experiments did indicate functional changes in HIGHTAU mice compared to 
WT and LOWTAU animals particularly at 13 months of age, when a large difference in 
NFT pathology existed between the two transgenic lines. This included a likely 
reduction in Pr at SC-CA1 synapses, changes in AMPA-R kinetics, as well as an 
inability to habituate, apparent reduction in anxiety-like behaviour and presentation of 
disinhibition. HIGHTAU animals of 13-months also presented with a decrease in the 
contribution of NMDA-Rs to the induction of LTP, possibly via disruption to the 
insertion and/or anchoring of NMDA-Rs to the PSD, depletion of the scaffold protein, 
PSD-95, or through influencing gene-expression. As is suggested by Warmus et al., 
(2014), boosting NMDA-R function via use of the Food and Drug Administration–
approved NMDA-R co-agonist cycloserine for example, may prove a beneficial 
treatment for neurodegenerative tauopathy disorders. The efficacy of the compensation 
of the reduction in NMDA-R-dependent LTP may, however, underlie the resistance of 
transgenic mice (and by inference, people with AD) to cognitive dysfunction until late in 
disease progression. 
Despite the fact that the majority of functional changes within the hippocampus 
corresponded to the manifestation of significant numbers of NFTs, it is not suggested 
that the presence of NFTs results in these changes. Taking the reduction in Pr at the SC-
CA1 synapse seen in HIGHTAU mice at 13–months compared to LOWTAU mice of the 
same age, one may reason that this reduction is due to the substantial increase in NFTs 
displayed by the HIGHTAU line. Yet, in studying PPR in LOWTAU mice at 24-months we 
observe no indication of a deficit in Pr, despite the extensive NFT load present. It is 
therefore possible that the increased overexpression of mutated human tau in HIGHTAU 
mice brings about a rise in soluble pathological tau that may cause any toxicity seen. 
Indeed, one of the earliest functional changes, a reduction in the Pr of mPP synapses, 
was found to occur prior to NFT development in either transgenic line at 4 months of 
age. This result indicates that changes in synaptic transmission can occur prior to the 
development of aggregates in cell groups vulnerable to tau dysfunction.  
 
There is also a significant rise in the expression of immune genes at an age displaying 
substantial neurodegeneration in the HIGHTAU line, with a particular emphasis on 
components of the complement cascade, paralleling data from a separate, similar model 
of tauopathy (Wes et al., 2014). However, it is also apparent that an upregulation of 
microglia is present prior to cell loss in HIGHTAU animals, suggesting that the increase in 
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the immune system may not simply be a consequence of cell death. It is therefore 
proposed that microglial activation in tauopathy disorders occurs prior to 
neurodegeneration, but only after pathology has matured to a point at which pathological 
tau is released from neurones, or neurones begin expressing a pathological signal. At this 
point, microglia begin to infiltrate the cell layer where they may influence cell survival.  
In contrast to HIGHTAU mice, a significant rise in immune gene-expression and 
substantial upregulation of microglia was also observed in the TASTPM mouse model of 
amyloid-" dysfunction at an early stage, in a manner directly relating to plaque load 
(Matarin et al., 2015). TASTPM mice do not, however, go on to display 
neurodegeneration. These data may suggest as an extracellular protein, amyloid-" is able 
to trigger an early increase in the immune response in TASTPM mice. Interestingly, in 
this model, microglia are not seen to infiltrate the cell body layers of the hippocampus, 
tending instead to associate with plaques. It is possible that this disparity in the location 
of increased microglia between models of tau and amyloid-" dysfunction alters their 
effect on neuronal survival. Potential differences in the consequential actions of 
microglia between activation by pathological tau or amyloid-" may also alter their 
contribution to neurodegeneration.  
 
In addition to the increased expression of elements of the complement cascade, other key 
genes associated with the immune response were found to be increased in both HIGHTAU 
animals and the TASTPM model of rising amyloid-" (Matarin et al., 2015), including 
certain genes highlighted as risk factors for the development of AD through genome-
wide association studies in humans. These included: Trem2 (Guerreiro et al., 2013, 
Jonsson et al., 2013), Cd33 (Naj et al., 2011) and Inpp5d (Lambert et al., 2013), which 
all play a role in the regulation or coordination of microglial activation. Together, these 
data highlight that the upregulation of the immune system provides a common event in 
animals modelling aspects of neurodegenerative disease, as well as lending support to 
the idea that modulating microglial activation may provide a potential therapeutic target 
for this class of disease (McGeer and McGeer, 2015). Microglia are indeed known to 
modulate synaptic function (Heneka et al., 2014), suggesting that changes in synaptic 
transmission resulting in the behavioural alterations such as disinhibition or a reduction 
in habituation may be the consequence of the upregulation of microglia in HIGHTAU mice 
of 13-months preceding cell loss. In contrast, deficits in overall cognitive function may 
be resistant to these changes, and are thus not observed prior to substantial 
neurodegeneration.  
 176 
APPENDIX 1 
 
An introduction to the theory of electrophysiology 
 
Whole-cell patch clamp recordings 
 
Original work published by Neher and Sakmann (1976) paved the way for modern 
electrophysiology. Here, they described a technique that allowed them to resolve single 
channel currents across a patch of membrane of frog skeletal muscle. In the following 
years the technique was refined, creating improved resolution (produced via generation 
of a ‘gigaohm (G&) seal’ between the glass pipette tip and the cell membrane) as well as 
various different cell-free and cell-attached recording configurations (Hamill et al., 
1981).  
 
The present study used the whole-cell voltage clamp configuration. In order to obtain 
this configuration; following the generation of a G& seal, the patch of membrane below 
the patch pipette is ruptured. This creates continuity between the cell and recording 
electrode located within the patch pipette. A ground electrode located within the 
extracellular solution is used to set the potential difference between the intracellular and 
bath solutions. The cell is ‘clamped’ to a defined voltage using a differential amplifier 
connected to the recording electrode. The membrane potential is continuously compared 
to the command voltage, and upon alterations in membrane potential (caused by the 
opening of ion channels), the differential amplifier passes an equal compensatory 
current. This compensatory current is recorded as representative of membrane 
conductance.  
 
Use of the acute hippocampal slice for patch clamp recordings, (without the need for 
enzyme treatment) was first described by Edwards et al., (1989). In contrast to the 
isolated cell preparations used prior to this, the acute slice allowed recordings to be made 
in the context of their endogenous surroundings, preserving network connections. Use of 
the acute preparation therefore allows for a more ‘true’ measurement of spontaneous 
activity received by the target cell (that is the spontaneous activity of the neuronal 
network generated by either spontaneous action potential firing or spontaneous quantal 
release). It is of course noted that acute slices do not fully represent physiological 
activity, however, they do provide improvements on isolated cell recordings and indeed 
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aim to detect any changes that may be relevant physiologically. In addition all genotypes 
are investigated under the same conditions, allowing for reliable comparisons. In using 
whole-cell voltage clamp techniques to record spontaneous activity, we are able to infer 
certain information about the presynaptic network within which this cell lies; such as, 
the frequency of action potential (AP) driven neurotransmitter release, number of release 
sites (n) and the neurotransmitter release probability of individual synapses (Pr). Certain 
postsynaptic conclusions may also be deduced, including basic cell properties and 
changes in neurotransmitter receptor density and conductance (based on quantal size (q) 
determined by miniature amplitude).  
 
Conclusions involving the n, Pr and q are made based on the quantal theory of 
neurotransmitter release developed during the 1950s (Del Castillo and Katz, 1954). 
While the theory was developed using the neuromuscular junction, its central ideas hold 
true for the fast central synapses under investigation in the present study. The theory is 
based on the idea that a single vesicle of neurotransmitter is the minimum amount 
available for release at a synapse, with all vesicles containing approximately the same 
amount of a specific neurotransmitter. 
By inhibiting AP firing using a sodium channel blocker, one can record the 
postsynaptic currents resulting from the spontaneous release of single quantum, known 
as miniature excitatory postsynaptic currents (mEPSCs). In contrast to the 
neuromuscular junction, one vesicle of neurotransmitter at fast central synapses is 
enough to cause near saturation of the relatively small number of postsynaptic receptors 
available (Edwards, 1995). It therefore follows that the amplitude of miniature currents 
(or quantal size, q) is determined by the density and conductance of these postsynaptic 
receptors, as an increase in release would bear little effect on the size of the response. 
The frequency at which these events occur infers information about the n and Pr of the 
afferents contacting the target cell. 
 
Evoked currents using whole-cell patch clamp recordings 
 
In addition to recording spontaneous activity, one can also record a response in the target 
cell by stimulating afferent fibres impinging on it. By applying two stimuli in close 
succession, and varying the time between the two pulses, one can calculate the paired-
pulse ratio (PPR) of the synapse under study, as well as determining the interval time at 
which the stimuli cease interacting. This ratio is calculated using the amplitude of the 
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two evoked postsynaptic current responses, and provides insight into the Pr of the 
presynaptic site.  
 
The ratio calculated can reveal both a facilitation of the second response (termed paired-
pulse facilitation (PPF)), or a reduction (termed paired-pulse depression (PPD)). The 
basic theory behind what causes either PPF or PPD is based on the residual calcium 
(Ca2+) and neurotransmitter vesicle availability resulting from the original Pr of that 
synapse (reviewed in: (Zucker, 1989, Zucker and Regehr, 2002)).  
For a group of synapses with an inherently low Pr (such as SC-CA1 synapses), 
the first pulse causes neurotransmitter release from only a small number of synapses. If 
the second pulse is delivered within a very short time frame (i.e. within 400ms), residual 
Ca2+ from the first stimulation remains within the presynaptic terminals. This is additive 
to the Ca2+ influx for the second pulse, resulting in neurotransmitter release from a 
greater number of synapses, and thus a larger postsynaptic current is recorded. The 
synapse has seen an increase in the reliability of release. For synapses with a high Pr, the 
first pulse will cause a depletion of the synaptic vesicles. While residual Ca2+ from the 
first response remains, the exhaustion of vesicles from the readily releasable pool of 
neurotransmitter results in a reduction in the size of the second response.  
This residual Ca2+ hypothesis, while most popular, provides a simplistic view of 
the cause of PPF and PPD, and in fact, the grounds for short-term plasticity (in particular 
for PPD) are likely exceedingly more complicated. Zucker and Regehr (2002) provide a 
detailed discussion of further contributing factors to PPD, including the role of 
metabotropic receptors, retrograde messengers, postsynaptic receptor desensitization and 
glial cell contributions.  
 
Extracellular field recordings 
 
Using the acute slice preparation, electrodes are placed extracellularly within the stratum 
radiatum of the CA1 area. Here, the stimulating electrode is able to elicit an AP in the 
SC axons of CA3 neurones, which can be recorded as a postsynaptic potential response 
from CA1 apical dendrites. Extracellular recording allows one to record the responses of 
a population of neurones, creating a ‘field’ potential. As the synapses under study use 
glutamate as the principle neurotransmitter, the responses recorded are known as field 
excitatory postsynaptic potentials or fEPSPs. Here, the postsynaptic responses are 
recorded as negative voltage deflections due to the current ‘sink’ of positive ions 
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(namely sodium ions, Na2+) created by the opening of glutamate receptor ion channels. 
By using a linear slope fit to the initial portion (10-50%) of the slope as a measure 
proportional to the response amplitude, we exclude possible interference from slower 
polysynaptic potentials, and thus this measure primarily reflects activation of the 
postsynaptic fast ionotropic AMPA-Rs. This method of analysis also excludes 
contamination caused by the firing of the target cells, known as a population spike. This 
population spike can be seen as an upward voltage deflection in the postsynaptic 
response, resulting from the current sink created near the cell body region and 
consequential passive current source in the dendritic (recording) region. 
 
I have exploited extracellular field recordings within this project to gain some 
understanding of synaptic plasticity within TauD35 mice at various ages. For studies into 
the long-term potentiation of synapses (discussed below), the ability to record 
extracellulary from a population of neurones provides benefits over single cell patch 
recordings. One large advantage lies in removing the consequence of intracellular 
washout produced by the use of whole-cell patch clamp techniques. Following the 
rupture of the area of membrane underneath the patch pipette, cell dialysis commences. 
Due to the large volume of intracellular pipette solution in comparison to the volume of 
intracellular cytosol, over time (<10 minutes) the cytosol is completely replaced with the 
pipette solution. This washout has large consequences on the maintenance (and possibly 
even induction, depending on the timing of stimulation) of long-term changes in synaptic 
transmission, due to the loss of essential kinases and other components of intracellular 
signaling cascades (discussed below). Alternatives to this problem lie in other forms of 
patch clamp recordings, such as perforated patch or intracellular recordings; however, 
these techniques allow only synaptic changes in a single cell to be recorded. 
Extracellular field recordings allow for changes in a population of neurones, in response 
to a given stimulus, to be recorded as a whole.  
  
Following the establishment of a stable baseline response and application of a high-
frequency tetanus, fEPSPs were recorded within the present study for 1 hour. The 
responses recorded post-tetanus can be divided temporally as: post-tetanic potentiation 
(PTP), defined as the 1st minute; short-term potentiation (STP), defined as 8-12 minutes; 
and LTP, defined as 51-60 minutes after induction (Figure A.1.).  
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PTP is observed as a large, and quickly decaying (<60s (Malenka, 1991)), increase in 
synaptic transmission occurring immediately post-tetanus. Previous experiments have 
established the resistance of PTP to NMDA-R antagonists (Malenka, 1991), and along 
with the observed decrease in PPR during PTP, it is agreed that this potentiation is result 
of residual Ca2+ within the presynaptic terminal.  
The story is, however, a little more complicated when looking at STP, with no 
consensus about what constitutes STP yet established. Recent attempts at clarifying this 
issue have split STP into two parts, distinguished pharmacologically, named STP1 and 
STP2 (Park et al., 2014). They conclude that STP1 may represent an early decremental 
form of LTP in that it requires NMDA-Rs composed of the same subunits (GluN2A and 
GluN2B) as those involved in LTP. This opinion, that STP represents an unstable part of 
LTP was often argued previously, however, Park et al., (2014) extend this, claiming a 
second component (STP2) dependent on NMDA-Rs formed from a different 
composition of subunits, namely GluN2B and GluN2D, also contributes to STP. The 
subunit combinations of NMDA-Rs contributing STP2 are not expressed within the 
synapse; this, along with observed changes in PPR during STP, complements the theory 
that this component of STP may be expressed presynaptically. Both forms of STP are 
highly dependent on induction protocol and the frequency of stimuli post-tetanus used to 
monitor synaptic transmission, with the number of monitoring (test) stimuli leading to 
the decay of STP. Park et al., (2014) used a theta-burst stimulation protocol to induce 
potentiation, followed by test stimulation at a frequency of 0.067Hz, concluding that 
STP1 decayed with a time constant of 7 minutes (~28 stimuli), whereas STP2 decayed 
more slowly, with a time constant of 16 minutes (~64 stimuli). The high frequency 
Figure A.1. Representative 
figure of a typical 
extracellular LTP recording 
from the SC-CA1 synapse. 
A stable baseline is 
established for 15 minutes 
prior to application of high-
frequency tetanic stimulation. 
Responses post-tetanus are 
divided temporally as PTP 
(1st minute), STP (8-12 
minutes) and LTP (51-60 
minutes). Error bars indicate 
SEM. 0 20 40 60
PTP STP LTP
TETANUS 
Baseline!
Time after conditioning (min)!
PTP!
1st min!
STP!
8-12 min!
LTP!
51-60 min!
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tetanus used in the present study is perhaps more conducive of STP than the theta-burst 
protocol utilised by Park et al., (2014); however, following LTP induction, transmission 
is monitored using a stimulation frequency (paired stimuli 50ms apart) of 0.1Hz. This 
test frequency would predict a more rapid decay time constant of STP than reported by 
Park et al., (2014), of approximately 5 minutes for STP1 and 11 minutes for STP2, with 
the paired stimuli likely altering these estimates. It is also possible the slightly lower 
recording temperature used in the present study (32.5 vs. 30±1°C) may also affect these 
decay times. Indeed a decremental potentiation is observed in the present LTP studies 
<15 minutes. STP is thus defined within the present experiments as the potentiation 
observed between 8 and 12 minutes post-tetanus. In addition to analysis of PTP (the first 
minute), this allows an overview of short-term forms of plasticity, prior to stabilization. 
The final 10 minutes of recording (51-60 minutes) was taken as a measure of LTP 
(discussed below).  
 
Long-term potentiation 
 
Long-term potentiation (LTP) describes one of the most important forms of experimental 
synaptic plasticity, providing one of the best ways in which to study the neuronal 
capability of long-lasting alterations likely used in learning and memory. 
Bliss and Lømo first discovered LTP in 1973 (Bliss and Lømo, 1973). Using 
both anaesthetized (Bliss and Lømo, 1973) or awake (Bliss and Gardner-Medwin, 1973) 
rabbits, Bliss, Lømo and Gardner-Medwin showed that extracellular application of high-
frequency electrical stimulation to the perforant path enhanced synaptic transmission, for 
hours and days respectively, between the stimulated axons and DG granule cells. The 
presynaptic stimulation applied caused persistent postsynaptic activity, sufficient to 
cause long-lasting changes to the postsynaptic response. Thus, these experiments 
supported the theory postulated in 1949 by Donald Hebb, that: 
‘When an axon of cell A is near enough to excite a cell B and 
repeatedly or persistently takes part in firing it, some growth process or 
metabolic change takes place in one or both cells such that A's efficiency, as 
one of the cells firing B, is increased’ (Hebb, 1949). 
 
Properties of LTP 
 
Since its discovery, it has become clear that the cellular mechanisms leading to the 
phenomenon of LTP can vary hugely; depending on the neuronal circuit, or indeed 
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synapse within which it is operating, the age or time point being studied and possibly 
even the induction protocol used. Still today, controversy also surrounds whether LTP is 
expressed via pre- or postsynaptic mechanisms (discussed in Bliss and Collingridge, 
2013). It has been suggested that both LTP and its opposing partner long-term 
depression (LTD), may be better thought of as general classes of synaptic phenomena, 
varying widely in the specific forms expressed (Malenka and Bear, 2004); and 
dependent on experimental situations, LTP can be expressed by both pre- or postsynaptic 
mechanisms.  
 
Below I review the widely accepted theory of NMDA-R-dependent LTP. This type of 
LTP is generally understood to underlie potentiation between CA1 and CA3 neurones at 
the SC-CA1 synapse (Collingridge et al., 1983, Malenka, 1991) and is by far the most 
extensively studied with regard to this diverse phenomenon. Other forms of LTP, which 
do not rely on the activation of NMDA-Rs (NMDA-R-independent forms), are discussed 
briefly.  
 
Properties of NMDA-R-dependent LTP 
 
LTP has, over the years, been so often described in terms of three basic properties: input 
specificity, cooperativity and associativity (Bliss and Collingridge, 1993). Input 
specificity describes that only synapses active at the time of stimulation are potentiated, 
LTP is not shown by neighbouring synapses that were not activated by the stimulation. 
In fact, the two terms cooperativity and associativity describe the same phenomenon, 
mistakenly interpreted (McNaughton, 2003) from the 1978 publication by McNaughton 
and Douglas. Indeed both describe the necessity of the induction stimulus of LTP to be 
supra-threshold. Be this via the ability of a ‘strong’ stimulus at a single site to induce the 
‘cooperation’ of many afferents, or the application of a ‘weak’ and ‘strong’ stimulation 
to separate but convergent inputs ‘associating’ to result in LTP. We find that this 
cooperative/ associative property of LTP was alluded to in Hebb’s postulate. The 
phrases, ‘...takes part in firing it’ and ‘...as one of the cells firing B’ suggests the idea 
that an input may be strengthened by way of other inputs.  
 
During the 1980s Hebb’s postulate received further support with a major discovery that 
gave the theory a molecular basis. Using a newly developed antagonist, specific for 
NMDA-Rs (2-amino-5-phosphonopentanoate, AP5) Collingridge et al., (1983) showed 
that, while blocking NMDA-Rs had no effect on basal synaptic transmission, or the 
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maintenance of already established LTP, it reversibly blocked the induction of LTP.  
This finding fuelled much research into NMDA-Rs and, by the end of the decade, much 
had been learnt about how this receptor worked. Crucial was the discovery that Mg2+ 
ions work to block the ion channel pore of the NMDA-R during basal synaptic 
transmission (Coan and Collingridge, 1985) and that this block is voltage-dependent 
(Nowak et al., 1984). This allows the NMDA-R to act as a coincidence detector, 
requiring presynaptic activity for glutamate release, along with sufficient postsynaptic 
depolarization to release the Mg2+ block. This ‘sufficient postsynaptic depolarization’ is 
described by the properties of cooperativity/ associativity and captured by the common 
reduction of Hebb’s postulate: ‘cells that fire together, wire together’. Input specificity 
is also given a mechanistic explanation, with the fact that depolarization is not enough to 
activate the NMDA-R; rather, it also requires the binding of glutamate, a process that 
provides synapse specificity.  
 
Induction and expression mechanisms of postsynaptic NMDA-R-dependent LTP 
 
As we have seen, the opening of the NMDA-R is reliant on sufficient depolarization of 
the postsynaptic membrane (by way of other glutamate receptors), allowing the release 
of Mg2+ from the ion pore at the centre of the receptor, along with the binding of 
glutamate (and glycine, usually ignored due to its high abundance) to the extracellular 
portion. Once open, the receptor permits the flow of Ca2+ (as well as Na+ and K+) into the 
cell. This rise in intracellular Ca2+ is known to be essential in the initiation of LTP; 
however, from this point, definitive answers on the required intracellular signalling 
components become a little hazier.  
 
It is however agreed, that the Ca2+/calmodulin-dependent protein kinase (CaMKII) 
plays a key role in the production of postsynaptic NMDA-R-dependent LTP. The influx 
of Ca2+ through the NMDA-R results in Ca2+ binding to calmodulin. This complex then 
binds CaMKII, leading to a conformational change in the kinase allowing for its auto-
phosphorylation. The resultant activated form of CaMKII is then able to instigate various 
downstream effects, within its activation period of approximately 1 minute (Lisman et 
al., 2012). One consequence of CaMKII activation is its binding to the GluN2B subunit 
of the NMDA-R (Strack and Colbran, 1998). This interaction anchors active CaMKII at 
the synapse, where it is therefore available to cause the phosphorylation of the GluA1 
subunit of the AMPA-R (Mammen et al., 1997), increasing conductance through the 
receptor. Active CaMKII can also lead to an increase in the numbers of synaptic AMPA-
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Rs, possibly via the phosphorylation of stargazin (an AMPA-R auxiliary protein), which 
allows the AMPA-Rs to bind to PSD-95, and thus captures extrasynaptic AMPA-Rs that 
have diffused into the synapse (Opazo et al., 2010). It is thus either the phosphorylation 
of existing AMPA-Rs or an increase in the number of synaptic AMPA-Rs (through 
insertion or capturing of extracellular receptors) that CaMKII is proposed to potentiate 
the postsynaptic response.  
 In addition to the enhancement of AMPA-R conductance at active synapses after 
potentiation, previously inactive ‘silent’ synapses can also be uncovered. This collection 
of synapses are described as silent due to an absence of excitatory postsynaptic currents 
(EPSCs), which has been argued to be caused by both pre- and postsynaptic factors 
depending on the synapse under study (reviewed by (Kerchner and Nicoll, 2008)). At 
hippocampal SC-CA1 synapses, evidence suggests the cause of the silence is due to a 
lack of postsynaptic AMPA-Rs (Isaac et al., 1995, Liao et al., 1995). Upon sub-threshold 
stimulation paired with postsynaptic depolarization, a slow, AP5-sensitive EPSC could 
be detected, indicating the lone expression of NMDA-Rs. During the high-intensity 
stimulation needed for LTP induction, the mechanisms described above come into play, 
with postsynaptic depolarization releasing the Mg2+ block from the NMDARs allowing 
Ca2+ influx. The subsequent activation of CaMKII results in the insertion of AMPA-Rs 
into the postsynaptic density (PSD), leading to the appearance of AMPA-R mediated 
EPSCs at this synapse.  
 
The roles of other kinases implicated in the induction of LTP are less well established, 
and it is unknown whether their presence is required, or if they only act to modify LTP. 
Protein kinase A (PKA or cAMP-dependent protein kinase) is believed to enhance 
CaMKII auto-phosphorylation through the inhibition of protein phosphatase 1. Protein 
kinase C (PKC), in particular in its constitutively active form PKM), has also been 
proposed as essential for LTP. While Ca2+ influx also activates Ras, a small G-protein, 
which works to trigger the mitogen-activated protein kinase (MAPK) cascade, thought to 
be important in LTP (Malenka and Bear, 2004).  
 
The mechanisms described so far explain a brief and simplified view on the procedures 
involved in the induction of LTP. These mechanisms are responsible for the increase in 
synaptic strength lasting up to 1 hour, and hence cover the period of time looked at 
within the present study.  
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The mechanisms allowing LTP to last for days require gene transcription and the 
synthesis of new protein. Various kinases are thought to link activity (and the subsequent 
Ca2+ rise) to the nucleus. Here they activate CREB, a key transcription factor in the 
maintenance of LTP. From this point, many morphological changes have been reported, 
including the growth of new dendritic spines as well as the enlargement of existing 
spines (discussed in (Malenka and Bear, 2004).  
 
NMDA-R-independent LTP: induction and expression 
 
Although the majority of studies have concentrated on investigating NMDA-R-
dependent forms of LTP, due to the wide variation in experimental preparation and 
protocol used, it is perhaps not surprising that some studies have reported forms of LTP 
independent of the NMDA-R.  
 
Using AP5, the same NMDA antagonist used by Collingridge et al., (1983) to 
demonstrate the NMDA-R-dependency of LTP, Grover and Teyler (1990) uncovered 
another component of LTP at SC-CA1 synapses, seemingly NMDA-R independent. This 
LTP component was reliant on increases in intracellular Ca2+, was dependent on 
stimulation frequency and only partially blocked by AP5. To test their theory that 
another channel could be responsible for the necessary rise in intracellular Ca2+ they 
applied the L-type voltage-gated calcium channel (VGCC) antagonist, nifedipine. 
Indeed, this fully ablated the remaining LTP seen after AP5 application. Due to the 
necessity of increased intracellular Ca2+, it was proposed that this form of LTP is 
maintained through the Ca2+-dependent mechanisms required for NMDA-R-dependent 
LTP. Later studies, however, discounted the possibility that both forms of LTP are 
maintained by exactly the same mechanisms, although some interaction between 
signalling pathways may occur (Grover and Teyler, 1995, Cavus and Teyler, 1996). 
Indeed, both NMDA-R-dependent and VGCC-dependent LTP have since been 
demonstrated in vivo, where they have shown to result in additive potentiation at SC-
CA1 synapses (Morgan and Teyler, 1999). The contribution of VGCCs on the induction 
of LTP at the SC-CA1 synapse is reliant on the intensity of stimulation protocol (Grover 
and Teyler, 1990) and may also alter with age (Shankar et al., 1998), providing some 
explanation for contradictory results when investigating LTP induction even at one 
synapse.  
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Variations in the synapse studied can also result in differences in the forms of LTP 
induction. The mossy fibre synapses onto CA3 pyramidal cells are one such example of 
this (Harris and Cotman, 1986). The mechanisms that have been proposed to explain the 
induction of LTP at these synapses revolve around an NMDAR-independent method, 
possibly involving a requirement for presynaptic metabotropic glutamate receptors as 
well as kainate receptors (reviewed by Bortolotto et al., 2005 and Nicoll and Schmitz, 
2005).  
While some controversy still surrounds the induction of LTP at the mossy fibre-
CA3 synapse, it is widely agreed that LTP is expressed presynaptically, via an increase 
in Pr resulting from the likely involvement of an increase in cyclic adenosine 
monophosphate (Nicoll and Schmitz, 2005). These examples show us that the induction 
and expression of LTP are not as straight forward as just postsynaptic NMDAR-
dependent LTP.  
 
Paired-pulse ratio as an indicator of the site of LTP expression 
 
As we have seen, the application of two stimuli in close succession allows one to 
calculate the PPR, with this ratio granting insight into the Pr of the synapse under study. 
For the PPR experiments discussed so far, the interval between the two stimuli is altered, 
allowing insight into the temporal properties of the resultant facilitation or depression. 
For the LTP recordings performed for this thesis, however, two stimuli were applied to 
the pathway at a constant interval of 50ms throughout the duration of the recording, both 
prior to and post tetanic stimulation. Analyzing the PPR in this way provides some 
indication as to whether short- and long-term changes in synaptic transmission are the 
result of a change in presynaptic Pr (McNaughton, 1982). A lack of change in PPR 
would therefore indicate that any alteration in synaptic transmission is due to 
postsynaptic modifications.  
 
Immediately following the application of the high frequency tetanus, it is characteristic 
to observe a reduction in PPR (Park et al., 2014). In the present study, this reduction in 
ratio returns to baseline over approximately 15-20 minutes, corresponding to a decrease 
in synaptic potentiation described as PTP and STP. The change in PPR during this time 
reveals the presynaptic nature of PTP (as well as possibly STP (ibid)), in that the 
synaptic potentiation witnessed is a result of increased glutamate release.  
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